

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [editorial.bmjopen@bmj.com](mailto:editorial.bmjopen@bmj.com)

# BMJ Open

## Impact of a specific training program on the neuromodulation of pain in fibromyalgia women (DouFiSport): a 24-month, controlled, randomised, double-blinded protocol.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023742
Article Type:	Protocol
Date Submitted by the Author:	03-May-2018
Complete List of Authors:	<p>Le Fur Bonnabesse, Anais; Universite de Bretagne Occidentale Faculte de Medecine et des Sciences de la Sante de Brest, Laboratory of Interactions Keratinocytes-Neurons, EA4685; Universite de Bretagne Occidentale UFR d'Odontologie</p> <p>Cabon, Mathilde; Universite de Bretagne Occidentale Faculte de Medecine et des Sciences de la Sante de Brest, Laboratory of Interactions Keratinocytes-Neurons, EA4685</p> <p>L'Heveder, Gildas; CHRU de Brest, Neurological functional explorations</p> <p>Kermarrec, Aurélie ; CHRU de Brest, Training institute of physiotherapy</p> <p>Quinio, Bertrand; CHRU de Brest, Assessment and treatment center of pain</p> <p>Woda, Alain; Universite Clermont Auvergne Faculte de Chirurgie Dentaire, CROC and Teaching Hospital EA3847</p> <p>Marchand, Serge; Universite de Sherbrooke Faculte de medecine et des sciences de la sante, Department of surgery</p> <p>Dubois, Amandine; Laboratoire de psychologie, Cognition, Behaviour, Communication (LP3C), EA1285; Universite de Bretagne Occidentale UFR Lettres et Sciences Humaines a Brest, Department of Psychology</p> <p>Giroux-Metges, Marie-Agnes; Universite de Bretagne Occidentale Faculte de Medecine et des Sciences de la Sante de Brest, ORPHY, Optimisation of Physiological Regulations, EA4324; CHRU de Brest, Respiratory Functional Exploration Unit</p> <p>Rannou, Fabrice; Universite de Bretagne Occidentale Faculte de Medecine et des Sciences de la Sante de Brest, ORPHY, Optimisation of Physiological Regulations, EA4324; CHRU de Brest, Respiratory Functional Exploration Unit</p> <p>Misery, Laurent; Universite de Bretagne Occidentale Faculte de Medecine et des Sciences de la Sante de Brest, Laboratory of Interactions Keratinocytes-Neurons, EA4685</p> <p>Bodéré, Céline; Universite de Bretagne Occidentale Faculte de Medecine et des Sciences de la Sante de Brest, Laboratory of Interactions Keratinocytes-Neurons, EA4685; Universite de Bretagne Occidentale UFR d'Odontologie</p>
Keywords:	PAIN MANAGEMENT, MEDICAL EDUCATION & TRAINING, REHABILITATION MEDICINE, FIBROMYALGIA

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Impact of a specific training program on the neuromodulation of pain in fibromyalgia women (DouFiSport): a 24-month, controlled, randomised, double-blinded protocol.

Anaïs Le Fur-Bonnabesse<sup>1,2,3</sup>, Mathilde Cabon<sup>1</sup>, Gildas L'Heveder<sup>4</sup>, Aurélie Kermarrec<sup>5</sup>, Bertrand Quinio<sup>3</sup>, Alain Woda<sup>6</sup>, Serge Marchand<sup>7</sup>, Amandine Dubois<sup>8,9,1</sup>, Marie-Agnès Giroux-Metges<sup>10,11</sup>, Fabrice Rannou<sup>10,11</sup>, Laurent Misery<sup>1</sup>, Céline Bodéré<sup>1,2,3</sup>.

1 Laboratory of Interactions Keratinocytes-Neurons, EA4685, Faculty of Medicine and Health Sciences, University of Western Brittany (UBO), Brest, France

2 Dental faculty, University of Western Brittany (UBO), Brest, France

3 Assessment and treatment center of pain, University Hospital of Brest, Brest, France

4 Neurological functional explorations, University Hospital of Brest, Brest, France.

5 Training institute of physiotherapy University Hospital of Brest, Brest, France.

6 University Clermont Auvergne, CROC and Teaching Hospital EA3847, Odontology Department, Clermont-Ferrand, France

7 Department of surgery, Faculty of medicine, University of Sherbrooke, Sherbrooke, Canada

8 Laboratory of psychology: Cognition, Behaviour, Communication (LP3C), EA1285, Rennes, France

9 Department of Psychology, University of Western Brittany (UBO), Brest, France.

10 ORPHY, Optimisation of Physiological Regulations, EA4324, Faculty of Medicine and Health Sciences, University of Western Brittany (UBO), Brest, France

11 Respiratory Functional Exploration Unit, University Hospital of Brest, Brest, France.

**Corresponding author: Anaïs Le Fur-Bonnabesse**

anais.lefurbonnabesse@univ-brest.fr

anais.bonnabesse@gmail.com

**ABSTRACT****INTRODUCTION**

The main symptom of fibromyalgia (FM) is diffuse pain. There is currently no etiological treatment for FM. However, all pain associations and best practice guidelines highly recommend the practice of aerobic physical activity to improve the symptoms of FM subjects. The mechanisms of dysfunctional pain are mostly central (1) and related to stress axis dysfunction (autonomic nervous system and corticotropic axis) (2). The main objective is to assess the effectiveness of a specific training program on endogenous pain control mechanisms in female fibromyalgia patients. Further aims include rebalancing the autonomic neurovegetative system, improving the quality of life and sleep quality and reintegrating patients into society and work.

**METHODS AND ANALYSIS**

110 FM women (according to the criteria of the ACR 2010), aged 18-65 years and respecting the inclusion criteria will be recruited and randomised in two groups (active or control). The training program consists of three 45-minute sessions per week of supervised, individualised physical activity over two years. Only the intensity of the exercises is different between the two groups (moderate-intensity versus low-intensity).

All outcome measures will be conducted at baseline (T0), after 6 to 9 months of training (T6-9), then after 24 months of training (T24). The primary endpoint is the improvement of pain modulation (activation of diffuse noxious inhibitory control (DNIC)) evaluated by the stimulation test (1). The secondary endpoint will assess pain, anxiety, depression, stress, sleep disorders, pain impact on life quality, heart rate, blood pressure and salivary cortisol.

**ETHICS AND DISSEMINATION:**

Approved by the Committee for the Protection of Persons West VI. Trial registration NCT02486965.

### Strengths and limitations of this study

- ▶ First randomised controlled double-blinded trial to assess the effects of a long-term training program (24 months) on pain control in fibromyalgia.
- ▶ To validate a training program acting on the autonomic system and to assess the neurovegetative rebalance on pain control.
- ▶ Physical activity intensity will be assessed objectively using a heart rate monitor.
- 
- ▶ The dropout rate in patients may be important. These elements were taken into account in sample size.
- ▶ Due to the nature of the intervention, the coaching staff cannot be blinded.

## *INTRODUCTION:*

Fibromyalgia affects 1.4 to 2.2% of the general population concerning predominately women (more than 80% of subjects). This syndrome is characterised by extensive and diffuse pain, mainly muscular and articular, impairing the functional abilities of the subjects. The symptoms most frequently described by fibromyalgia patients are chronic fatigue, sleep disorders, cognitive disorders and emotional disturbances (3,4). This symptomatology leads to a serious deterioration in quality of life, sometimes with a physical disability leading to social isolation and difficulties in staying in employment (recurrent work stoppages).

The diagnosis is based on the symptoms and their severity as described by the patients (5–8). Currently, there is no etiological treatment for fibromyalgia syndrome. The treatments are therefore only symptomatic.

### **Physiopathology of fibromyalgia**

The mechanisms of dysfunctional pain, without any identifiable organic lesions, are mostly central (1) and related to dysfunction of the stress axis (autonomic nervous system and corticotropic axis) (9–11).

At rest, fibromyalgia patients showed an increased sympathetic response and decreased parasympathetic tone (12,13). This neurovegetative dystonia is a marker of dysfunction of the stress axis (14).

Malfuncions of the corticotropic axis in fibromyalgia have been described multiple times, also marking the dysfunction of the stress axis. But the form taken by this dysfunction differs according to the different studies (15–19). The variability of salivary cortisol in response to stress reflects that of plasma free cortisol. Salivary cortisol is therefore a method of choice in experimental stress studies (20). Whatever form they take, these dysfunctions compromise the body's adaptation to daily stressful stimuli.

Studies show that this deficit of the stress axis (neurovegetative dystonia and dysfunctional corticotropic axis) is concurrent with fibromyalgia (21) and

1  
2  
3 associated with alteration of pain control (9–11). Pain control system and stress  
4 axis have close anatomical and functional links. Nociceptive, neurovegetative and  
5 corticotropic systems interact with the central nervous system. The central  
6 neuromediators implicated in the regulation of the stress axis are mostly  
7 common with those of the pain neuromodulation (endogenous opioids,  
8 norepinephrine, serotonin, etc.).  
9  
10  
11  
12  
13

### 14 **Elite athlete's overtraining syndrome: model of stress axis** 15 **dysfunction**

16  
17  
18 An overtraining elite athlete may be considered as a model of dysfunction of the  
19 stress axis associated with neurovegetative dystonia. The physical and  
20 psychological effort of training is known to induce stress. High-level athletes  
21 could present an overtraining syndrome when adaptation limits of the stress axis  
22 are reached. This stress-induced phenomenon corresponds to an imbalance  
23 between training quantity and recovery. Overtrained athletes present a  
24 deconditioning syndrome close to fibromyalgia symptoms (chronic pain, sleep  
25 disorders, neurovegetative dystonia, etc.) (22–26).  
26  
27  
28  
29  
30  
31  
32

### 33 **Physical activity and fibromyalgia**

34  
35 Most studies have shown that physical activity is more efficient compared to  
36 pharmacological treatments on fibromyalgia symptoms (27,28). Literature  
37 reviews and meta-analyses highly support the benefits of physical training in  
38 fibromyalgia patients (decreased pain and depression and improvement in  
39 overall health and physical abilities) (29)(30). Practice of aerobic exercise in  
40 fibromyalgia patients is strongly recommended by The American Pain Society  
41 (31), the Association of Medical Scientific Societies in Germany (32), the  
42 Canadian Rheumatology Association (5) and the European League Against  
43 Rheumatism (EULAR) (33). Physical exercise is the first-line treatment  
44 recommended in fibromyalgia. However there is still no consensus on the  
45 modalities of these types of training (frequency, duration, and intensity).  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Currently, the mechanisms underlying those specific training effects have to be  
defined.



1  
2  
3  
4 The steady physical activity rebalancing autonomic system is associated with  
5 cardiovascular benefits. Fundamental endurance increases parasympathetic tone  
6 and decrease sympathetic response (34–37). Thus, strategies to rebalance the  
7 autonomic system are the most promising therapies for fibromyalgia (13,36,37).  
8  
9

10  
11  
12 In this study, we propose to validate a therapeutic alternative that aims to treat  
13 fibromyalgia by rebalancing the stress axis. This treatment consists of a specific  
14 supervised and individualised training program, over 2 years. This training  
15 protocol is individually adjusted in order to rebalance the neurovegetative  
16 system (parasympathetic and sympathetic). Central neuroplasticity induced by  
17 training should regulate endogenous pain control mechanisms. This specific  
18 protocol will be associated with psychotherapeutic approaches. In addition to  
19 the training program, multidisciplinary bio-psycho-social cares will be given in  
20 the pain centre of the university hospital of Brest (5).  
21  
22  
23  
24  
25  
26  
27  
28

## 29 **Objectives**

30  
31 The *main objective* is to assess the effectiveness of a specific training program on  
32 endogenous pain controls in fibromyalgia patients. The *secondary objectives* are  
33 to rebalance the autonomic nervous system and the corticotropic axis, to  
34 improve life and sleep quality and to reintegrate patients into society and work.  
35  
36  
37  
38

## 39 **METHODS AND ANALYSIS:**

### 40 **Design and setting**

41  
42 This randomised double-blind trial will compare an "active" program to a  
43 "control" program in fibromyalgia patients. Patients will be recruited at the pain  
44 center of the university hospital of Brest on the basis of general criteria. Patients  
45 should follow a re-exercise program for 24 months. The assessments will take  
46 place (i) before, (ii) between 6 to 9 months (depending the training level) and  
47 (iii) at the end of the training (24 months), in the neurological functional  
48 explorations department of the university hospital of Brest (fig.1).  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Patient and public involvement

The specific training program of this study was developed based on the results of a pilot study (39), literature data and experiences of fibromyalgia patients followed in the pain centre of the University Hospital of Brest. These patients reported benefits, constraints, difficulties, and effects on their symptoms of their training program. These information have allowed for adjust the specific training program. Patients are not involved in the recruitment and conduct of the study. During the last assessment visit, patient will be asked for assess the burden of the intervention. Upon request, a report outlining the study findings will be given to study participants.

## Study population

110 fibromyalgia patients will be included. The inclusion criteria are: female subjects; aged of 18 to 65 years; with a diagnosis of fibromyalgia clearly established according to the criteria of the American College of Rheumatology (ACR) 2010; with a body mass index (BMI) between 18.5 and 29.9kg/m<sup>2</sup>; spontaneous pain intensity higher than 3/10 on a visual analog scale (VAS); pain experienced at least 3 days a week; pain caused by palpation equal to or higher than 4/10 on a VAS.

The non-inclusion criteria are: patients with a systemic disease (treated or not) generating pain of the musculoskeletal system; presenting pain other than fibromyalgia; presenting a contraindication to physical activity; having any active pathology; having modified in the last 2 months any pharmacological treatment; having a psychiatric diagnosis; taking drugs that affect cortisol secretion (decrease or increase); non-cooperating.

## Sample size

Population size is based on an expected difference of 20 points (stimulation test) (1) between the two groups, for a quantitative primary endpoint (delta VAS) of standard deviation equal to 35, and a power set at 80%. Therefore a minimum of

1  
2  
3 48 subjects per group is required for assessment. In order to take into account  
4 loss to follow-up, the sample of 110 subjects, 55 per group will be recruited.  
5  
6

## 7 8 **Randomisation**

9  
10 Patients will be randomised at the end of the first stimulation test, which is just  
11 before the initiation of the training. Randomisation will be conducted by the  
12 Center of Clinical Investigation (CIC) at the hospital university of Brest  
13 (electronic randomisation via Capture System). The test is stratified by age and  
14 BMI. The cut off is set at 50 years for age and 25kg/m<sup>2</sup> for BMI (two strata [18-  
15 25] and ]25-30 ]).  
16  
17  
18  
19  
20

## 21 **Intervention: Training program**

22  
23 The training program is planned over two years (24 months) for both groups  
24 (active/control). A minimum of 4 to 6 weeks is needed to observe a decrease in  
25 symptoms (39). This two-year duration is the minimum average training time  
26 (depending on the individual progress of each patient), necessary to regain  
27 central neuroplasticity sufficient to put back into operation diffuse noxious  
28 inhibitory controls (DNIC) and neurovegetative system (39).  
29  
30  
31  
32

33 The frequency, intensity, and duration of these training sessions are based upon  
34 the results of a preliminary study. Pain was significantly reduced and symptoms,  
35 such as quality of life, sleep quality, anxiety, were also highly improved in  
36 subjects undergoing this specific training after 5 years (39).  
37  
38  
39  
40

41 The American Pain Society recommends an intensity of 60 to 70% of the age-  
42 adjusted maximum heart rate (HRmax). At the early stage, the intensity and  
43 duration of the training sessions will be adapted to the physical condition of each  
44 subject. The intensity exercise will be 3 on the Borg CR10 scale (38). In order to  
45 promote adherence of our patients and to limit pain exacerbation, exercise  
46 intensity will start very low and then gradually increase to reach the  
47 neurovegetative goal (31)(40).  
48  
49  
50  
51  
52

53 The ideal frequency is 3 training sessions per week during 45 minutes each  
54 (38,39).  
55  
56  
57  
58  
59  
60

**Active training group:**

*The first 6 to 9 months:* fundamental endurance training.

Subjects will perform 3 sessions per week of 45 minutes of fundamental endurance (moderate-intensity continuous training MICT: 60% HRmax), including 2 sessions supervised by a physiotherapist and 1 independent session.

*From 6-9 months (according to the rhythm, abilities, and limits) to 24 months:*

Patients will begin the second stage of training: 3 sessions per week of 45 minutes each (moderate-intensity continuous training MICT (60% HRmax) and high-intensity interval training HIIT) with 1 supervised session and 2 independent sessions. When the patient reaches the initial HR goal, “fundamental endurance” will be associated with “interval training” at a high frequency intensity. HIIT will consist of 5 stages of 1 to 4 minutes at 85-90% HRmax (80-85%  $\dot{V}O_2$ max), interspersed by 1 to 4 minutes of active recovery at 60-75% HRmax (50-70%  $\dot{V}O_2$ max). Intensity will be assessed objectively using a heart rate monitor (FT2, Polar). □At baseline, Tanaka’s age-based prediction equation ( $208-0.7 \times \text{age}$ ) will calculate HRmax. After 6-9 months of training, a maximal-effort graded exercise test will determine HRmax and  $\dot{V}O_2$ max for each patient.

**Control group:**

Patients will perform the same infra active training (low-intensity continuous training: LICT <50% HRmax) over two years. Supervision, monitoring, and frequency of sessions (3 x 45 minutes per week) in both groups will be equivalent.

**Training follow-up (for both groups):**

Patients will be contacted to record progress, difficulties and if necessary, to encourage them to adhere to their program. These calls will improve the compliance and will limit patients lost to follow-up.

Patients will perform a 6-minute walk test (6MWT) every 6 months (with physiotherapist). If a patient cannot achieve the specific training requested after 9 months of study, the patient will not complete the second phase of training.

1  
2  
3 Nevertheless, she will carry out all assessment visits. The main analysis will be  
4 performed on an intent-to-treat basis.  
5  
6  
7  
8  
9

## 10 **Clinical Data, Measurements and Assessments**

### 11 **Sociodemographic and clinical data**

12 At baseline, data on age, sex, marital status, education level, and occupation will  
13 be collected. Height and weight will be recorded. Medical background and pain  
14 characteristics will be noted. All current drug and non-drug therapies (including  
15 tried and stopped) will also be collected, as well as their effectiveness on pain.  
16  
17  
18  
19  
20  
21

### 22 **Questionnaires and pain assessments**

23 Measurements and questionnaires will be carried out (i) at baseline, (ii) between  
24 6 to 9 months, and (iii) at the end of the 24 months of training.  
25  
26

- 27 • The **assessment of pain** will be performed by a simple verbal scale and  
28 using a visual analog scale (VAS). The Saint Antoine Pain Questionnaire  
29 (QDSA) will also assess pain. A **pain quantitative assessment** will be  
30 performed with a pressure algometer (pressure pain threshold: PPT).  
31  
32
- 33 • The Hospital Anxiety Depression Scale (HADS) will assess the **patient**  
34 **anxiodepressive state** (41).  
35  
36
- 37 • The Fibromyalgia Impact Questionnaire (FIQ) will assess **the impact of**  
38 **fibromyalgia on daily life** (42).  
39  
40
- 41 • The Pittsburgh Sleep Quality Index (PSQI) will assess **sleep quality and**  
42 **quantity** (43,44).  
43  
44
- 45 • The International Physical Activity Questionnaire (IPAQ) will record the  
46 **level of physical activity and the sedentary lifestyle**. The French long  
47 telephone questionnaire will be used (45).  
48  
49
- 50 • The Perceived Stress Scale (PSS) will assess **the antecedents of**  
51 **perceived stress** (46).  
52  
53

### 54 **Stimulation test**

55  
56  
57  
58  
59  
60

1  
2  
3 In order to assess endogenous pain mechanisms, such as diffuse noxious  
4 inhibitory controls (DNIC), temporal summation (TS) and perception of pain, we  
5 will use an experimental method developed by Tousignant-Laflamme and  
6 Marchand (2008). According to this well-characterised paradigm, we will induce  
7 in single session two tonic heat pain stimulations separated by a cold pressor  
8 test (1,47–49).  
9  
10  
11  
12

13  
14 - Thermode test or temporal summation test (**P1**): a tonic heat pain will be  
15 administered for 2 minutes on the patient's right arm, using a thermode (CE  
16 marking n°226). The starting temperature is 32°C (skin temperature under  
17 normal conditions in temperate room (20-22°C)) (50) and will quickly reach a  
18 fixed value. The experimental temperature will be individually determined to  
19 induce 50/100 on a VAS and will remain constant during the test period (2  
20 minutes). Throughout this entire period, the patient will evaluate their pain  
21 intensity using a Computerised Visual Analog Scale (CoVAS).  
22  
23  
24  
25  
26  
27  
28

29 - Cold pressor test (**P2**): to elicit a prolonged pain sensation in order to  
30 trigger diffuse noxious inhibitory control (DNIC) (51), the patient's right arm will  
31 be immersed for 2 minutes in a cold water bath maintained at 12°C. The patient  
32 will continuously evaluate their pain intensity using a CoVAS.  
33  
34  
35

36 Following this cold pressor test, the thermode test will be again performed (**P3**).  
37 Pain difference between the two (P3/P1) tonic heat pain stimulations will  
38 measure DNIC activation and represents pain modulation.  
39  
40  
41

### 42 **Measurement of salivary cortisol and salivary flow**

43  
44 Corticotropic axis will be assessed using measurement of salivary cortisol.  
45 Cortisol release is pulsatile (10 to 20 peaks per day) and follows a nycthemeral  
46 cycle. Maximum cortisol level is reached in the early morning. In the morning of  
47 each consultation (at baseline, in the middle and at the end of training), patients  
48 will collect salivary sample (i) for 2 minutes, when they wake up and (ii) for 2  
49 minutes, 30 minutes later. The salivary cortisol level is measured in nmol/l. The  
50 flow rate is calculated in ml.min<sup>-1</sup>. Samples will be frozen at -20°C. As salivary  
51 cortisol is stable, samples can be stored for many weeks in the freezer (52). After  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 completion of all assessment sessions, sample analysis will be completed. To  
4 avoid inter-laboratory variation, the same laboratory will assay the samples.  
5  
6

### 7 **Recording of Blood Pressure (BP) and Heart Rate (HR)**

8 After 10 minutes at rest, lying down, BP and HR will be recorded. Then, BP and  
9 HR will be measured when the patient stands up and once per minute during 4  
10 minutes when the patient remains standing.  
11  
12  
13  
14

### 15 **Blinding strategy**

16 Patients will not be informed of their group (active/control). The investigators  
17 will not know the patient's group. Due to the nature of the intervention (physical  
18 activity protocol), the coaching staff will not be blinded.  
19  
20  
21  
22  
23

### 24 **Statistical analysis**

25 *Primary endpoint analysis:* The VAS improvements (stimulation test) obtained in  
26 the both groups will be compared using the Student's test. If the required  
27 normality assumption is not sustainable, a nonparametric Wilcoxon test will be  
28 used. An alpha risk of 0.05 will be set as the limit of statistical significance. The  
29 main analysis will be performed on an intent-to-treat basis. A complementary  
30 analysis using a linear model with adjustment for age and BMI factors will be  
31 completed.  
32  
33  
34  
35  
36  
37  
38

39 *The secondary endpoints* (quantitative: salivary cortisol, blood pressure, PPT  
40 quantified by pain threshold pressure, questionnaires assessment) will be  
41 analysed in a similar way by comparing the improvements obtained between  
42 both groups.  
43  
44  
45  
46  
47

### 48 **Methodological limitations**

49 The methodology of this protocol is consistent with the recommendations of the  
50 Standard Protocol Items for Randomised Trials (SPIRIT). However, because of  
51 the nature of the intervention, the coaching staff cannot be blinded. Patients and  
52 investigators will be blinded.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 According to the study duration (2 years), the potential participant dropout and  
4 potential patients lost to follow-up may be important. These elements were  
5 taken into account in sample size. To limit dropout, patients will be called to  
6 encourage them and to discuss any difficulties. In second stage of training and to  
7 limit a possible long-term monotonous effect, physical activity type could be  
8 diversified in both groups. The training session will be adapted in the active  
9 group (MICT will be associated with HIIT) to reduce sympathetic hyperactivity. In  
10 order to improve compliance and long-term achievement of training, the patient  
11 may choose the physical activity type performed without supervision.  
12  
13  
14  
15  
16  
17  
18

## 19 ***ETHICS AND DISSEMINATION***

### 20 **Ethics approval and consent to participate**

21  
22 The Committee for the Protection of Persons West VI approved this study.  
23 Patients will be informed of the objectives, constraints, risks and benefits of the  
24 study. To be included, patients will sign informed written consent. Data will be  
25 collected anonymously. The investigators will take all necessary precautions to  
26 ensure the confidentiality of the information in particular with regard to patient  
27 identity.  
28  
29  
30  
31  
32  
33  
34

### 35 **Dissemination plan**

36 The results of this study will be published in specialised scientific journals. These  
37 results will also be presented in pain and/or physical activity congresses. In  
38 addition, a doctoral thesis will be carried out on this project.  
39  
40  
41  
42  
43

44 TRIAL REGISTRATION NUMBER: NCT02486965

### 45 **Acknowledgements**

46 The authors thank Julie Lelièvre, Marie Le Bellego, Youenn-Thor Bodéré for  
47 designing and implementing this protocol, and Phillipa Perrot for English  
48 language revision.  
49  
50  
51  
52

### 53 **Contributors**

54 CB initiated the idea for the project. CB and ALFB developed the study design.  
55 MC, GL, BQ, AK, AW, SM, MAGM, FC, FR, LM and AD provided advice for the study  
56 design. GL and CB were responsible for supervision of project. CB will conduct  
57  
58  
59  
60



1  
2  
3 the recruitment. AK will conduct the training programme. CB, ALFB and MC will  
4 conduct the outcomes assessments and will contribute to the analysis and  
5 interpretation of the data. Both authors will contribute to the analyses and  
6 interpretation of the data. ALFB, CB and MC wrote early drafts of the manuscript.  
7 All authors approved the final version of this protocol.  
8

### 9 **Funding Statement**

10 This work is supported by the French Ministry of Health (Programme Hospitalier  
11 de Recherche Clinique Interrégional 2014, project no 2014-A00743-44) PHRCi  
12 13-100  
13

### 14 **Competing Interests**

15 None declared.  
16  
17

### 18 **Ethics approval**

19 Comité de Protection des Personnes Grand Ouest VI.  
20  
21

### 22 **Provenance and peer review**

23 Not commissioned; externally peer reviewed.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Tousignant-Laflamme Y, Pagé S, Goffaux P, Marchand S. An experimental model to measure excitatory and inhibitory pain mechanisms in humans. *Brain Res.* 16 sept 2008;1230:73-9.
2. Woda A, L'heveder G, Ouchchane L, Bodéré C. Effect of experimental stress in 2 different pain conditions affecting the facial muscles. *J Pain Off J Am Pain Soc.* mai 2013;14(5):455-66.
3. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. *Arthritis Rheum.* févr 1990;33(2):160-72.
4. Cánovas R, León I, Roldán MD, Astur R, Cimadevilla JM. Virtual reality tasks disclose spatial memory alterations in fibromyalgia. *Rheumatol Oxf Engl.* oct 2009;48(10):1273-8.
5. Fitzcharles M, Shir Y, Ablin JN, Buskila D, Amital H, Henningsen P, et al. Classification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines. *Evid-Based Complement Altern Med ECAM.* 2013;2013:528952.
6. Egloff N, von Känel R, Müller V, Egle UT, Kokinogenis G, Lederbogen S, et al. Implications of proposed fibromyalgia criteria across other functional pain syndromes. *Scand J Rheumatol.* 2015;44(5):416-24.
7. Moyano S, Kilstein JG, Alegre de Miguel C. New diagnostic criteria for fibromyalgia: Here to stay? *Reumatol Clin.* août 2015;11(4):210-4.
8. Wolfe F, Fitzcharles M-A, Goldenberg DL, Häuser W, Katz RL, Mease PJ, et al. Comparison of Physician-Based and Patient-Based Criteria for the Diagnosis of Fibromyalgia. *Arthritis Care Res.* mai 2016;68(5):652-9.
9. Bodéré C, Woda A. La douleur orofaciale idiopathique: une douleur fonctionnelle. *Douleur Analgésie.* 21 juin 2009;22(2):89-95.
10. Woda A, Dao T, Gremeau-Richard C. Steroid dysregulation and stomatodynia (burning mouth syndrome). *J Orofac Pain.* 2009;23(3):202-10.
11. Woda A, L'heveder G, Ouchchane L, Bodéré C. Effect of experimental stress in 2 different pain conditions affecting the facial muscles. *J Pain Off J Am Pain Soc.* mai 2013;14(5):455-66.
12. Cohen H, Neumann L, Shore M, Amir M, Cassuto Y, Buskila D. Autonomic dysfunction in patients with fibromyalgia: application of power spectral analysis of heart rate variability. *Semin Arthritis Rheum.* févr 2000;29(4):217-27.
13. da Cunha Ribeiro RP, Roschel H, Artioli GG, Dassouki T, Perandini LA, Calich AL, et al. Cardiac autonomic impairment and chronotropic incompetence in fibromyalgia. *Arthritis Res Ther.* 2011;13(6):R190.
14. Martinez-Lavin M. Fibromyalgia as a sympathetically maintained pain syndrome. *Curr Pain Headache Rep.* oct 2004;8(5):385-9.
15. Kadetoff D, Kosek E. Evidence of reduced sympatho-adrenal and hypothalamic-pituitary activity during static muscular work in patients with fibromyalgia. *J Rehabil Med.* sept 2010;42(8):765-72.
16. Tak LM, Cleare AJ, Ormel J, Manoharan A, Kok IC, Wessely S, et al. Meta-analysis and meta-regression of hypothalamic-pituitary-adrenal axis activity in functional somatic disorders. *Biol Psychol.* mai 2011;87(2):183-94.
17. Riva R, Mork PJ, Westgaard RH, Lundberg U. Comparison of the cortisol

- 1  
2  
3 awakening response in women with shoulder and neck pain and women with  
4 fibromyalgia. *Psychoneuroendocrinology*. févr 2012;37(2):299-306.
- 5 18. Geiss A, Rohleder N, Anton F. Evidence for an association between an  
6 enhanced reactivity of interleukin-6 levels and reduced glucocorticoid sensitivity  
7 in patients with fibromyalgia. *Psychoneuroendocrinology*. mai  
8 2012;37(5):671-84.
- 9 19. Bote ME, García JJ, Hinchado MD, Ortega E. Inflammatory/stress feedback  
10 dysregulation in women with fibromyalgia. *Neuroimmunomodulation*.  
11 2012;19(6):343-51.
- 12 20. Hellhammer DH, Wüst S, Kudielka BM. Salivary cortisol as a biomarker in  
13 stress research. *Psychoneuroendocrinology*. févr 2009;34(2):163-71.
- 14 21. Clauw D, Ablin J. The relationship between « stress » and pain: lessons  
15 learned from fibromyalgia and related conditions. In: *Current topics in pain*.  
16 Castro-Lopes editor. XIIth World Congress on Pain. Seattle: IASP press; 2009. p.  
17 p.245-270.
- 18 22. McKenzie DC. Markers of excessive exercise. *Can J Appl Physiol Rev Can*  
19 *Physiol Appl*. févr 1999;24(1):66-73.
- 20 23. MacKinnon LT. Special feature for the Olympics: effects of exercise on the  
21 immune system: overtraining effects on immunity and performance in athletes.  
22 *Immunol Cell Biol*. oct 2000;78(5):502-9.
- 23 24. Iellamo F, Pigozzi F, Parisi A, Di Salvo V, Vago T, Norbiato G, et al. The  
24 stress of competition dissociates neural and cortisol homeostasis in elite  
25 athletes. *J Sports Med Phys Fitness*. déc 2003;43(4):539-45.
- 26 25. Baumert M, Brechtel L, Lock J, Hermsdorf M, Wolff R, Baier V, et al. Heart  
27 rate variability, blood pressure variability, and baroreflex sensitivity in  
28 overtrained athletes. *Clin J Sport Med Off J Can Acad Sport Med*. sept  
29 2006;16(5):412-7.
- 30 26. Kajaia T, Maskhulia L, Chelidze K, Akhalkatsi V, Kakhabrishvili Z. The  
31 effects of non-functional overreaching and overtraining on autonomic nervous  
32 system function in highly trained athletes. *Georgian Med News*. mars  
33 2017;(264):97-103.
- 34 27. Fontenele JB, Felix FHC. Exercise for fibromyalgia: evidence for an  
35 integrated modulation of autonomic and nociception neural regulation.  
36 *Rheumatol Int*. déc 2012;32(12):4075-6.
- 37 28. Rossy LA, Buckelew SP, Dorr N, Hagglund KJ, Thayer JF, McIntosh MJ, et al.  
38 A meta-analysis of fibromyalgia treatment interventions. *Ann Behav Med Publ*  
39 *Soc Behav Med*. 1999;21(2):180-91.
- 40 29. Busch AJ, Webber SC, Brachaniec M, Bidonde J, Bello-Haas VD, Danyliw  
41 AD, et al. Exercise therapy for fibromyalgia. *Curr Pain Headache Rep*. oct  
42 2011;15(5):358-67.
- 43 30. Woda A, L'heveder G, Ouchchane L, Bodéré C. Effect of experimental  
44 stress in 2 different pain conditions affecting the facial muscles. *J Pain Off J Am*  
45 *Pain Soc*. mai 2013;14(5):455-66.
- 46 31. Society AP, éditeur. *Guideline for the Management of Fibromyalgia*  
47 *Syndrome Pain in Adults and Children*. American Pain Society; 2005. 109 p.
- 48 32. Häuser W, Arnold B, Eich W, Felde E, Flügge C, Henningsen P, et al.  
49 Management of fibromyalgia syndrome – an interdisciplinary evidence-based  
50 guideline. *GMS Ger Med Sci*. 2008;6:Doc14.
- 51 33. Macfarlane GJ, Kronisch C, Atzeni F, Häuser W, Choy EH, Amris K, et al.  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 EULAR recommendations for management of fibromyalgia. *Ann Rheum Dis.* déc  
4 2017;76(12):e54.
- 5 34. Melanson EL, Freedson PS. The effect of endurance training on resting  
6 heart rate variability in sedentary adult males. *Eur J Appl Physiol.* sept  
7 2001;85(5):442-9.
- 8 35. Reland S, Ville NS, Wong S, Gauvrit H, Kervio G, Carré F. Exercise heart  
9 rate variability of older women in relation to level of physical activity. *J Gerontol*  
10 *A Biol Sci Med Sci.* juill 2003;58(7):585-91.
- 11 36. de Abreu SB, Lenhard A, Mehanna A, de Souza HCD, Correa FM de A,  
12 Hasser EM, et al. Role of paraventricular nucleus in exercise training-induced  
13 autonomic modulation in conscious rats. *Auton Neurosci Basic Clin.* 15 juin  
14 2009;148(1-2):28-35.
- 15 37. Martins-Pinge MC. Cardiovascular and autonomic modulation by the  
16 central nervous system after aerobic exercise training. *Braz J Med Biol Res Rev*  
17 *Bras Pesqui Médicas E Biológicas Soc Bras Biofísica Al.* sept 2011;44(9):848-54.
- 18 38. Häuser W, Klose P, Langhorst J, Moradi B, Steinbach M, Schiltenswolf M, et  
19 al. Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a  
20 systematic review and meta-analysis of randomised controlled trials. *Arthritis*  
21 *Res Ther.* 2010;12(3):R79.
- 22 39. Bodéré C, Bodéré YT, Quinio B, Woda A, Misery L. Specific training  
23 program for the treatment of fibromyalgia: a prospective controlled study. In:  
24 14th world congress on pain - TF505. Milan, Italy: IASP; 2012.
- 25 40. Lannersten L, Kosek E. Dysfunction of endogenous pain inhibition during  
26 exercise with painful muscles in patients with shoulder myalgia and  
27 fibromyalgia. *Pain.* oct 2010;151(1):77-86.
- 28 41. Krag NJ, Nørregaard J, Larsen JK, Dannekiold-Samsøe B. A blinded,  
29 controlled evaluation of anxiety and depressive symptoms in patients with  
30 fibromyalgia, as measured by standardized psychometric interview scales. *Acta*  
31 *Psychiatr Scand.* juin 1994;89(6):370-5.
- 32 42. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact  
33 questionnaire: development and validation. *J Rheumatol.* mai  
34 1991;18(5):728-33.
- 35 43. Osorio CD, Gallinaro AL, Lorenzi-Filho G, Lage LV. Sleep quality in patients  
36 with fibromyalgia using the Pittsburgh Sleep Quality Index. *J Rheumatol.* sept  
37 2006;33(9):1863-5.
- 38 44. Omachi TA. Measures of sleep in rheumatologic diseases: Epworth  
39 Sleepiness Scale (ESS), Functional Outcome of Sleep Questionnaire (FOSQ),  
40 Insomnia Severity Index (ISI), and Pittsburgh Sleep Quality Index (PSQI).  
41 *Arthritis Care Res.* nov 2011;63 Suppl 11:S287-296.
- 42 45. Crinière L, Lhomme C, Caille A, Giraudeau B, Lecomte P, Couet C, et al.  
43 Reproducibility and validity of the French version of the long international  
44 physical activity questionnaire in patients with type 2 diabetes. *J Phys Act Health.*  
45 août 2011;8(6):858-65.
- 46 46. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress.  
47 *J Health Soc Behav.* déc 1983;24(4):385-96.
- 48 47. Marchand S, Arsenault P. Spatial summation for pain perception:  
49 interaction of inhibitory and excitatory mechanisms. *Pain.* févr  
50 2002;95(3):201-6.
- 51 48. Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in  
52  
53  
54  
55  
56  
57  
58  
59

1  
2  
3 fibromyalgia is related to a deficit of endogenous pain inhibition. *Pain*. mars  
4 2005;114(1-2):295-302.


5 49. Granot M, Granovsky Y, Sprecher E, Nir R-R, Yarnitsky D. Contact heat-  
6 evoked temporal summation: tonic versus repetitive-phasic stimulation. *Pain*.  
7 juin 2006;122(3):295-305.


8 50. Barrett KE, Barman SM, Boitano S, Brooks H. *Ganong's Review of Medical*  
9 *Physiology*, 24th Edition. 24 edition. New York: McGraw-Hill Education /  
10 Medical; 2012. 768 p.

11 51. Potvin S, Paul-Savoie E, Morin M, Bourgault P, Marchand S. Temporal  
12 summation of pain is not amplified in a large proportion of fibromyalgia patients.  
13 *Pain Res Treat*. 2012;2012:938595.

14 52. Kirschbaum C, Hellhammer DH. Salivary cortisol in  
15 psychoneuroendocrine research: recent developments and applications.  
16 *Psychoneuroendocrinology*. 1994;19(4):313-33.

Figure 1:  
Flow chart  
of  
DouFiSport





Flow chart of DouFiSport

209x296mm (150 x 150 DPI)



**NOTICE D'INFORMATION ET FORMULAIRE DE CONSENTEMENT****IMPACT D'UN PROGRAMME D'ENTRAÎNEMENT SPECIFIQUE SUR LA NEUROMODULATION DES DOULEURS CHEZ LES SUJETS FIBROMYALGIQUES**

N° IDRCB: 2014-A00743-44

**Promoteur :** CHRU de Brest – 2 Avenue Foch, 29609 Brest cedex

**Investigateur coordonnateur**

**Docteur L'heveder Gildas,**  
MD, neurologue, MSc  
Chef du pôle Neurolocomoteur, Gériatrique et Infectiologique  
EFN, Hôpital La Cavale Blanche, CHRU Brest  
29609 Brest Cedex

Madame,

Nous vous invitons à participer à une étude clinique intitulée *Impact d'un programme d'entraînement spécifique sur la neuromodulation des douleurs chez les sujets fibromyalgiques (DouFiSport)*. Le CHRU de Brest est le promoteur de cette étude, il en est responsable et en assure l'organisation.

Avant d'accepter de participer à ce projet de recherche, veuillez prendre le temps de lire, de comprendre et de considérer attentivement les renseignements qui suivent. Ce document vous explique le but de ce projet de recherche, ses procédures, avantages, risques et inconvénients. Nous vous invitons à poser toutes les questions que vous jugerez utiles au médecin qui vous présente ce document. Votre décision de participer ou non à cette étude n'affectera en rien la qualité des soins qui vous sont offerts actuellement ou à l'avenir. Si vous décidez de participer à cette recherche, vous devrez signer un formulaire de consentement en fin de ce document. Cette signature confirmera que vous êtes d'accord de participer à cette étude.

### **1- CONTEXTE CLINIQUE**

La fibromyalgie touche aujourd'hui 1,4 à 2,2 % de la population générale. Le principal symptôme est la présence de douleurs diffuses souvent musculaires et articulaires. Nous savons aujourd'hui qu'il existe un dysfonctionnement des contrôles de la douleur chez le sujet fibromyalgique. Nous allons évaluer la neuromodulation de la douleur c'est-à-dire la modification de votre perception de la douleur par l'adaptation de votre système nerveux. Notre hypothèse est qu'un programme d'entraînement spécifique permettrait de rééquilibrer les contrôles de la douleur.

De plus, plusieurs études ont mis en évidence que l'activité physique avait des effets plus importants sur les symptômes de la fibromyalgie que la plupart des traitements pharmacologiques. La société américaine de la douleur (2005), l'association des sociétés médicales scientifiques en Allemagne (2008) et la société canadienne de rhumatologie (2012), recommandent, avec le plus haut grade, la pratique des exercices aérobies chez les patients souffrants de douleurs diffuses.

A ce jour, les thérapeutiques traditionnellement proposées ne permettent pas de traiter les syndromes douloureux diffus, mais permettent simplement une amélioration temporaire des symptômes.

**Paraphe Investigateur**

**Paraphe Volontaire**



## 2- OBJECTIF

Le but de cette étude est d'obtenir grâce à un programme d'entraînement spécifique, une réduction (voire la suppression) des douleurs chez les patients souffrants de douleurs diffuses. L'objectif, à terme, serait de proposer une politique de santé publique qui serait systématiquement proposée aux patients en sus des prises en charge globales afin de soigner la fibromyalgie. Il s'agit d'un essai randomisé en simple aveugle (vous ne connaîtrez pas le groupe auquel vous appartenez), comparant un programme d'entraînement actif à un programme contrôle.

Vous êtes une femme et vous souffrez de douleurs diffuses. Vous avez entre 18 et 65 ans, et possédez un certificat d'aptitude au sport, nous vous proposons de participer à l'étude.

## 3- DEROULEMENT DE L'ETUDE

Cette étude se déroule dans le centre d'étude et de traitement de la douleur (CETD) de Brest. Au total 110 femmes souffrant de douleurs diffuses y participeront.

Les participantes seront réparties au hasard dans 2 groupes :

- groupe « entraînement »
- groupe « contrôle »

Les patientes ne seront pas informées du groupe auquel elles appartiennent.

Le groupe contrôle est un programme d'entraînement encadré par des kinésithérapeutes et des professeurs en Activité Physique Adaptée, identique au programme actif dans son suivi, mais dont l'intensité des séances est plus faible.

Le programme d'entraînement est prévu sur deux ans. La fréquence, la durée, le suivi et l'encadrement des séances sont identiques pour les 2 groupes. Seule l'intensité des exercices demandés sera modifiée entre le groupe « entraînement » et le groupe « contrôle ».

Votre participation consistera à suivre un programme d'entraînement spécifique, encadré et individualisé pendant 2 ans et à vous présenter à 4 visites. Les visites sont prévues **au service des explorations fonctionnelles (adresse)**

### **L'entraînement :**

Le programme d'entraînement consiste en **3 séances de 45 minutes d'activité physique par semaine durant 2 ans**. L'intensité des exercices est initialement très faible et sera progressivement augmentée en fonction de vos capacités et de votre tolérance à l'effort.

Durant les 6 à 9 premiers mois, il vous sera demandé de réaliser chaque semaine, deux séances d'entraînement individuelles, encadrées par un kinésithérapeute à son cabinet, et une séance en autonomie à domicile, en extérieur ou en club de sport. Le kinésithérapeute est un kinésithérapeute libéral, spécialisé en réentraînement à l'effort et spécifiquement formé à l'étude par l'équipe investigatrice. Il encadrera vos gestes sportifs, vous donnera les conseils adaptés à votre posture et lors des étirements. Les coordonnées du kinésithérapeute et les horaires de vos séances d'entraînement vous seront transmis lors des visites d'évaluation.

Une montre cardiofréquencemètre vous sera donnée afin que vous puissiez mesurer vous-même, l'intensité de votre effort.

Après cette période de 6 à 9 mois, vous réaliserez un test d'effort maximal afin d'évaluer votre capacité physique et d'adapter avec plus de précision vos séances d'entraînement. Ce test aura lieu.....

Adresse du service (CHRU de Brest) et sera réalisé par un cardiologue.

Les mois suivants et jusqu'à la fin de l'étude (2 ans), il vous sera demandé de réaliser une séance d'entraînement en petit groupe (5 à 6 personnes), encadré par un professeur en Activité Physique Adaptée (APA) spécifiquement formé, et deux séances en autonomie à domicile, en extérieur ou en club de sport. Cet entraînement aura lieu dans une salle de sport spécialisée dans le réentraînement à l'effort. Votre professeur en APA sera spécifiquement formé

1 par l'équipe investigatrice. Il encadrera vos gestes sportifs, vous donnera les conseils adaptés à votre posture et lors  
2 des étirements.  
3

4  
5 Pour le suivi de votre entraînement, vous recevrez un appel téléphonique chaque semaine durant les 3 premiers  
6 mois, puis un appel téléphonique tous les 15 jours durant les mois suivants et jusqu'à la fin de l'étude. Cet appel  
7 permettra de suivre votre entraînement, et si nécessaire de vous motiver.

8 Pour le suivi de votre progression un test de marche de 6 minutes (TM6) sera réalisé par le kinésithérapeute puis  
9 par le professeur en APA tous les 6 mois. Il vous sera simplement demandé de marcher la distance la plus grande  
10 durant 6 minutes.

11 Vous recevrez en sus du programme d'entraînement, une prise en charge multidisciplinaire habituelle, biologique  
12 (traitements médicamenteux inchangés), un suivi psychologique et une prise en charge par une assistante sociale au  
13 besoin, au centre d'étude et de traitement de la douleur (CETD) dans lequel vous êtes suivi.

#### 14 **Les Visites :**

##### 15 - Première visite (durée approximative 1 heure) :

16 Cette visite consistera en un entretien d'une heure environ au cours duquel nous recueillerons vos données  
17 démographiques (âge, niveau d'éducation, profession). Vous complétez 5 questionnaires (QDSA, HADS, FIQ,  
18 IQSP, PSS) portant sur votre douleur et votre sensibilité, l'impact de la fibromyalgie sur vous, votre niveau  
19 d'anxiété (absent, faible, élevé), votre stress et la qualité de votre sommeil, ainsi que 2 échelles d'évaluation de la  
20 douleur (EVA et EVS). Nous compléterons ensemble un questionnaire portant sur vos activités physiques des 7  
21 derniers jours (IPAQ) et mesurerons votre seuil douloureux à la pression (PPT) à l'aide d'un algomètre à pression.  
22 L'algomètre applique une pression croissante sur un point gâchette (Les points gâchettes - "trigger points" sont des  
23 points à partir desquels la douleur se déclenche lors du mouvement ou de la palpation). La pression est arrêtée dès  
24 l'instant où vous ressentirez une douleur.  
25

26 A l'issue de cette visite, il vous sera remis un kit salivaire afin de mesurer le taux de cortisol (hormone qui joue un  
27 rôle de régulation de l'organisme face au stress) et le débit salivaire. Vous réaliserez ce test salivaire le matin de la  
28 visite suivante. Cette seconde visite sera programmée +/- 7 jours après la première visite.  
29

##### 30 - Deuxième visite (durée approximative 2 heures) :


31 Le matin de cette 2<sup>ème</sup> visite, vous réaliserez vous-même à votre domicile, deux prélèvements salivaires à l'aide du  
32 kit remis lors de la visite précédente. Il vous faudra cracher dans le kit à votre réveil pendant 2 minutes, puis 30  
33 minutes après votre lever pendant 2 minutes également. Ces prélèvements salivaires vont permettre de mesurer  
34 votre taux de cortisol salivaire et le débit salivaire.  
35

36 Avant de commencer l'entraînement au CHU, nous procéderons au test d'évaluation de la douleur de deux heures  
37 environ. Ce test consiste à placer sur votre avant bras droit une sonde thermique nommée thermode (cf. figure ci-  
38 dessous), qui diffusera une chaleur chaude pendant 2 minutes. Cette chaleur aura été déterminée au préalable pour  
39 qu'elle atteigne le seuil d'une douleur modérée (inférieure ou égale à 5 sur une échelle comprise entre 0 et 10).  
40 Nous évaluerons l'intensité de votre douleur en continu à l'aide d'une échelle d'évaluation électronique de la  
41 douleur EVA. Puis, nous plongerons votre avant bras gauche pendant 2 minutes dans un bain d'eau froide à 12°C.  
42 Nous évaluerons de nouveau l'intensité de votre douleur en continu. Enfin, nous évaluerons à nouveau pendant 2  
43 minutes votre douleur à la chaleur par la sonde thermique sur votre bras droit. Avant le test de la thermode, la  
44 pression artérielle et la fréquence cardiaque seront enregistrés.  
45

46 Avant votre retour à votre domicile, nous vous proposerons une dernière entrevue de 10 minutes, selon vos attentes,  
47 afin d'échanger sur l'étude, les ressentis et vos questionnements. Vous retournerez à votre domicile dès que vous le  
48 souhaitez.

49 Les coordonnées de votre kinésithérapeute, ainsi que les horaires de vos séances d'entraînement vous seront  
50 transmises.  
51

52 Des kits de prélèvement salivaire, ainsi que les auto-questionnaires, vous seront remis pour la visite suivante.  
53



A l'issue de cette deuxième visite, vous serez répartie au hasard dans le groupe « entraînement » ou dans le groupe « contrôle ». Vous ne connaîtrez pas le groupe dans lequel vous êtes situé.

Vous commencerez vos séances d'entraînement, encadrées par votre kinésithérapeute, dans la semaine suivant cette seconde visite.

- Troisième visite (durée approximative 2 heures 30 min) :

Cette visite aura lieu après 6 à 9 mois d'entraînement. Un membre de l'équipe investigatrice vous appellera pour fixer la date et l'horaire de cette visite. Elle consistera en un entretien d'une heure, puis à l'enregistrement des neurophysiologiques d'une durée de deux heures.

Le matin de cette 3<sup>ème</sup> visite, vous réaliserez vous-même à votre domicile, deux prélèvements salivaires à l'aide du kit remis lors de la visite précédente. Il vous faudra cracher dans le kit à votre réveil pendant 2 minutes, puis 30 minutes après votre lever pendant 2 minutes également. Ces prélèvements salivaires vont permettre de mesurer votre taux de cortisol salivaire et le débit salivaire.

Au cours de l'entretien (60 min), vous complétez les questionnaires portant sur votre douleur et votre sensibilité, l'impact de la fibromyalgie sur vous, votre niveau d'anxiété (absent, faible, élevé), votre stress et la qualité de votre sommeil ainsi qu'une échelle d'évaluation de la douleur (EVA).

Si vous le souhaitez, vous aurez la possibilité de remplir ces auto-questionnaires chez vous lors de la semaine précédent cette visite. Si vous le préférez, ces auto-questionnaires pourront être remplis directement sur place, lors de cette troisième visite, avec l'aide d'un membre de l'équipe investigatrice. Nous compléterons ensemble le questionnaire concernant votre activité physique (IPAQ) et nous mesurerons votre seuil de douleur à la pression à l'aide d'un algomètre à pression (PPT).

Puis nous procéderons au deuxième test d'évaluation de la douleur (test de la thermode) (90 min). Cette évaluation est en tout point identique à celle de la visite précédente. Les mêmes évaluations complémentaires seront réalisées : prélèvement salivaire le matin, ressenti douloureux avant le test de la thermode et enregistrement de la pression artérielle et de la fréquence cardiaque avant le test de la thermode.

1  
2 Avant votre retour à votre domicile, nous vous proposerons une dernière entrevue de 10 minutes, selon vos attentes,  
3 afin d'échanger sur l'étude, les ressentis et vos questionnements. Vous retournerez à votre domicile dès que vous le  
4 souhaitez.

5  
6 En fonction de vos capacités physiques et de la tolérance à l'effort, le kinésithérapeute assurant l'encadrement de  
7 l'entraînement décidera de votre poursuite à la deuxième partie de l'étude. Si vous ne poursuivez pas cette  
8 deuxième partie, vous continuerez votre prise en charge habituelle.

9  
10 Dans quinzaine de jours suivant cette visite, les patientes des 2 groupes réaliseront un test d'effort maximal sur  
11 ergocycle dans le service de médecine du sport du CHRU de Brest, afin d'adapter l'intensité des séances  
12 d'entraînement.

13  
14 Les coordonnées de votre professeur en APA, ainsi que les horaires de vos séances d'entraînement vous seront  
15 transmises. Vous commencerez vos séances d'entraînement, encadrées par votre professeur en APA, dans les 7  
16 jours suivant cette troisième visite.

17  
18 - Quatrième visite (durée approximative 2 heures) :

19 Cette dernière visite aura lieu après les deux ans d'entraînement. Un membre de l'équipe investigatrice vous  
20 appellera pour fixer la date et l'horaire de cette visite.

21 Dans le mois précédent cette visite, vous recevrez par voie postale les kits de prélèvements salivaires, ainsi que les  
22 auto-questionnaires.

23  
24 Le matin de cette 4<sup>ème</sup> visite, vous réaliserez vous-même à votre domicile, deux prélèvements salivaires à l'aide du  
25 kit remis lors de la visite précédente. Il vous faudra cracher dans le kit à votre réveil pendant 2 min, puis 30 minutes  
26 après votre lever pendant 2 min également. Ces prélèvements salivaires vont permettre de mesurer votre taux de  
27 cortisol salivaire et le débit salivaire.

28  
29 Comme lors de la visite précédente, elle consistera en un entretien d'une heure au cours duquel vous complétez  
30 les 5 questionnaires portant sur votre douleur et votre sensibilité, l'impact de la fibromyalgie sur vous, votre niveau  
31 d'anxiété (absent, faible, élevé), votre stress et la qualité de votre sommeil, ainsi que 2 échelles d'évaluation de la  
32 douleur (EVA et EVS). Si vous le souhaitez, vous aurez la possibilité de remplir ces auto-questionnaires chez vous  
33 lors de la semaine précédente cette visite. Si vous le préférez, ces auto-questionnaires pourront être remplis  
34 directement sur place, lors de cette quatrième visite, avec l'aide d'un membre de l'équipe investigatrice. Nous  
35 compléterons ensemble le questionnaire concernant votre activité physique (IPAQ) et nous mesurerons votre seuil  
36 de douleur à la pression à l'aide d'un algomètre à pression (PPT).

37  
38 Puis nous procéderons au troisième et dernier test d'évaluation de la douleur (test de la thermode) d'une durée de  
39 une heure et 30 minutes. Cette évaluation est en tout point identique à celle des deux visites précédentes. Les  
40 mêmes évaluations complémentaires seront réalisées : prélèvement salivaire le matin, ressentie douloureux avant le  
41 test de la thermode et enregistrement de la pression artérielle et de la fréquence cardiaque avant le test de la  
42 thermode.

43  
44 **4- BENEFCES**

45 Votre participation à cette recherche a pour but d'améliorer la prise en charge de la douleur des patients souffrants  
46 de douleurs diffuses, voire de proposer une option thérapeutique pour ces patients. Votre participation a également  
47 pour but de mieux comprendre les mécanismes physiopathologiques à l'origine des douleurs diffuses.

48  
49 A titre individuel, les bénéfices attendus sont une réduction (voire la suppression) des douleurs, une amélioration de  
50 la qualité de vie et une amélioration du sommeil.

51  
52 A cela, s'ajoute également les bénéfices reconnus de la pratique sportive sur le maintien de la santé : prévention du  
53 surpoids et de l'obésité, diminution du stress oxydant, prévention des pathologies cardiovasculaires, réduction des  
54 dysfonctions métaboliques, évacuation du stress, prévention des cancers...

## 5- RISQUES

Les risques de l'étude sont ceux liés à la pratique sportive. Un bilan cardiovasculaire sera réalisé avant de débiter l'entraînement. D'autre part, cette pratique sera encadrée tout au long de l'étude par un kinésithérapeute puis par un professeur en APA, afin de limiter les risques de blessures.

Les évaluations mises en place vont induire une douleur expérimentale qualifiée de modérée, aiguë et temporaire. Elles n'entraîneront aucune lésion de l'organisme. Cette intensité de douleur permet d'induire une sensation douloureuse suffisante mais non excessive et de mobiliser l'ensemble des mécanismes du système douloureux. La sensation ressentie est d'une part ponctuelle et disparaît dès l'arrêt de la stimulation thermique. Différentes études ont déjà utilisées cette méthode et aucun effet secondaire n'a été relevé. Les risques sont donc mineurs et ne dépasseront pas le temps imparti au recueil des données neurophysiologiques. Par ailleurs, vous aurez la possibilité de mettre fin à la stimulation dès que vous le souhaitez. Si toutefois la douleur ressentie est persistante ou jugée trop intense, l'étude est arrêtée et le médecin qui vous suit pourra vous administrer un antalgique adapté à la douleur (palier 1 ou 2) selon son appréciation.

Le risque psychologique de ce protocole est que vous vous sentiez découragée par votre incapacité à maintenir un effort physique. Afin d'éviter cette situation, le programme d'entraînement a été conçu pour que la progression soit individuellement adaptée avec des objectifs à la séance, à moyen et à long terme, et ce programme est accompagné par un kinésithérapeute, puis par un professeur en APA.

## 6- PARTICIPATION VOLONTAIRE

Votre participation à cette étude est entièrement volontaire. Vous êtes libre de refuser d'y participer ainsi que de mettre un terme à votre participation à n'importe quel moment, sans encourir aucune responsabilité ni aucun préjudice. Dans ce cas, vous devez informer le médecin qui vous suit de votre décision.

Dans le cas où vous retiriez votre consentement, nous effectuerons un traitement informatique de vos données personnelles sauf opposition écrite de votre part.

Durant l'étude, vous serez avertie par votre médecin, si des faits nouveaux pouvaient affecter votre volonté de participer à l'étude.

Les Autorités de Santé, votre médecin investigateur ou le promoteur peuvent décider de mettre un terme à votre participation à l'étude à n'importe quel moment sans votre consentement préalable. Si cela devait se produire, vous en serez averti et les raisons vous seraient expliquées.

D'autre part, pour votre participation complète à cette étude, une indemnisation des frais de déplacements est prévue, pour les visites à J0, 1 an et à 2 ans, aux frais réels dans la limite de 50 euros par visite.

## 7- OBTENTION D'INFORMATIONS COMPLEMENTAIRES

Si vous le souhaitez, le Docteur [.....], que vous pourrez joindre au numéro de téléphone suivant [.....], pourra répondre, aux horaires ouvrés, à toutes vos questions concernant cette étude.

A l'issue de l'étude, et à votre demande, vous pourrez être informée des résultats globaux de la recherche par votre médecin investigateur.

## 8- CONFIDENTIALITE ET UTILISATION DES DONNEES MEDICALES

Dans le cadre de la recherche biomédicale à laquelle le CHRU de Brest et votre médecin vous propose de participer, un traitement de vos données personnelles va être mis en œuvre pour permettre d'analyser les résultats de la recherche au regard de l'objectif de cette dernière, qui vous a été présenté. A cette fin, les données médicales recueillies, y compris tout questionnaire et les données relatives à vos habitudes de vie vous concernant, seront transmises au Promoteur de la recherche. Ces données seront identifiées par un numéro de code et vos initiales.

1  
2 Le personnel impliqué dans l'étude est soumis au secret professionnel, tout comme votre médecin traitant. Ces  
3 données pourront également, dans des conditions assurant leur confidentialité, être transmises aux autorités de santé  
4 françaises.

5  
6 Conformément aux dispositions de loi relative à l'informatique aux fichiers et aux libertés (loi du 6 janvier 1978),  
7 vous disposez d'un droit d'accès et de rectification. Vous disposez également d'un droit d'opposition à la  
8 transmission des données couvertes par le secret professionnel susceptibles d'être utilisées dans le cadre de cette  
9 recherche et d'être traitées.

10 Vous pouvez également accéder directement ou par l'intermédiaire d'un médecin de votre choix à l'ensemble de  
11 vos données médicales en application des dispositions de l'article L 1111-7 du Code de la Santé Publique. Ces  
12 droits s'exercent auprès du médecin qui vous suit dans le cadre de la recherche et qui connaît votre identité.

### 13 14 **9- ASSURANCE**

15  
16 Un contrat d'assurance HDI Gerling – Tour Opus 12,77, Esplanade de la Défense – 92914 Paris la Défense,  
17 n° 0101214214002-150015-10998 a été souscrit par le promoteur de l'essai, le CHRU de Brest, pour couvrir les  
18 risques liés à cette recherche. Cette assurance couvre la responsabilité du promoteur en tant que promoteur d'une  
19 recherche biomédicale et celle de tout autre intervenant, en accord avec l'article L 1121-7 du Code de la Santé  
20 Publique.

### 21 22 **10- AVIS FAVORABLE DU CPP**

23  
24 Conformément à la loi n°2004-806 du 9 août 2004 relative à la politique de santé publique, le Comité de Protection  
25 des Personnes Ouest VI a étudié ce projet de recherche et a émis un avis favorable à sa réalisation le 02 Décembre  
26 2014.

### 27 28 **11- AUTORISATION DE L'ANSM**

29  
30 Conformément à la loi n°2004-806 du 9 août 2004 relative à la politique de santé publique, l'ANSM a étudié ce  
31 projet de recherche et a émis une autorisation à sa réalisation le 25 Juin 2014.



**FORMULAIRE DE CONSENTEMENT**

**DOUFISPORT : IMPACT D'UN PROGRAMME D'ENTRAINEMENT SPECIFIQUE SUR LA NEUROMODULATION DES DOULEURS CHEZ LES SUJETS FIBROMYALGIQUES**

*Promoteur : CHRU de Brest – 2 Avenue Foch – 29609 Brest Cedex.*

**De :** Mme : .....  
 Adresse : .....

**Le Docteur** ..... (Tél : \_\_ / \_\_ / \_\_ / \_\_ / \_\_ / \_\_)  
 Du Centre de (adresse)..... **m'a proposé de participer à l'étude clinique DouFiSport. Je suis informée que la durée de l'étude est prévue sur 2 ans** Je pourrai à tout moment, lui demander des informations complémentaires. J'ai lu et compris la notice d'information, dont j'ai obtenu la copie. Le médecin investigateur a répondu à toutes mes questions concernant l'étude.

J'ai eu le temps nécessaire pour réfléchir à mon implication dans cette étude, et je suis consciente que ma participation est entièrement volontaire et que cette étude n'engendrera aucun surcoût à ma charge. Je peux à tout moment décider de quitter l'étude sans motiver ma décision et sans qu'elle n'entraîne de conséquences dans la qualité de ma prise en charge.

J'ai compris que les données collectées à l'occasion de la recherche seront protégées dans le respect de la confidentialité. Elles pourront uniquement être consultées par les personnes soumises au secret professionnel appartenant à l'équipe du médecin investigateur, mandatées par le promoteur ou les représentants des autorités de santé.

J'accepte le traitement informatisé des données à caractère personnel me concernant dans les conditions prévues par la loi Informatique et liberté. J'ai été informé de mon droit d'accès et de rectification des données me concernant.

Je certifie être affiliée au régime de la Sécurité Sociale.

J'ai été informée que, conformément à la réglementation sur les études cliniques, le CPP Ouest VI a rendu un avis favorable pour la réalisation de cette recherche et que l'ANSM l'a également autorisée.

Fait en deux exemplaires originaux

À ....., le .....

Nom, prénom de l'investigateur :

Nom, prénom du volontaire :

Signature :

Signature :

**Un exemplaire cosigné pour le volontaire, un exemplaire cosigné pour l'investigateur et une copie pour le promoteur**



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description
<b>Administrative information</b>		
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry
	2b	All items from the World Health Organization Trial Registration Data Set
Protocol version	3	Date and version identifier
Funding	4	Sources and types of financial, material, and other support
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors
	5b	Name and contact information for the trial sponsor
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)
<b>Introduction</b>		
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention
	6b	Explanation for choice of comparators
Objectives	7	Specific objectives or hypotheses
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)



## Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size

## Methods: Assignment of interventions (for controlled trials)

### Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions
---------------------	-----	--

1			
2	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central
3	concealment		telephone; sequentially numbered, opaque, sealed envelopes),
4	mechanism		describing any steps to conceal the sequence until interventions are
5			assigned
6			
7	Implementation	16c	Who will generate the allocation sequence, who will enrol participants,
8			and who will assign participants to interventions
9			
10	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial
11	(masking)		participants, care providers, outcome assessors, data analysts), and
12			how
13			
14		17b	If blinded, circumstances under which unblinding is permissible, and
15			procedure for revealing a participant's allocated intervention during
16			the trial
17			

### 18 **Methods: Data collection, management, and analysis**

19			
20	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other
21	methods		trial data, including any related processes to promote data quality (eg,
22			duplicate measurements, training of assessors) and a description of
23			study instruments (eg, questionnaires, laboratory tests) along with
24			their reliability and validity, if known. Reference to where data
25			collection forms can be found, if not in the protocol
26			
27			
28		18b	Plans to promote participant retention and complete follow-up,
29			including list of any outcome data to be collected for participants who
30			discontinue or deviate from intervention protocols
31			
32	Data	19	Plans for data entry, coding, security, and storage, including any
33	management		related processes to promote data quality (eg, double data entry;
34			range checks for data values). Reference to where details of data
35			management procedures can be found, if not in the protocol
36			
37	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.
38	methods		Reference to where other details of the statistical analysis plan can be
39			found, if not in the protocol
40			
41			
42		20b	Methods for any additional analyses (eg, subgroup and adjusted
43			analyses)
44			
45		20c	Definition of analysis population relating to protocol non-adherence
46			(eg, as randomised analysis), and any statistical methods to handle
47			missing data (eg, multiple imputation)
48			

### 49 **Methods: Monitoring**

50			
51	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role
52			and reporting structure; statement of whether it is independent from
53			the sponsor and competing interests; and reference to where further
54			details about its charter can be found, if not in the protocol.
55			Alternatively, an explanation of why a DMC is not needed
56			
57			
58			
59			
60			

	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor

### **Ethics and dissemination**

Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions
	31b	Authorship eligibility guidelines and any intended use of professional writers
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code

## Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable

---

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description
<b>Administrative information</b>		
Title	1	Impact of a specific training program on the neuromodulation of pain in fibromyalgia women (DouFiSport): a 24-month, controlled, randomised, double-blinded protocol.
Trial registration	2a	NCT02486965
Protocol version	3	version number 5.0 of 21/06/2016
Funding	4	This work is supported by the French Ministry of Health (Programme Hospitalier de Recherche Clinique Interrégional 2014) PHRCi 13-100

Roles and responsibilities

5a Names, affiliations, and roles of protocol contributors:

Anaïs Le Fur-Bonnabesse<sup>1,2,3</sup>, investigator  
 Mathilde Cabon<sup>1</sup>, investigator  
 Gildas L'Heveder<sup>4</sup>, co-ordinating investigator  
 Aurélie Kermarrec<sup>5</sup>, coaching staff (physiotherapist)  
 Bertrand Quinio<sup>3</sup>, scientific associate  
 Alain Woda<sup>6</sup>, scientific associate  
 Serge Marchand<sup>7</sup>, scientific associate  
 Amandine Dubois<sup>8,9,1</sup>, investigator  
 Marie-Agnès Giroux-Metges<sup>10,11</sup>, scientific associate  
 Fabrice Rannou<sup>10,11</sup> scientific associate  
 Laurent Misery<sup>1</sup>, scientific associate  
 Céline Bodéré<sup>1,2,3</sup>, principal investigator, scientific responsible

1 Laboratory of Interactions Keratinocytes-Neurons, EA4685, Faculty of Medicine and Health Sciences, University of Western Brittany (UBO), Brest, France

2 Dental faculty, University of Western Brittany (UBO), Brest, France

3 Assessment and treatment center of pain, University Hospital of Brest, Brest, France

4 Neurological functional explorations, University Hospital of Brest, Brest, France.

5 Training institute of physiotherapy University Hospital of Brest, Brest, France.

6 University Clermont Auvergne, CROC and Teaching Hospital EA3847, Odontology Department, Clermont-Ferrand, France

7 Department of surgery, Faculty of medicine, University of Sherbrooke, Sherbrooke, Canada

8 Laboratory of psychology: Cognition, Behaviour, Communication (LP3C), EA1285, Rennes, France

9 Department of Psychology, University of Western Brittany (UBO), Brest, France.

10 ORPHY, Optimisation of Physiological Regulations, EA4324, Faculty of Medicine and Health Sciences, University of Western Brittany (UBO), Brest, France

11 Respiratory Functional Exploration Unit, University Hospital of Brest, Brest, France.

CB initiated the idea for the project.

CB and ALFB developed the study design.

MC, GL, BQ, AK, AW, SM, MAGM, FR, LM and AD provided advice for the study design.

GL and CB are responsible for supervision of project. CB will conduct the recruitment.

AK will conduct the training programme.

CB, ALFB and MC will conduct the outcomes assessments and will contribute to the analysis and interpretation of the data.

Both authors will contribute to the analyses and interpretation of the data.

ALFB, CB and MC wrote early drafts of the manuscript.

All authors approved the final version of this protocol.

1  
2 5b Name and contact information for the trial sponsor:  
3

4 Rémi BRAJEUL, directeur adjoint  
5 Délégation à la Recherche Clinique et à l'Innovation (DRCI)  
6 CHRU de Brest  
7 2 Avenue Foch  
8 29609 Brest Cedex  
9 France  
10

11  
12  
13 5c Role of study sponsor and funders :  
14

- 15 - Evaluation of serious adverse events
  - 16 - Transmission of annual safety reports
  - 17 - Quality assurance and monitoring activities
  - 18 - Approval of any amendment of the protocol
- 19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Background and 6a Fibromyalgia affects 1.4 to 2.2% of the general population concerning  
2 rationale 6a predominately women (more than 80% of subjects). This syndrome is  
3 characterised by extensive and diffuse pain, mainly muscular and  
4 articular, impairing the functional abilities of the subjects. The  
5 symptoms most frequently described by fibromyalgia patients are  
6 chronic fatigue, sleep disorders, cognitive disorders and emotional  
7 disturbances (3,4). This symptomatology leads to a serious  
8 deterioration in quality of life, sometimes with a physical disability  
9 leading to social isolation and difficulties in staying in employment  
10 (recurrent work stoppages).  
11 The diagnosis is based on the symptoms and their severity as  
12 described by the patients (5–8). Currently, there is no etiological  
13 treatment for fibromyalgia syndrome. The treatments are therefore  
14 only symptomatic.  
15  
16  
17  
18

### 19 **Physiopathology of fibromyalgia**

20 The mechanisms of dysfunctional pain, without any identifiable organic  
21 lesions, are mostly central (1) and related to dysfunction of the stress  
22 axis (autonomic nervous system and corticotropic axis) (9–11).  
23 At rest, fibromyalgia patients showed an increased sympathetic  
24 response and decreased parasympathetic tone (12,13). This  
25 neurovegetative dystonia is a marker of dysfunction of the stress axis  
26 (14).  
27 Malfunctions of the corticotropic axis in fibromyalgia have been  
28 described multiple times, also marking the dysfunction of the stress  
29 axis. But the form taken by this dysfunction differs according to the  
30 different studies (15–19). The variability of salivary cortisol in response  
31 to stress reflects that of plasma free cortisol. Salivary cortisol is  
32 therefore a method of choice in experimental stress studies (20).  
33 Whatever form they take, these dysfunctions compromise the body's  
34 adaptation to daily stressful stimuli.  
35  
36  
37  
38

39 Studies show that this deficit of the stress axis (neurovegetative  
40 dystonia and dysfunctional corticotropic axis) is concurrent with  
41 fibromyalgia (21) and associated with alteration of pain control (9–11).  
42 Pain control system and stress axis have close anatomical and  
43 functional links. Nociceptive, neurovegetative and corticotropic  
44 systems interact with the central nervous system. The central  
45 neuromediators implicated in the regulation of the stress axis are  
46 mostly common with those of the pain neuromodulation (endogenous  
47 opioids, norepinephrine, serotonin, etc.).  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



### Elite athlete's overtraining syndrome: model of stress axis dysfunction

An overtraining elite athlete may be considered as a model of dysfunction of the stress axis associated with neurovegetative dystonia. The physical and psychological effort of training is known to induce stress. High-level athletes could present an overtraining syndrome when adaptation limits of the stress axis are reached. This stress-induced phenomenon corresponds to an imbalance between training quantity and recovery. Overtrained athletes present a deconditioning syndrome close to fibromyalgia symptoms (chronic pain, sleep disorders, neurovegetative dystonia, etc.) (22–26).

### Physical activity and fibromyalgia

Most studies have shown that physical activity is more efficient compared to pharmacological treatments on fibromyalgia symptoms (27,28). Literature reviews and meta-analyses highly support the benefits of physical training in fibromyalgia patients (decreased pain and depression and improvement in overall health and physical abilities) (29)(30). Practice of aerobic exercise in fibromyalgia patients is strongly recommended by The American Pain Society (31), the Association of Medical Scientific Societies in Germany (32), the Canadian Rheumatology Association (5) and the European League Against Rheumatism (EULAR) (33). Physical exercise is the first-line treatment recommended in fibromyalgia. However there is still no consensus on the modalities of these types of training (frequency, duration, and intensity). Currently, the mechanisms underlying those specific training effects have to be defined.

The steady physical activity rebalancing autonomic system is associated with cardiovascular benefits. Fundamental endurance increases parasympathetic tone and decrease sympathetic response (34–37). Thus, strategies to rebalance the autonomic system are the most promising therapies for fibromyalgia (13,36,37).

In this study, we propose to validate a therapeutic alternative that aims to treat fibromyalgia by rebalancing the stress axis. This treatment consists of a specific supervised and individualised training program, over 2 years. This training protocol is individually adjusted in order to rebalance the neurovegetative system (parasympathetic and sympathetic). Central neuroplasticity induced by training should regulate endogenous pain control mechanisms.

Objectives 7 The *main objective* is to assess the effectiveness of a specific training program on endogenous pain controls in fibromyalgia patients. The *secondary objectives* are to rebalance the autonomic nervous system and the corticotropic axis, to improve life and sleep quality and to reintegrate patients into society and work.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Trial design	8	This randomised double-blinded trial will compare an "active" program to a "control" program in fibromyalgia patients.
--------------	---	--

### Methods: Participants, interventions, and outcomes

Study setting	9	Patients will be recruited at the pain center of the university hospital of Brest on the basis of general criteria. Patients should follow a re-exercise program for 24 months. The assessments will take place (i) before, (ii) between 6 to 9 months (depending the training level) and (iii) at the end of the training (24 months), in the neurological functional explorations department of the university hospital of Brest (France).
---------------	---	--

Eligibility criteria	10	The inclusion criteria are: female subjects; aged of 18 to 65 years; with a diagnosis of fibromyalgia clearly established according to the criteria of the American College of Rheumatology (ACR) 2010; with a body mass index (BMI) between 18.5 and 29.9kg/m <sup>2</sup> ; spontaneous pain intensity higher than 3/10 on a visual analog scale (VAS); pain experienced at least 3 days a week; pain caused by palpation equal to or higher than 4/10 on a VAS.
----------------------	----	--

The non-inclusion criteria are: patients with a systemic disease (treated or not) generating pain of the musculoskeletal system; presenting pain other than fibromyalgia; presenting a contraindication to physical activity; having any active pathology; having modified in the last 2 months any pharmacological treatment; having a psychiatric diagnosis; taking drugs that affect cortisol secretion (decrease or increase); non-cooperating.

1 Interventions 11a The training program is planned over two years (24 months) for both  
2 groups (active/control). A minimum of 4 to 6 weeks is needed to  
3 observe a decrease in symptoms (38). This two-year duration is the  
4 minimum average training time (depending on the individual progress  
5 of each patient), necessary to regain central neuroplasticity sufficient  
6 to put back into operation diffuse noxious inhibitory controls (DNIC)  
7 and neurovegetative system (39).  
8 The frequency, intensity, and duration of these training sessions are  
9 based upon the results of a preliminary study. Pain was significantly  
10 reduced and symptoms, such as quality of life, sleep quality, anxiety,  
11 were also highly improved in subjects undergoing this specific training  
12 after 5 years (39). The American Pain Society recommends an  
13 intensity of 60 to 70% of the age-adjusted maximum heart rate  
14 (HRmax). At the early stage, the intensity and duration of the training  
15 sessions will be adapted to the physical condition of each subject. In  
16 order to promote adherence of our patients and to limit pain  
17 exacerbation, exercise intensity will start very low and then gradually  
18 increase to reach the neurovegetative goal (31)(40).  
19  
20  
21  
22  
23

#### **Active training group:**

*The first 6 to 9 months:* fundamental endurance training.

Subjects will perform 3 sessions per week of 45 minutes of fundamental endurance (moderate-intensity continuous training MICT: 60% HRmax), including 2 sessions supervised by a physiotherapist and 1 independent session.

*From 6-9 months (according to the rhythm, abilities, and limits) to 24 months:* Patients will begin the second stage of training: 3 sessions per week of 45 minutes each (moderate-intensity continuous training MICT (60% HRmax) and high-intensity interval training HIIT) with 1 supervised session and 2 independent sessions. When the patient reaches the initial HR goal, "fundamental endurance" will be associated with "interval training" at a high frequency intensity. HIIT will consist of 5 stages of 1 to 4 minutes at 85-90% HRmax (80-85%  $\dot{V}O_2$ max), interspersed by 1 to 4 minutes of active recovery at 60-75% HRmax (50-70%  $\dot{V}O_2$ max). Intensity will be assessed objectively using a heart rate monitor (FT2, Polar). □At baseline, Tanaka's age-based prediction equation ( $208-0.7 \times \text{age}$ ) will calculate HRmax. After 6-9 months of training, a maximal-effort graded exercise test will determine HRmax and  $\dot{V}O_2$ max for each patient.

#### **Control group:**

Patients will perform the same infra active training (low-intensity continuous training: LICT <50% HRmax) over two years. Supervision, monitoring, and frequency of sessions (3 x 45 minutes per week) in both groups will be equivalent.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant: If a patient cannot achieve the specific training requested after 9 months of study, the patient will not complete the second phase of training.
- 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence: Patients will be contacted to record progress, difficulties and if necessary, to encourage them to adhere to their program. These calls will improve the compliance and will limit patients lost to follow-up.  
Patients will perform a 6-minute walk test (6MWT) every 6 months (with physiotherapist).
- 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial: This specific protocol will be associated with psychotherapeutic approaches. In addition to the training program, multidisciplinary bio-psycho-social cares will be given in the pain center of the university hospital of Brest (France).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Outcomes 12 **Primary outcomes:** In order to assess endogenous pain mechanisms, such as diffuse noxious inhibitory controls (DNIC), temporal summation (TS) and perception of pain, we will use an experimental method developed by Tousignant-Laflamme and Marchand (2008). According to this well-characterised paradigm, we will induce in single session two tonic heat pain stimulations separated by a cold pressor test (1,47–49). The VAS improvements (stimulation test) obtained in the both groups will be compared.


**Secondary outcomes:**  
A simple verbal scale, a visual analog scale, and the Saint Antoine Pain Questionnaire (QDSA), will perform the **assessment of pain**. A **pain quantitative assessment** will be performed with a pressure algometer (pressure pain threshold: PPT).  
Questionnaires will assess **patient anxiodepressive state** (Hospital Anxiety Depression Scale), **the impact of fibromyalgia on daily life** (Fibromyalgia Impact Questionnaire), **sleep quality and quantity** (Pittsburgh Sleep Quality Index), **the level of physical activity and the sedentary lifestyle** (International Physical Activity Questionnaire), **the antecedents of perceived stress** (Perceived Stress Scale).  
**Blood Pressure** (BP) and **Heart Rate** (HR) will be recorded.  
**Corticotropic axis** will be assessed using measurement of salivary cortisol and salivary flow.

Quantitative assessment (salivary cortisol, blood pressure, PPT quantified by pain threshold pressure, questionnaires assessment) will be analysed by comparing the improvements obtained between both groups.

Participant  
timeline

13 The training program is planned over two years (24 months) for both  
groups (active/control). Subjects will perform 3 training sessions per  
week of 45 minutes.  
Patient will participate in 4 visits (1 inclusion visit and 3 assessment  
visits) during these two years.

Figure 1:  
Flow chart  
of  
DouFiSport



1			
2	Sample size	14	Population size is based on an expected difference of 20 points
3			(stimulation test) (1) between the two groups, for a quantitative primary
4			endpoint (delta VAS) of standard deviation equal to 35, and a power
5			set at 80%. Therefore a minimum of 48 subjects per group is required
6			for assessment. In order to take into account loss to follow-up, the
7			sample of 110 subjects, 55 per group will be recruited.
8			
9	Recruitment	15	Patients will be recruited at the pain centre of the university hospital of
10			Brest on the basis of general criteria.
11			

### 12 **Methods: Assignment of interventions (for controlled trials)**

#### 13 Allocation:

14			
15			
16	Sequence	16a	Patients will be randomised at the end of the first stimulation test
17	generation		(second visit: V2), which is just before the initiation of the training. The
18			test is stratified by age and BMI. The cut off is set at 50 years for age
19			and 25kg/m <sup>2</sup> for BMI (two strata [18-25] and ]25-30 []).
20			
21			
22	Allocation	16b	Electronic randomisation via Capture System
23	concealment		
24	mechanism		
25			
26	Implementation	16c	The allocation sequence will generate by the Center of Clinical
27			Investigation (CIC) at the hospital university of Brest (France).
28			The principal investigator will enrol participants, and will assign
29			participants to interventions.
30			
31			
32	Blinding	17a	Who will be blinded after assignment to interventions:
33	(masking)		Patients will be blinded (they will not be informed of their group
34			(active/control)).
35			The investigators, outcome assessors and data analysts will be
36			blinded.
37			
38		17b	If blinded, circumstances under which unblinding is permissible:
39			Due to the nature of the intervention (physical activity protocol), the
40			coaching staff will not be blinded.
41			
42			
43			

### 44 **Methods: Data collection, management, and analysis**



1 Data collection methods 18a Measurements and questionnaires will be carried out (i) at baseline,  
2 (ii) between 6 to 9 months, and (iii) at the end of the 24 months of  
3 training.

#### 4 **Sociodemographic and clinical data**

5 At baseline, data on age, sex, marital status, education level, and  
6 occupation will be collected. Height and weight will be recorded.  
7 Medical background and pain characteristics will be noted. All current  
8 drug and non-drug therapies (including tried and stopped) will also be  
9 collected, as well as their effectiveness on pain.

#### 10 **Questionnaires and pain assessments**

- 11 • The **assessment of pain** will be performed by a simple verbal  
12 scale and using a visual analog scale (VAS). The Saint Antoine  
13 Pain Questionnaire (QDSA) will also assess pain. A **pain**  
14 **quantitative assessment** will be performed with a pressure  
15 algometer (pressure pain threshold: PPT).  
16 • The Hospital Anxiety Depression Scale (HADS) will assess the  
17 **patient anxiodepressive state** (41).  
18 • The Fibromyalgia Impact Questionnaire (FIQ) will assess **the**  
19 **impact of fibromyalgia on daily life** (42).  
20 • The Pittsburgh Sleep Quality Index (PSQI) will assess **sleep**  
21 **quality and quantity** (43,44).  
22 • The International Physical Activity Questionnaire (IPAQ) will  
23 record the **level of physical activity and the sedentary**  
24 **lifestyle**. The French long telephone questionnaire will be used  
25 (45).  
26 • The Perceived Stress Scale (PSS) will assess **the**  
27 **antecedents of perceived stress** (46).

#### 28 **Stimulation test**

29 In order to assess endogenous pain mechanisms, such as diffuse  
30 noxious inhibitory controls (DNIC), temporal summation (TS) and  
31 perception of pain, we will use an experimental method developed by  
32 Tousignant-Laflamme and Marchand (2008) (1,47–49).

33 - **Thermode test or temporal summation test (P1):** a tonic heat  
34 pain will be administered for 2 minutes on the patient's right arm, using  
35 a thermode (CE marking n°226). The starting temperature is 32°C  
36 (skin temperature under normal conditions in temperate room (20-  
37 22°C)) (50) and will quickly reach a fixed value. The experimental  
38 temperature will be individually determined to induce 50/100 on a VAS  
39 and will remain constant during the test period (2 minutes).

40 Throughout this entire period, the patient will evaluate their pain  
41 intensity using a Computerised Visual Analog Scale (CoVAS).

42 - **Cold pressor test (P2):** to elicit a prolonged pain sensation in  
43 order to trigger diffuse noxious inhibitory control (DNIC) (51), the  
44 patient's right arm will be immersed for 2 minutes in a cold water bath  
45 maintained at 12°C. The patient will continuously evaluate their pain  
46 intensity using a CoVAS.

47 Following this cold pressor test, the thermode test will be again  
48 performed (**P3**).

49 Pain difference between the two (P3/P1) tonic heat pain stimulations  
50 will measure DNIC activation and represents pain modulation.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Measurement of salivary cortisol and salivary flow**

Corticotropic axis will be assessed using measurement of salivary cortisol. Cortisol release is pulsatile (10 to 20 peaks per day) and follows a nycthemeral cycle. Maximum cortisol level is reached in the early morning. In the morning of each consultation (at baseline, in the middle and at the end of training), patients will collect salivary sample (i) for 2 minutes, when they wake up and (ii) for 2 minutes, 30 minutes later. The salivary cortisol level is measured in nmol/l. The flow rate is calculated in ml.min<sup>-1</sup>. Samples will be frozen at -20°C. As salivary cortisol is stable, samples can be stored for many weeks in the freezer (52). After completion of all assessment sessions, sample analysis will be completed. To avoid inter-laboratory variation, the same laboratory will assay the samples.

**Recording of Blood Pressure (BP) and Heart Rate (HR)**

After 10 minutes at rest, lying down, BP and HR will be recorded. Then, BP and HR will be measured when the patient stands up and once per minute during 4 minutes when the patient remains standing.

- 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols: To limit dropout, patients will be called to encourage them and to discuss any difficulties. In second stage of training and to limit a possible long-term monotonous effect, physical activity type could be diversified in both groups. The training session will be adapted in the active group (MICT will be associated with HIIT) to reduce sympathetic hyperactivity. In order to improve compliance and long-term achievement of training, the patient may choose the physical activity type performed without supervision. If a patient cannot achieve the specific training requested after 9 months of study, the patient will not complete the second phase of training. Nevertheless, she will carry out all assessment visits. The main analysis will be performed on an intent-to-treat basis.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Data management

19 **Case report forms (CRF):**

All data collected must be recorded in the CRF immediately after the procedure. Each missing data will have to be coded. The researcher will carry out a double data entry. In addition, Checks on the consistency of these data will be instantly carried out.

Data on individuals included in the study will be made anonymous.

Only the first letter of the subject's name, and the first letter of her first name will be recorded, with a specific code number.

**Quality Assurance and Control:**

A researcher commissioned by the study sponsor will ensure proper achievement of the study and, of data collection, recording and, reporting.

**Storage:**

During the study period, documents will be stored in the neurological functional explorations department of the university hospital of Brest. At the end of the study period, all archived documents will be transferred to a centralized archiving site (Central Archives Service - Brest) and, will be placed under the sponsor responsibility for 15 years according to institutional practices.

29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

Statistical methods

20a

*Primary outcome analysis:* The VAS improvements (stimulation test) obtained in the both groups will be compared using the Student's test. If the required normality assumption is not sustainable, a nonparametric Wilcoxon test will be used. An alpha risk of 0.05 will be set as the limit of statistical significance. The main analysis will be performed on an intent-to-treat basis. A complementary analysis using a linear model with adjustment for age and BMI factors will be completed.

*The secondary outcomes* (quantitative: salivary cortisol, blood pressure, PPT quantified by pain threshold pressure, questionnaires assessment) will be analysed in a similar way by comparing the improvements obtained between both groups.

**Methods: Monitoring**

49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Data monitoring

21a

Because of the nature of the study (excluding health product and, duration of the study), a monitoring committee independent from the sponsor will not be constituted.

A researcher commissioned by the study sponsor will ensure proper achievement of the study, and of data collection, recording and reporting.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

21b The study may be stopped early for reasons of safety (in the event of unexpected serious adverse event occurrences), efficacy or futility. The sponsor reserves the right to stop the study at any time, if the desired sample size is not achieved.

## Harms

22 **The investigator** is responsible for recording and reporting all serious adverse events (EvIG) occurring during the entire study period. Regardless of the causal relationship between EvIG and the study, any EvIG will be described on the form dedicated to this matter («EvIG initial report» or «EvIG follow-up report») and will be notified to the sponsor within a time frame of 24 hours after the event occurs.

All other adverse events (non-serious adverse events) will be reported on adverse event form of the CRF. The date of occurrence, description, intensity, duration, treatment, aetiology, accountability and the decisions taken will be specified.

**The sponsor** has to analyse EvIG (the causality of the EvIG and their expected or unexpected character). The sponsor have to report all unexpected EvIG to Eudravigilance (European pharmacovigilance database), the French Health Authorities (ANSM), the Committee for the Protection of Persons (CPP) and, to the investigators. Each year, the sponsor will draft a safety report that will include:

- the list of unexpected and expected EvIG,
- a concise and critical analysis of the safety of patients included in the study.

Each adverse events will be monitored until the it will be completely resolved even if after the study period.

## Auditing

23 A researcher commissioned by the sponsor will audit trial conduct. The investigator and his team undertake to make themselves available during regular Quality Control visits by this researcher. During these visits, informed consent, adherence to study protocol and, CRF data quality, will be reviewed. The investigator undertakes to accept quality control audits carried out by the sponsor, and by the competent authorities.

## Ethics and dissemination

Research ethics approval 24 The Committee for the Protection of Persons West VI approved this study on 02/12/2014.

1			
2	Protocol	25	Important protocol modifications by the investigator (eg, changes to
3	amendments		eligibility criteria, outcomes, analyses) have to be approved by the
4			sponsor. The sponsor must obtain a favourable opinion of the CPP
5			and an authorization of the «Agence nationale de sécurité du
6			médicament et des produits de santé» (ANSM) to enable the
7			application of these amendments. A new consent of the patient
8			participating will be collected if necessary.
9			
10	Consent or assent	26a	Patients will be informed of the objectives, constraints, risks and
11			benefits of the study. Patients will be informed of their rights to refuse
12			to participate or to withdraw from the study at any time. All information
13			will be on information and consent form given to the patient. To be
14			included, patients will sign informed written consent. The investigator
15			will collect free, informed, and written consent of the patient before
16			definitive inclusion in the study.
17			
18			
19		26b	Additional consent provisions for collection and use of participant data
20			and biological specimens in ancillary studies, if applicable: No
21			collection will be formed.
22			
23	Confidentiality	27	Data on individuals included in the study will be made anonymous.
24			Only the first letter of the subject's name, and the first letter of her first
25			name will be recorded, with a specific code number. The investigators
26			will take all necessary precautions to ensure the confidentiality of the
27			information in particular with regard to patient identity.
28			
29			
30	Declaration of	28	None declared.
31	interests		
32			
33	Access to data	29	In accordance with good clinical practice, the sponsor is responsible
34			for seeking the agreement of those involved in this research with a
35			view to ensure direct access to source data, source documents and
36			reports in all research place (particularly during quality control).
37			In accordance with the legislative provisions in force (articles L.1121-3
38			et R.5121-13 of the French Public Health Code), the investigators will
39			be making documents and necessary individual data available to
40			researcher charged with study control and monitoring.
41			
42			
43			
44	Ancillary and	30	Pursuant to the provisions of article L1121-10 of the French Public
45	post-trial care		Health Code, the sponsor (CHRU of Brest) undertakes to take out a
46			civil liability insurance contract.
47			
48	Dissemination	31a	The results of this study will be published in specialised scientific
49	policy		journals. These results will be presented to participants and the public
50			at a free public lecture organised by the health promotion department
51			of the city of Brest. These results will also be presented to healthcare
52			professionals and other relevant groups in pain and/or physical activity
53			congresses. In addition, a doctoral thesis will be carried out on this
54			project.
55			
56			
57			
58			
59			
60			

## Appendices

Informed consent materials	32	See attached documentation
Biological specimens	33	Not applicable.

---

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

## References

1. Tousignant-Laflamme Y, Pagé S, Goffaux P, Marchand S. An experimental model to measure excitatory and inhibitory pain mechanisms in humans. *Brain Res.* 16 sept 2008;1230:73•9.
2. Woda A, L'heveder G, Ouchchane L, Bodéré C. Effect of experimental stress in 2 different pain conditions affecting the facial muscles. *J Pain Off J Am Pain Soc.* mai 2013;14(5):455•66.
3. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. *Arthritis Rheum.* févr 1990;33(2):160•72.
4. Cánovas R, León I, Roldán MD, Astur R, Cimadevilla JM. Virtual reality tasks disclose spatial memory alterations in fibromyalgia. *Rheumatol Oxf Engl.* oct 2009;48(10):1273•8.
5. Fitzcharles M, Shir Y, Ablin JN, Buskila D, Amital H, Henningsen P, et al. Classification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines. *Evid-Based Complement Altern Med ECAM.* 2013;2013:528952.
6. Egloff N, von Känel R, Müller V, Egle UT, Kokinogenis G, Lederbogen S, et al. Implications of proposed fibromyalgia criteria across other functional pain syndromes. *Scand J Rheumatol.* 2015;44(5):416•24.
7. Moyano S, Kilstein JG, Alegre de Miguel C. New diagnostic criteria for fibromyalgia: Here to stay? *Reumatol Clin.* août 2015;11(4):210•4.
8. Wolfe F, Fitzcharles M-A, Goldenberg DL, Häuser W, Katz RL, Mease PJ, et al. Comparison of Physician-Based and Patient-Based Criteria for the Diagnosis of Fibromyalgia. *Arthritis Care Res.* mai 2016;68(5):652•9.
9. Bodéré C, Woda A. La douleur orofaciale idiopathique: une douleur fonctionnelle. *Douleur Analgésie.* 21 juin 2009;22(2):89•95.
10. Woda A, Dao T, Gremeau-Richard C. Steroid dysregulation and stomatodynia (burning mouth syndrome). *J Orofac Pain.* 2009;23(3):202•10.
11. Woda A, L'heveder G, Ouchchane L, Bodéré C. Effect of experimental stress in 2 different pain conditions affecting the facial muscles. *J Pain Off J Am Pain Soc.* mai 2013;14(5):455•66.

- 1 12. Cohen H, Neumann L, Shore M, Amir M, Cassuto Y, Buskila D. Autonomic  
2 dysfunction in patients with fibromyalgia: application of power spectral analysis of heart rate  
3 variability. *Semin Arthritis Rheum.* févr 2000;29(4):217•27.
- 4 13. da Cunha Ribeiro RP, Roschel H, Artioli GG, Dassouki T, Perandini LA, Calich AL, et  
5 al. Cardiac autonomic impairment and chronotropic incompetence in fibromyalgia. *Arthritis*  
6 *Res Ther.* 2011;13(6):R190.
- 7 14. Martinez-Lavin M. Fibromyalgia as a sympathetically maintained pain syndrome. *Curr*  
8 *Pain Headache Rep.* oct 2004;8(5):385•9.
- 9 15. Kadetoff D, Kosek E. Evidence of reduced sympatho-adrenal and hypothalamic-  
10 pituitary activity during static muscular work in patients with fibromyalgia. *J Rehabil Med.*  
11 sept 2010;42(8):765•72.
- 12 16. Tak LM, Cleare AJ, Ormel J, Manoharan A, Kok IC, Wessely S, et al. Meta-analysis  
13 and meta-regression of hypothalamic-pituitary-adrenal axis activity in functional somatic  
14 disorders. *Biol Psychol.* mai 2011;87(2):183•94.
- 15 17. Riva R, Mork PJ, Westgaard RH, Lundberg U. Comparison of the cortisol awakening  
16 response in women with shoulder and neck pain and women with fibromyalgia.  
17 *Psychoneuroendocrinology.* févr 2012;37(2):299•306.
- 18 18. Geiss A, Rohleder N, Anton F. Evidence for an association between an enhanced  
19 reactivity of interleukin-6 levels and reduced glucocorticoid sensitivity in patients with  
20 fibromyalgia. *Psychoneuroendocrinology.* mai 2012;37(5):671•84.
- 21 19. Bote ME, García JJ, Hinchado MD, Ortega E. Inflammatory/stress feedback  
22 dysregulation in women with fibromyalgia. *Neuroimmunomodulation.* 2012;19(6):343•51.
- 23 20. Hellhammer DH, Wüst S, Kudielka BM. Salivary cortisol as a biomarker in stress  
24 research. *Psychoneuroendocrinology.* févr 2009;34(2):163•71.
- 25 21. Clauw D, Ablin J. The relationship between « stress » and pain: lessons learned from  
26 fibromyalgia and related conditions. In: *Current topics in pain.* Castro-Lopes editor. XIIth  
27 World Congress on Pain. Seattle: IASP press; 2009. p. p.245-270.
- 28 22. McKenzie DC. Markers of excessive exercise. *Can J Appl Physiol Rev Can Physiol*  
29 *Appl.* févr 1999;24(1):66•73.
- 30 23. MacKinnon LT. Special feature for the Olympics: effects of exercise on the immune  
31 system: overtraining effects on immunity and performance in athletes. *Immunol Cell Biol.* oct  
32 2000;78(5):502•9.
- 33 24. Iellamo F, Pigozzi F, Parisi A, Di Salvo V, Vago T, Norbiato G, et al. The stress of  
34 competition dissociates neural and cortisol homeostasis in elite athletes. *J Sports Med Phys*  
35 *Fitness.* déc 2003;43(4):539•45.
- 36 25. Baumert M, Brechtel L, Lock J, Hermsdorf M, Wolff R, Baier V, et al. Heart rate  
37 variability, blood pressure variability, and baroreflex sensitivity in overtrained athletes. *Clin J*  
38 *Sport Med Off J Can Acad Sport Med.* sept 2006;16(5):412•7.
- 39 26. Kajaia T, Maskhulia L, Chelidze K, Akhalkatsi V, Kakhbrishvili Z. The effects of non-  
40 functional overreaching and overtraining on autonomic nervous system function in highly  
41 trained athletes. *Georgian Med News.* mars 2017;(264):97•103.
- 42 27. Fontenele JB, Felix FHC. Exercise for fibromyalgia: evidence for an integrated  
43 modulation of autonomic and nociception neural regulation. *Rheumatol Int.* déc  
44 2012;32(12):4075•6.
- 45 28. Rossy LA, Buckelew SP, Dorr N, Hagglund KJ, Thayer JF, McIntosh MJ, et al. A  
46 meta-analysis of fibromyalgia treatment interventions. *Ann Behav Med Publ Soc Behav Med.*  
47 1999;21(2):180•91.

- 1 29. Busch AJ, Webber SC, Brachaniec M, Bidonde J, Bello-Haas VD, Danyliw AD, et al.  
2 Exercise therapy for fibromyalgia. *Curr Pain Headache Rep.* oct 2011;15(5):358•67.
- 3 30. Woda A, L'heveder G, Ouchchane L, Bodéré C. Effect of experimental stress in 2  
4 different pain conditions affecting the facial muscles. *J Pain Off J Am Pain Soc.* mai  
5 2013;14(5):455•66.
- 6 31. Society AP, éditeur. *Guideline for the Management of Fibromyalgia Syndrome Pain  
7 in Adults and Children.* American Pain Society; 2005. 109 p.
- 8 32. Häuser W, Arnold B, Eich W, Felde E, Flügge C, Henningsen P, et al. Management  
9 of fibromyalgia syndrome – an interdisciplinary evidence-based guideline. *GMS Ger Med  
10 Sci.* 2008;6:Doc14.
- 11 33. Macfarlane GJ, Kronisch C, Atzeni F, Häuser W, Choy EH, Amris K, et al. EULAR  
12 recommendations for management of fibromyalgia. *Ann Rheum Dis.* déc 2017;76(12):e54.
- 13 34. Melanson EL, Freedson PS. The effect of endurance training on resting heart rate  
14 variability in sedentary adult males. *Eur J Appl Physiol.* sept 2001;85(5):442•9.
- 15 35. Reland S, Ville NS, Wong S, Gauvrit H, Kervio G, Carré F. Exercise heart rate  
16 variability of older women in relation to level of physical activity. *J Gerontol A Biol Sci Med  
17 Sci.* juill 2003;58(7):585•91.
- 18 36. de Abreu SB, Lenhard A, Mehanna A, de Souza HCD, Correa FM de A, Hasser EM,  
19 et al. Role of paraventricular nucleus in exercise training-induced autonomic modulation in  
20 conscious rats. *Auton Neurosci Basic Clin.* 15 juin 2009;148(1•2):28•35.
- 21 37. Martins-Pinge MC. Cardiovascular and autonomic modulation by the central nervous  
22 system after aerobic exercise training. *Braz J Med Biol Res Rev Bras Pesqui Médicas E  
23 Biológicas Soc Bras Biofísica Al.* sept 2011;44(9):848•54.
- 24 38. Häuser W, Klose P, Langhorst J, Moradi B, Steinbach M, Schiltenswolf M, et al.  
25 Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review  
26 and meta-analysis of randomised controlled trials. *Arthritis Res Ther.* 2010;12(3):R79.
- 27 39. Bodéré C, Bodéré YT, Quinio B, Woda A, Misery L. Specific training program for the  
28 treatment of fibromyalgia: a prospective controlled study. In: 14th world congress on pain -  
29 TF505. Milan, Italy: IASP; 2012.
- 30 40. Lannersten L, Kosek E. Dysfunction of endogenous pain inhibition during exercise  
31 with painful muscles in patients with shoulder myalgia and fibromyalgia. *Pain.* oct  
32 2010;151(1):77•86.
- 33 41. Krag NJ, Nørregaard J, Larsen JK, Danneskiold-Samsøe B. A blinded, controlled  
34 evaluation of anxiety and depressive symptoms in patients with fibromyalgia, as measured  
35 by standardized psychometric interview scales. *Acta Psychiatr Scand.* juin  
36 1994;89(6):370•5.
- 37 42. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire:  
38 development and validation. *J Rheumatol.* mai 1991;18(5):728•33.
- 39 43. Osorio CD, Gallinaro AL, Lorenzi-Filho G, Lage LV. Sleep quality in patients with  
40 fibromyalgia using the Pittsburgh Sleep Quality Index. *J Rheumatol.* sept  
41 2006;33(9):1863•5.
- 42 44. Omachi TA. Measures of sleep in rheumatologic diseases: Epworth Sleepiness Scale  
43 (ESS), Functional Outcome of Sleep Questionnaire (FOSQ), Insomnia Severity Index (ISI),  
44 and Pittsburgh Sleep Quality Index (PSQI). *Arthritis Care Res.* nov 2011;63 Suppl 11:S287-  
45 296.
- 46 45. Crinière L, Lhommet C, Caille A, Giraudeau B, Lecomte P, Couet C, et al.  
47 Reproducibility and validity of the French version of the long international physical activity  
48 questionnaire in patients with type 2 diabetes. *J Phys Act Health.* août 2011;8(6):858•65.
- 49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59

- 1 46. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *J Health*  
2 *Soc Behav.* déc 1983;24(4):385•96.
- 3 47. Marchand S, Arsenault P. Spatial summation for pain perception: interaction of  
4 inhibitory and excitatory mechanisms. *Pain.* févr 2002;95(3):201•6.
- 5 48. Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in fibromyalgia is  
6 related to a deficit of endogenous pain inhibition. *Pain.* mars 2005;114(1•2):295•302.
- 7 49. Granot M, Granovsky Y, Sprecher E, Nir R-R, Yarnitsky D. Contact heat-evoked  
8 temporal summation: tonic versus repetitive-phasic stimulation. *Pain.* juin  
9 2006;122(3):295•305.
- 10 50. Barrett KE, Barman SM, Boitano S, Brooks H. *Ganong's Review of Medical*  
11 *Physiology*, 24th Edition. 24 edition. New York: McGraw-Hill Education / Medical; 2012. 768  
12 p.
- 13 51. Potvin S, Paul-Savoie E, Morin M, Bourgault P, Marchand S. Temporal summation of  
14 pain is not amplified in a large proportion of fibromyalgia patients. *Pain Res Treat.*  
15 2012;2012:938595.
- 16 52. Kirschbaum C, Hellhammer DH. Salivary cortisol in psychoneuroendocrine research:  
17 recent developments and applications. *Psychoneuroendocrinology.* 1994;19(4):313•33.
- 18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



# BMJ Open

## Impact of a specific training program on the neuromodulation of pain in fibromyalgia women (DouFiSport): a 24-month, controlled, randomised, double-blinded protocol.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023742.R1
Article Type:	Protocol
Date Submitted by the Author:	19-Jul-2018
Complete List of Authors:	<p>Le Fur Bonnabesse, Anais; Universite de Bretagne Occidentale Faculte de Medecine et des Sciences de la Sante de Brest, LIEN, EA4685; Universite de Bretagne Occidentale UFR d'Odontologie</p> <p>Cabon, Mathilde; Universite de Bretagne Occidentale Faculte de Medecine et des Sciences de la Sante de Brest, LIEN, EA4685</p> <p>L'Heveder, Gildas; CHRU de Brest, Explorations fonctionnelles neurologiques</p> <p>Kermarrec, Aurélie ; CHRU de Brest, IFMK</p> <p>Quinio, Bertrand; CHRU de Brest, Centre d'évaluation et de traitement de la douleur</p> <p>Woda, Alain; Universite Clermont Auvergne Faculte de Chirurgie Dentaire, CROC EA3847</p> <p>Marchand, Serge; Universite de Sherbrooke Faculte de medecine et des sciences de la sante, Department of surgery</p> <p>Dubois, Amandine; Laboratoire de psychologie, Cognition, Behaviour, Communication (LP3C), EA1285; Universite de Bretagne Occidentale UFR Lettres et Sciences Humaines a Brest, Département de psychologie</p> <p>Giroux-Metges, Marie-Agnes; Universite de Bretagne Occidentale Faculte de Medecine et des Sciences de la Sante de Brest, ORPHY EA4324; CHRU de Brest, Explorations fonctionnelles respiratoires</p> <p>Rannou, Fabrice; Universite de Bretagne Occidentale Faculte de Medecine et des Sciences de la Sante de Brest, ORPHY EA4324; CHRU de Brest, Explorations fonctionnelles respiratoires</p> <p>Misery, Laurent; Universite de Bretagne Occidentale Faculte de Medecine et des Sciences de la Sante de Brest, LIEN EA4685</p> <p>Bodéré, Céline; Universite de Bretagne Occidentale Faculte de Medecine et des Sciences de la Sante de Brest, LIEN EA4685; CHRU de Brest, Centre d'évaluation et de traitement de la douleur</p>
<b>Primary Subject Heading</b>:	Sports and exercise medicine
Secondary Subject Heading:	Medical education and training, Rehabilitation medicine, Rheumatology, Pharmacology and therapeutics
Keywords:	PAIN MANAGEMENT, MEDICAL EDUCATION & TRAINING, REHABILITATION MEDICINE, FIBROMYALGIA

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Impact of a specific training program on the neuromodulation of pain in fibromyalgia women (DouFiSport): a 24-month, controlled, randomised, double-blinded protocol.

Anaïs Le Fur-Bonnabesse<sup>1,2,3</sup>, Mathilde Cabon<sup>1</sup>, Gildas L'Heveder<sup>4</sup>, Aurélie Kermarrec<sup>5</sup>, Bertrand Quinio<sup>3</sup>, Alain Woda<sup>6</sup>, Serge Marchand<sup>7</sup>, Amandine Dubois<sup>8,9,1</sup>, Marie-Agnès Giroux-Metges<sup>10,11</sup>, Fabrice Rannou<sup>10,11</sup>, Laurent Misery<sup>1</sup>, Céline Bodéré<sup>1,2,3</sup>.

1 Laboratory of Interactions Keratinocytes-Neurons, EA4685, Faculty of Medicine and Health Sciences, University of Western Brittany (UBO), Brest, France

2 Dental faculty, University of Western Brittany (UBO), Brest, France

3 Assessment and treatment centre of pain, University Hospital of Brest, Brest, France

4 Neurological functional explorations, University Hospital of Brest, Brest, France.

5 Training institute of physiotherapy University Hospital of Brest, Brest, France.

6 University Clermont Auvergne, CROC and Teaching Hospital EA3847, Odontology Department, Clermont-Ferrand, France

7 Department of surgery, Faculty of medicine, University of Sherbrooke, Sherbrooke, Canada.

8 Laboratory of psychology: Cognition, Behaviour, Communication (LP3C), EA1285, Rennes, France.

9 Department of Psychology, University of Western Brittany (UBO), Brest, France.

10 ORPHY, Optimisation of Physiological Regulations, EA4324, Faculty of Medicine and Health Sciences, University of Western Brittany (UBO), Brest, France.

11 Respiratory Functional Exploration Unit, University Hospital of Brest, Brest, France.

**Corresponding author: Anaïs Le Fur-Bonnabesse**

anais.lefurbonnabesse@univ-brest.fr

anais.bonnabesse@gmail.com

**ABSTRACT****INTRODUCTION**

The main symptom of fibromyalgia (FM) is diffuse pain. There is currently no etiological treatment for FM. However, all pain associations and best practice guidelines highly recommend the practice of aerobic physical activity to improve the symptoms of FM subjects. The mechanisms of dysfunctional pain are mostly central (1) and related to stress axis dysfunction (autonomic nervous system and corticotropic axis) (2). The main objective is to assess the effectiveness of a specific training program on endogenous pain control mechanisms in female fibromyalgia patients. Further aims include rebalancing the autonomic neurovegetative system, improving the quality of life and sleep quality and reintegrating patients into society and work.

**METHODS AND ANALYSIS**

110 FM women (according to the criteria of the ACR 2010), aged 18-65 years and respecting the inclusion criteria will be recruited and randomised in two groups (active or semi-active). The training program consists of three 45-minute sessions per week of supervised, individualised physical activity over two years. Only the intensity of the exercises is different between the two groups (moderate-intensity versus low-intensity).

All outcome measures will be conducted at baseline (T0), after 6 to 9 months of training (T6-9), then after 24 months of training (T24). The primary endpoint is the improvement of pain modulation (activation of diffuse noxious inhibitory control (DNIC)) evaluated by the stimulation test (1). The secondary endpoint will assess pain, anxiety, depression, stress, sleep disorders, pain impact on life quality, heart rate, blood pressure and salivary cortisol.

**ETHICS AND DISSEMINATION:**

Approved by the Committee for the Protection of Persons West VI. Trial registration NCT02486965.

## Strengths and limitations of this study

- ▶ First randomised controlled double-blinded trial to assess the effects of a long-term training program (24 months) on pain control in fibromyalgia.
- ▶ To validate a training program acting on the autonomic system and to assess the neurovegetative rebalance on pain control.
- ▶ Physical activity intensity will be assessed objectively using a heart rate monitor.
- 
- ▶ The dropout rate in patients may be important. These elements were taken into account in sample size.
- ▶ Due to the nature of the intervention, the coaching staff cannot be blinded.

## *INTRODUCTION:*

Fibromyalgia affects 1.4 to 2.2% of the general population concerning predominately women (more than 80% of subjects). This syndrome is characterised by extensive and diffuse pain, mainly muscular and articular, impairing the functional abilities of the subjects. The symptoms most frequently described by fibromyalgia patients are chronic fatigue, sleep disorders, cognitive disorders and emotional disturbances (3,4). This symptomatology leads to a serious deterioration in quality of life, sometimes with a physical disability leading to social isolation and difficulties in staying in employment (recurrent work stoppages).

The diagnosis is based on the symptoms and their severity as described by the patients (5–8). Currently, there is no etiological treatment for fibromyalgia syndrome. The treatments are therefore only symptomatic.

### **Physiopathology of fibromyalgia**

The mechanisms of dysfunctional pain, without any identifiable organic lesions, are mostly central (1) and related to dysfunction of the stress axis (autonomic nervous system and corticotropic axis) (9–11).

At rest, fibromyalgia patients showed an increased sympathetic response and decreased parasympathetic tone (12,13). This neurovegetative dystonia is a marker of dysfunction of the stress axis (14).

Malfunctions of the corticotropic axis in fibromyalgia have been described multiple times, also marking the dysfunction of the stress axis. But the form taken by this dysfunction differs according to the different studies (15–19). The variability of salivary cortisol in response to stress reflects that of plasma free cortisol. Salivary cortisol is therefore a method of choice in experimental stress studies (20). Whatever form they take, these dysfunctions compromise the body's adaptation to daily stressful stimuli.

Studies show that this deficit of the stress axis (neurovegetative dystonia and dysfunctional corticotropic axis) is concurrent with fibromyalgia (21) and

1  
2  
3 associated with alteration of pain control (9–11). Pain control system and stress  
4 axis have close anatomical and functional links. Nociceptive, neurovegetative and  
5 corticotropic systems interact with the central nervous system. The central  
6 neuromediators implicated in the regulation of the stress axis are mostly  
7 common with those of the pain neuromodulation (endogenous opioids,  
8 norepinephrine, serotonin, etc.).  
9  
10  
11  
12  
13

### 14 **Elite athlete's overtraining syndrome: model of stress axis** 15 **dysfunction**

16  
17  
18 An overtraining elite athlete may be considered as a model of dysfunction of the  
19 stress axis associated with neurovegetative dystonia. The physical and  
20 psychological effort of training is known to induce stress. High-level athletes  
21 could present an overtraining syndrome when adaptation limits of the stress axis  
22 are reached. This stress-induced phenomenon corresponds to an imbalance  
23 between training quantity and recovery. Overtrained athletes present a  
24 deconditioning syndrome close to fibromyalgia symptoms (chronic pain, sleep  
25 disorders, neurovegetative dystonia, etc.) (22–26).  
26  
27  
28  
29  
30  
31  
32

### 33 **Physical activity and fibromyalgia**

34  
35 Most studies have shown that physical activity is more efficient compared to  
36 pharmacological treatments on fibromyalgia symptoms (27,28). Literature  
37 reviews and meta-analyses highly support the benefits of physical training in  
38 fibromyalgia patients (decreased pain and depression and improvement in  
39 overall health and physical abilities) (29)(30). Practice of aerobic exercise in  
40 fibromyalgia patients is strongly recommended by The American Pain Society  
41 (31), the Association of Medical Scientific Societies in Germany (32), the  
42 Canadian Rheumatology Association (5) and the European League Against  
43 Rheumatism (EULAR) (33). Physical exercise is the first-line treatment  
44 recommended in fibromyalgia. However there is still no consensus on the  
45 modalities of these types of training (frequency, duration, and intensity).  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Currently, the mechanisms underlying those specific training effects have to be  
defined.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
The steady physical activity rebalancing autonomic system is associated with cardiovascular benefits. Physical activity increases parasympathetic tone and decreases sympathetic response (34–37). Mechanisms and structures involved in the activation and regulation of the neurovegetative system could interact with the central nervous system. Central relationships between the neurovegetative system and, the motor cortex, the limbic system, the hypothalamus, the pituitary gland and the basal ganglia will result in release of analgesic neurotransmitters such as adrenergic neurotransmitters (noradrenalin), serotonin and endogenous opioid (38)(39). This release of neurotransmitters due to exercise leads to increased endogenous inhibition and therefore decreases diffuse pain in FM (38). Central nervous system plasticity induced by physical training could regulate both cardiovascular adaptations (37) and endogenous pain control mechanisms (40)(41). Thus, strategies to rebalance the autonomic system are the most promising therapies for fibromyalgia (13,36,37).

31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
In this study, we propose to validate a therapeutic alternative that aims to treat fibromyalgia by rebalancing the stress axis. This treatment consists of a specific supervised and individualised training program, over 2 years. This training protocol is individually adjusted in order to rebalance the neurovegetative system (parasympathetic and sympathetic). Central neuroplasticity induced by training should regulate endogenous pain control mechanisms. This specific protocol will be associated with psychotherapeutic approaches. In addition to the training program, multidisciplinary bio-psycho-social cares will be given in the pain centre of the university hospital of Brest (5).

## 49 50 51 52 53 54 55 56 57 58 59 60 **Objectives**

The *main objective* is to assess the effectiveness of a specific training program on endogenous pain controls in fibromyalgia patients. The *secondary objectives* are to rebalance the autonomic nervous system and the corticotropic axis, to improve life and sleep quality and to reintegrate patients into society and work.



## *METHODS AND ANALYSIS:*

### **Design and setting**

This randomised double-blind trial will compare an "active" program to a "semi-active" program in fibromyalgia patients. Patients will be recruited at the pain centre of the university hospital of Brest on the basis of general criteria. Patients should follow a re-exercise program for 24 months. The assessments will take place (i) before, (ii) between 6 to 9 months (depending the training level) and (iii) at the end of the training (24 months), in the neurological functional explorations department of the university hospital of Brest (fig.1).

### **Patient and public involvement**

The specific training program of this study was developed based on the results of a pilot study (42), data from literature and the experiences of fibromyalgia patients recorded at the pain centre of the University Hospital of Brest. These patients reported the benefits, constraints, difficulties, and effects of their training program on their symptoms. This information has allowed for adjustments to be made to the specific training program. Patients are not involved in the recruitment and conduct of the study. During the last assessment visit, patients will be asked to assess the burden of the intervention. Upon request, a report outlining the study findings will be given to study participants.

### **Study population**

110 fibromyalgia patients will be included. The inclusion criteria are: female subjects; aged of 18 to 65 years; with a diagnosis of fibromyalgia clearly established according to the criteria of the American College of Rheumatology (ACR) 2010; with a body mass index (BMI) between 18.5 and 29.9kg/m<sup>2</sup>; spontaneous pain intensity higher than 3/10 on a visual analog scale (VAS); pain experienced at least 3 days a week; pain caused by palpation equal to or higher than 4/10 on a VAS.

1  
2  
3 The non-inclusion criteria are: patients with a systemic disease (treated or not)  
4 generating pain of the musculoskeletal system; presenting pain other than  
5 fibromyalgia; presenting a contraindication to physical activity; having any  
6 active pathology; having modified in the last 2 months any pharmacological  
7 treatment; having a psychiatric diagnosis; taking drugs that affect cortisol  
8 secretion (decrease or increase); non-cooperating.  
9  
10  
11  
12  
13

### 14 **Sample size**

15  
16 Population size is based on an expected difference of 20 points (stimulation test)  
17 (1) between the two groups, for a quantitative primary endpoint (delta VAS) of  
18 standard deviation equal to 35, and a power set at 80%. Therefore a minimum of  
19 48 subjects per group is required for assessment. In order to take into account  
20 loss to follow-up, the sample of 110 subjects, 55 per group will be recruited.  
21  
22  
23  
24  
25

### 26 **Randomisation**

27  
28 Patients will be randomised at the end of the first stimulation test, which is just  
29 before the initiation of the training. Randomisation will be conducted by the  
30 Center of Clinical Investigation (CIC) at the hospital university of Brest  
31 (electronic randomisation via Capture System). The test is stratified by age and  
32 BMI. The cut off is set at 50 years for age and 25kg/m<sup>2</sup> for BMI (two strata [18-  
33 25] and ]25-30 [).  
34  
35  
36  
37  
38  
39

### 40 **Intervention: Training program**

41  
42 The training program is planned over two years (24 months) for both groups  
43 (active/semi-active). A minimum of 4 to 6 weeks is needed to observe a decrease  
44 in symptoms (42). This two-year duration is the minimum average training time  
45 (depending on the individual progress of each patient), necessary to regain  
46 central neuroplasticity sufficient to put back into operation diffuse noxious  
47 inhibitory controls (DNIC) and neurovegetative system (43).  
48  
49

50 The frequency, intensity, and duration of these training sessions are based upon  
51 both data from literature (42,44) and the results of a preliminary study. Pain was  
52 significantly reduced and symptoms, such as quality of life, sleep quality, anxiety,  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 were also highly improved in subjects undergoing this specific training after 5  
4 years (43).  
5  
6

7  
8 The American Pain Society recommends an intensity of 60 to 70% of the age-  
9 adjusted maximum heart rate (HRmax). At the early stage, the intensity and  
10 duration of the training sessions will be adapted to the physical condition of each  
11 subject. The intensity exercise will be 3 on the Borg CR10 scale (42). In order to  
12 promote adherence of our patients and to limit pain exacerbation, exercise  
13 intensity will start very low and then gradually increase to reach the  
14 neurovegetative goal (31)(45).  
15  
16

17  
18 The ideal frequency is 3 training sessions per week during 45 minutes each  
19 (42,43).  
20  
21  
22

### 23 24 **Active training group:**

25  
26 *The first 6 to 9 months:*

27  
28 Subjects will perform 3 sessions per week of 45 minutes of Moderate-Intensity  
29 Continuous Training MICT (65-75% HRmax), including 2 sessions supervised by  
30 a physiotherapist specially trained and 1 independent session.  
31

32  
33 *From 6-9 months (according to the rhythm, abilities, and limits) to 24 months:*

34  
35 Patients will begin the second stage of training: 3 sessions per week of at least 45  
36 minutes each (MICT and High-Intensity Interval Training (HIIT)) with 1  
37 supervised session and 2 independent sessions. When the patient reaches the  
38 initial HR goal, continuous training will be associated with interval training. HIIT  
39 will consist of 5 stages of 1 to 4 minutes at 85-90% HRmax, interspersed by 1 to  
40 4 minutes of active recovery at 65-75% HRmax. Intensity will be assessed  
41 objectively using a heart rate monitor (FT2, Polar). At baseline, Tanaka's age-  
42 based prediction equation ( $208-0.7 \times \text{age}$ ) will calculate HRmax. After 6-9 months  
43 of training, a maximal-effort graded exercise test will determine HRmax and  
44  $\dot{V}O_2\text{max}$  for each patient.  
45  
46  
47  
48  
49  
50

### 51 52 **Semi-Active group:**

53  
54 Patients will perform the same infra active training (low-intensity continuous  
55 training: LICT <50% HRmax) over two years. Supervision, monitoring, and  
56  
57  
58  
59  
60

1  
2  
3 frequency of sessions (3 x 45 minutes per week) in both groups will be  
4 equivalent.  
5  
6

### 7 **Training follow-up (for both groups):**

8 Patients will be contacted to record progress, difficulties and if necessary, to  
9 encourage them to adhere to their program. These calls will improve the  
10 compliance and will limit patients lost to follow-up (46,47). Subjects will note the  
11 characteristics (frequency, duration, intensity, type of activity, and supervision)  
12 of each training session (both supervised and independent) in a specific training  
13 logbook. The physiotherapist will frequently ask patients about their  
14 independent training session to provide advice and to motivate them. The  
15 follow-up at the pain centre will assess the compliance with the training  
16 protocol.  
17  
18

19 Patients will perform a 6-minute walk test (6MWT) every 6 months (with  
20 physiotherapist). If a patient cannot achieve the specific training requested after  
21 9 months of study, the patient will not complete the second phase of training.  
22 Nevertheless, she will carry out all assessment visits. The main analysis will be  
23 performed on an intent-to-treat basis.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

## 37 **Clinical Data, Measurements and Assessments**

### 38 **Sociodemographic and clinical data**

39 At baseline, data on age, sex, marital status, education level, and occupation will  
40 be collected. Height and weight will be recorded. Medical background and pain  
41 characteristics will be noted. All current drug and non-drug therapies (including  
42 tried and stopped) will also be collected, as well as their effectiveness on pain.  
43  
44  
45  
46  
47  
48

### 49 **Questionnaires and pain assessments**

50 Measurements and questionnaires will be carried out (i) at baseline, (ii) between  
51 6 to 9 months, and (iii) at the end of the 24 months of training.  
52

- 53 • The **assessment of pain** will be performed by a simple verbal scale and  
54 using a visual analog scale (VAS). The Saint Antoine Pain Questionnaire  
55  
56  
57  
58  
59

(QDSA) will also assess pain. A **pain quantitative assessment** will be performed with a pressure algometer (pressure pain threshold: PPT).

- The Hospital Anxiety Depression Scale (HADS) will assess the **patient anxiodepressive state** (48).
- The Fibromyalgia Impact Questionnaire (FIQ) will assess **the impact of fibromyalgia on daily life** (49).
- The Pittsburgh Sleep Quality Index (PSQI) will assess **sleep quality and quantity** (50,51).
- The International Physical Activity Questionnaire (IPAQ) will record the **level of physical activity and the sedentary lifestyle**. The French long telephone questionnaire will be used (52).
- The Perceived Stress Scale (PSS) will assess **the antecedents of perceived stress** (53).

### Stimulation test

In order to assess endogenous pain mechanisms, such as diffuse noxious inhibitory controls (DNIC), temporal summation (TS) and perception of pain, we will use an experimental method developed by Tousignant-Laflamme and Marchand (2008). According to this well-characterised paradigm, we will induce in single session two tonic heat pain stimulations separated by a cold pressor test (1,54–56).

- Thermode test or temporal summation test (**P1**): a tonic heat pain will be administered for 2 minutes on the patient's right arm, using a thermode (CE marking n°226). The starting temperature is 32°C (skin temperature under normal conditions in temperate room (20-22°C)) (57) and will quickly reach a fixed value. The experimental temperature will be individually determined to induce 50/100 on a VAS and will remain constant during the test period (2 minutes). Throughout this entire period, the patient will evaluate their pain intensity using a Computerised Visual Analog Scale (CoVAS).

- Cold pressor test (**P2**): to elicit a prolonged pain sensation in order to trigger diffuse noxious inhibitory control (DNIC) (58), the patient's right arm will

1  
2  
3 be immersed for 2 minutes in a cold water bath maintained at 12°C. The patient  
4 will continuously evaluate their pain intensity using a CoVAS.

5  
6 Following this cold pressor test, the thermode test will be again performed **(P3)**.  
7  
8 Pain difference between the two (P3/P1) tonic heat pain stimulations will  
9 measure DNIC activation and represents pain modulation.  
10

### 11 12 13 **Measurement of salivary cortisol and salivary flow**

14 Corticotropic axis will be assessed using measurement of salivary cortisol.  
15 Cortisol release is pulsatile (10 to 20 peaks per day) and follows a nycthemeral  
16 cycle. Maximum cortisol level is reached in the early morning. In the morning of  
17 each consultation (at baseline, in the middle and at the end of training), patients  
18 will collect salivary sample (i) for 2 minutes, when they wake up and (ii) for 2  
19 minutes, 30 minutes later. The salivary cortisol level is measured in nmol/l. The  
20 flow rate is calculated in ml.min<sup>-1</sup>. Samples will be frozen at -20°C. As salivary  
21 cortisol is stable, samples can be stored for many weeks in the freezer (59). After  
22 completion of all assessment sessions, sample analysis will be completed. To  
23 avoid inter-laboratory variation, the same laboratory will assay the samples.  
24  
25  
26  
27  
28  
29  
30  
31

### 32 33 **Recording of Blood Pressure (BP) and Heart Rate (HR)**

34 After 10 minutes at rest, lying down, BP and HR will be recorded. Then, BP and  
35 HR will be measured when the patient stands up and once per minute during 4  
36 minutes when the patient remains standing.  
37  
38  
39  
40

### 41 42 **Blinding strategy**

43 Patients will not be informed of their group (active/semi-active). The  
44 investigators will not know the patient's group. Due to the nature of the  
45 intervention (physical activity protocol), the coaching staff will not be blinded.  
46  
47  
48  
49

### 50 51 **Statistical analysis**

52 *Primary endpoint analysis:* The VAS improvements (stimulation test) obtained in  
53 the both groups will be compared using the Student's test. If the required  
54 normality assumption is not sustainable, a nonparametric Wilcoxon test will be  
55 used. An alpha risk of 0.05 will be set as the limit of statistical significance. The  
56  
57  
58  
59  
60

1  
2  
3 main analysis will be performed on an intent-to-treat basis. A complementary  
4 analysis using a linear model with adjustment for age and BMI factors will be  
5 completed.  
6  
7

8  
9 *The secondary endpoints* (quantitative: salivary cortisol, blood pressure, PPT  
10 quantified by pain threshold pressure, questionnaires assessment) will be  
11 analysed in a similar way by comparing the improvements obtained between  
12 both groups.  
13  
14  
15

### 16 17 **Methodological limitations**

18  
19 The methodology of this protocol is consistent with the recommendations of the  
20 Standard Protocol Items for Randomised Trials (SPIRIT). However, because of  
21 the nature of the intervention, the coaching staff cannot be blinded. Patients and  
22 investigators will be blinded.  
23  
24

25  
26 According to the study duration (2 years), the potential participant dropout and  
27 potential patients lost to follow-up may be important. These elements were  
28 taken into account in sample size. To limit dropout, patients will be called to  
29 encourage them and to discuss any difficulties. In second stage of training and  
30 to limit a possible long-term monotonous effect, physical activity type could be  
31 diversified in both groups. The training session will be adapted in the active  
32 group (MICT will be associated with HIIT) to reduce sympathetic hyperactivity. In  
33 order to improve compliance and long-term achievement of training, the patient  
34 may choose the physical activity type performed without supervision.  
35  
36  
37  
38  
39  
40  
41

### 42 43 ***ETHICS AND DISSEMINATION***

#### 44 45 **Ethics approval and consent to participate**

46  
47 The Committee for the Protection of Persons West VI approved this study.  
48 Patients will be informed of the objectives, constraints, risks and benefits of the  
49 study. To be included, patients will sign informed written consent. Data will be  
50 collected anonymously. The investigators will take all necessary precautions to  
51 ensure the confidentiality of the information in particular with regard to patient  
52 identity.  
53  
54  
55  
56  
57  
58  
59  
60

### Dissemination plan

The results of this study will be published in specialised scientific journals. These results will also be presented in pain and/or physical activity congresses. In addition, a doctoral thesis will be carried out on this project.

TRIAL REGISTRATION NUMBER: NCT02486965

### Acknowledgements

The authors thank Julie Lelièvre, Marie Le Bellego, Youenn-Thor Bodéré for designing and implementing this protocol. The authors thank the translation service of the University of Western Brittany and Phillipa Perrot for English language revision.

### Contributors

CB initiated the idea for the project. CB and ALFB developed the study design. MC, GL, BQ, AK, AW, SM, MAGM, FR, LM and AD provided advice for the study design. GL and CB were responsible for supervision of project. CB will conduct the recruitment. AK will conduct the training programme. CB, ALFB and MC will conduct the outcomes assessments and will contribute to the analysis and interpretation of the data. Both authors will contribute to the analyses and interpretation of the data. ALFB, CB and MC wrote early drafts of the manuscript. All authors approved the final version of this protocol.

### Funding Statement

This work is supported by the French Ministry of Health (Programme Hospitalier de Recherche Clinique Interrégional 2014, project no 2014-A00743-44) PHRCi 13-100

### Competing Interests

None declared.

### Ethics approval

Committee for the Protection of Persons West VI

### Provenance and peer review

Not commissioned; externally peer reviewed.



## References

1. Tousignant-Laflamme Y, Pagé S, Goffaux P, Marchand S. An experimental model to measure excitatory and inhibitory pain mechanisms in humans. *Brain Res.* 16 sept 2008;1230:73-9.
2. Woda A, L'heveder G, Ouchchane L, Bodéré C. Effect of experimental stress in 2 different pain conditions affecting the facial muscles. *J Pain Off J Am Pain Soc.* mai 2013;14(5):455-66.
3. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. *Arthritis Rheum.* févr 1990;33(2):160-72.
4. Cánovas R, León I, Roldán MD, Astur R, Cimadevilla JM. Virtual reality tasks disclose spatial memory alterations in fibromyalgia. *Rheumatol Oxf Engl.* oct 2009;48(10):1273-8.
5. Fitzcharles M, Shir Y, Ablin JN, Buskila D, Amital H, Henningsen P, et al. Classification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines. *Evid-Based Complement Altern Med ECAM.* 2013;2013:528952.
6. Egloff N, von Känel R, Müller V, Egle UT, Kokinogenis G, Lederbogen S, et al. Implications of proposed fibromyalgia criteria across other functional pain syndromes. *Scand J Rheumatol.* 2015;44(5):416-24.
7. Moyano S, Kilstein JG, Alegre de Miguel C. New diagnostic criteria for fibromyalgia: Here to stay? *Reumatol Clin.* août 2015;11(4):210-4.
8. Wolfe F, Fitzcharles M-A, Goldenberg DL, Häuser W, Katz RL, Mease PJ, et al. Comparison of Physician-Based and Patient-Based Criteria for the Diagnosis of Fibromyalgia. *Arthritis Care Res.* mai 2016;68(5):652-9.
9. Bodéré C, Woda A. La douleur orofaciale idiopathique: une douleur fonctionnelle. *Douleur Analgésie.* 21 juin 2009;22(2):89-95.
10. Woda A, Dao T, Gremeau-Richard C. Steroid dysregulation and stomatodynia (burning mouth syndrome). *J Orofac Pain.* 2009;23(3):202-10.
11. Woda A, L'heveder G, Ouchchane L, Bodéré C. Effect of experimental stress in 2 different pain conditions affecting the facial muscles. *J Pain Off J Am Pain Soc.* mai 2013;14(5):455-66.
12. Cohen H, Neumann L, Shore M, Amir M, Cassuto Y, Buskila D. Autonomic dysfunction in patients with fibromyalgia: application of power spectral analysis of heart rate variability. *Semin Arthritis Rheum.* févr 2000;29(4):217-27.
13. da Cunha Ribeiro RP, Roschel H, Artioli GG, Dassouki T, Perandini LA, Calich AL, et al. Cardiac autonomic impairment and chronotropic incompetence in fibromyalgia. *Arthritis Res Ther.* 2011;13(6):R190.
14. Martinez-Lavin M. Fibromyalgia as a sympathetically maintained pain syndrome. *Curr Pain Headache Rep.* oct 2004;8(5):385-9.
15. Kadetoff D, Kosek E. Evidence of reduced sympatho-adrenal and hypothalamic-pituitary activity during static muscular work in patients with fibromyalgia. *J Rehabil Med.* sept 2010;42(8):765-72.
16. Tak LM, Cleare AJ, Ormel J, Manoharan A, Kok IC, Wessely S, et al. Meta-analysis and meta-regression of hypothalamic-pituitary-adrenal axis activity in functional somatic disorders. *Biol Psychol.* mai 2011;87(2):183-94.

17. Riva R, Mork PJ, Westgaard RH, Lundberg U. Comparison of the cortisol awakening response in women with shoulder and neck pain and women with fibromyalgia. *Psychoneuroendocrinology*. févr 2012;37(2):299-306.
18. Geiss A, Rohleder N, Anton F. Evidence for an association between an enhanced reactivity of interleukin-6 levels and reduced glucocorticoid sensitivity in patients with fibromyalgia. *Psychoneuroendocrinology*. mai 2012;37(5):671-84.
19. Bote ME, García JJ, Hinchado MD, Ortega E. Inflammatory/stress feedback dysregulation in women with fibromyalgia. *Neuroimmunomodulation*. 2012;19(6):343-51.
20. Hellhammer DH, Wüst S, Kudielka BM. Salivary cortisol as a biomarker in stress research. *Psychoneuroendocrinology*. févr 2009;34(2):163-71.
21. Clauw D, Ablin J. The relationship between « stress » and pain: lessons learned from fibromyalgia and related conditions. In: Current topics in pain. Castro-Lopes editor. XIIth World Congress on Pain. Seattle: IASP press; 2009. p. 245-270.
22. McKenzie DC. Markers of excessive exercise. *Can J Appl Physiol Rev Can Physiol Appl*. févr 1999;24(1):66-73.
23. MacKinnon LT. Special feature for the Olympics: effects of exercise on the immune system: overtraining effects on immunity and performance in athletes. *Immunol Cell Biol*. oct 2000;78(5):502-9.
24. Iellamo F, Pigozzi F, Parisi A, Di Salvo V, Vago T, Norbiato G, et al. The stress of competition dissociates neural and cortisol homeostasis in elite athletes. *J Sports Med Phys Fitness*. déc 2003;43(4):539-45.
25. Baumert M, Brechtel L, Lock J, Hermsdorf M, Wolff R, Baier V, et al. Heart rate variability, blood pressure variability, and baroreflex sensitivity in overtrained athletes. *Clin J Sport Med Off J Can Acad Sport Med*. sept 2006;16(5):412-7.
26. Kajaia T, Maskhulia L, Chelidze K, Akhalkatsi V, Kakhabrishvili Z. The effects of non-functional overreaching and overtraining on autonomic nervous system function in highly trained athletes. *Georgian Med News*. mars 2017;(264):97-103.
27. Fontenele JB, Felix FHC. Exercise for fibromyalgia: evidence for an integrated modulation of autonomic and nociception neural regulation. *Rheumatol Int*. déc 2012;32(12):4075-6.
28. Rossy LA, Buckelew SP, Dorr N, Hagglund KJ, Thayer JF, McIntosh MJ, et al. A meta-analysis of fibromyalgia treatment interventions. *Ann Behav Med Publ Soc Behav Med*. 1999;21(2):180-91.
29. Busch AJ, Webber SC, Brachaniec M, Bidonde J, Bello-Haas VD, Danyliw AD, et al. Exercise therapy for fibromyalgia. *Curr Pain Headache Rep*. oct 2011;15(5):358-67.
30. Woda A, L'heveder G, Ouchchane L, Bodéré C. Effect of experimental stress in 2 different pain conditions affecting the facial muscles. *J Pain Off J Am Pain Soc*. mai 2013;14(5):455-66.
31. Society AP, éditeur. Guideline for the Management of Fibromyalgia Syndrome Pain in Adults and Children. American Pain Society; 2005. 109 p.
32. Häuser W, Arnold B, Eich W, Felde E, Flügge C, Henningsen P, et al. Management of fibromyalgia syndrome – an interdisciplinary evidence-based

- 1  
2  
3 guideline. *GMS Ger Med Sci* [Internet]. 9 déc 2008 [cité 7 févr 2018];6. Disponible  
4 sur: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2703259/>
- 5 33. Macfarlane GJ, Kronisch C, Atzeni F, Häuser W, Choy EH, Amris K, et al.  
6 EULAR recommendations for management of fibromyalgia. *Ann Rheum Dis*. déc  
7 2017;76(12):e54.
- 8 34. Melanson EL, Freedson PS. The effect of endurance training on resting  
9 heart rate variability in sedentary adult males. *Eur J Appl Physiol*. sept  
10 2001;85(5):442-9.
- 11 35. Reland S, Ville NS, Wong S, Gauvrit H, Kervio G, Carré F. Exercise heart  
12 rate variability of older women in relation to level of physical activity. *J Gerontol*  
13 *A Biol Sci Med Sci*. juill 2003;58(7):585-91.
- 14 36. de Abreu SB, Lenhard A, Mehanna A, de Souza HCD, Correa FM de A,  
15 Hasser EM, et al. Role of paraventricular nucleus in exercise training-induced  
16 autonomic modulation in conscious rats. *Auton Neurosci Basic Clin*. 15 juin  
17 2009;148(1-2):28-35.
- 18 37. Martins-Pinge MC. Cardiovascular and autonomic modulation by the  
19 central nervous system after aerobic exercise training. *Braz J Med Biol Res Rev*  
20 *Bras Pesqui Médicas E Biológicas Soc Bras Biofísica Al*. sept 2011;44(9):848-54.
- 21 38. Brito RG, Rasmussen LA, Sluka KA. Regular physical activity prevents  
22 development of chronic muscle pain through modulation of supraspinal opioid  
23 and serotonergic mechanisms. *Pain Rep*. sept 2017;2(5):e618.
- 24 39. Da Silva Santos R, Galdino G. Endogenous systems involved in exercise-  
25 induced analgesia. *J Physiol Pharmacol Off J Pol Physiol Soc*. févr  
26 2018;69(1):3-13.
- 27 40. Naugle KM, Naugle KE, Fillingim RB, Samuels B, Riley JL. Intensity  
28 thresholds for aerobic exercise-induced hypoalgesia. *Med Sci Sports Exerc*. avr  
29 2014;46(4):817-25.
- 30 41. Law LF, Sluka KA. How does physical activity modulate pain? *Pain*.  
31 2017;158(3):369-70.
- 32 42. Häuser W, Klose P, Langhorst J, Moradi B, Steinbach M, Schiltenswolf M, et  
33 al. Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a  
34 systematic review and meta-analysis of randomised controlled trials. *Arthritis*  
35 *Res Ther*. 2010;12(3):R79.
- 36 43. Bodéré C, Bodéré YT, Quinio B, Woda A, Misery L. Specific training  
37 program for the treatment of fibromyalgia: a prospective controlled study. In:  
38 14th world congress on pain - TF505. Milan, Italy: IASP; 2012.
- 39 44. Bidonde J, Busch AJ, Bath B, Milosavljevic S. Exercise for adults with  
40 fibromyalgia: an umbrella systematic review with synthesis of best evidence.  
41 *Curr Rheumatol Rev*. 2014;10(1):45-79.
- 42 45. Lannersten L, Kosek E. Dysfunction of endogenous pain inhibition during  
43 exercise with painful muscles in patients with shoulder myalgia and  
44 fibromyalgia. *Pain*. oct 2010;151(1):77-86.
- 45 46. Franke K-J, Domanski U, Schroeder M, Jansen V, Artmann F, Weber U, et al.  
46 Telemonitoring of home exercise cycle training in patients with COPD. *Int J*  
47 *Chron Obstruct Pulmon Dis*. 2016;11:2821-9.
- 48 47. Yasmin F, Banu B, Zakir SM, Sauerborn R, Ali L, Souares A. Positive  
49 influence of short message service and voice call interventions on adherence and  
50 health outcomes in case of chronic disease care: a systematic review. *BMC Med*  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Inform Decis Mak. 22 avr 2016;16:46.

4 48. Krag NJ, Nørregaard J, Larsen JK, Danneskiold-Samsøe B. A blinded,  
5 controlled evaluation of anxiety and depressive symptoms in patients with  
6 fibromyalgia, as measured by standardized psychometric interview scales. *Acta*  
7 *Psychiatr Scand.* juin 1994;89(6):370-375.

8 49. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact  
9 questionnaire: development and validation. *J Rheumatol.* mai  
10 1991;18(5):728-733.

11 50. Osorio CD, Gallinaro AL, Lorenzi-Filho G, Lage LV. Sleep quality in patients  
12 with fibromyalgia using the Pittsburgh Sleep Quality Index. *J Rheumatol.* sept  
13 2006;33(9):1863-1868.

14 51. Omachi TA. Measures of sleep in rheumatologic diseases: Epworth  
15 Sleepiness Scale (ESS), Functional Outcome of Sleep Questionnaire (FOSQ),  
16 Insomnia Severity Index (ISI), and Pittsburgh Sleep Quality Index (PSQI).  
17 *Arthritis Care Res.* nov 2011;63 Suppl 11:S287-296.

18 52. Crinière L, Lhomme C, Caille A, Giraudeau B, Lecomte P, Couet C, et al.  
19 Reproducibility and validity of the French version of the long international  
20 physical activity questionnaire in patients with type 2 diabetes. *J Phys Act Health.*  
21 août 2011;8(6):858-865.

22 53. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress.  
23 *J Health Soc Behav.* déc 1983;24(4):385-396.

24 54. Marchand S, Arsenault P. Spatial summation for pain perception:  
25 interaction of inhibitory and excitatory mechanisms. *Pain.* févr  
26 2002;95(3):201-206.

27 55. Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in  
28 fibromyalgia is related to a deficit of endogenous pain inhibition. *Pain.* mars  
29 2005;114(1-2):295-302.

30 56. Granot M, Granovsky Y, Sprecher E, Nir R-R, Yarnitsky D. Contact heat-  
31 evoked temporal summation: tonic versus repetitive-phasic stimulation. *Pain.*  
32 juin 2006;122(3):295-305.

33 57. Barrett KE, Barman SM, Boitano S, Brooks H. *Ganong's Review of Medical*  
34 *Physiology*, 24th Edition. 24 edition. New York: McGraw-Hill Education /  
35 Medical; 2012. 768 p.

36 58. Potvin S, Paul-Savoie E, Morin M, Bourgault P, Marchand S. Temporal  
37 summation of pain is not amplified in a large proportion of fibromyalgia patients.  
38 *Pain Res Treat.* 2012;2012:938595.

39 59. Kirschbaum C, Hellhammer DH. Salivary cortisol in  
40 psychoneuroendocrine research: recent developments and applications.  
41 *Psychoneuroendocrinology.* 1994;19(4):313-323.

1  
2  
3 **Figure legends:**

4 Figure 1: Flow Chart of DouFiSport  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only




Figure 1: Flow Chart of DouFiSPort

209x297mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description
<b>Administrative information</b>		
Title	1	Impact of a specific training program on the neuromodulation of pain in fibromyalgia women (DouFiSport): a 24-month, controlled, randomised, double-blinded protocol.
Trial registration	2a	NCT02486965
Protocol version	3	version number 5.0 of 21/06/2016
Funding	4	This work is supported by the French Ministry of Health (Programme Hospitalier de Recherche Clinique Interrégional 2014) PHRCi 13-100



Roles and responsibilities

5a Names, affiliations, and roles of protocol contributors:

Anaïs Le Fur-Bonnabesse<sup>1,2,3</sup>, investigator  
 Mathilde Cabon<sup>1</sup>, investigator  
 Gildas L'Heveder<sup>4</sup>, co-ordinating investigator  
 Aurélie Kermarrec<sup>5</sup>, coaching staff (physiotherapist)  
 Bertrand Quinio<sup>3</sup>, scientific associate  
 Alain Woda<sup>6</sup>, scientific associate  
 Serge Marchand<sup>7</sup>, scientific associate  
 Amandine Dubois<sup>8,9,1</sup>, investigator  
 Marie-Agnès Giroux-Metges<sup>10,11</sup>, scientific associate  
 Fabrice Rannou<sup>10,11</sup> scientific associate  
 Laurent Misery<sup>1</sup>, scientific associate  
 Céline Bodéré<sup>1,2,3</sup>, principal investigator, scientific responsible

1 Laboratory of Interactions Keratinocytes-Neurons, EA4685, Faculty of Medicine and Health Sciences, University of Western Brittany (UBO), Brest, France

2 Dental faculty, University of Western Brittany (UBO), Brest, France

3 Assessment and treatment center of pain, University Hospital of Brest, Brest, France

4 Neurological functional explorations, University Hospital of Brest, Brest, France.

5 Training institute of physiotherapy University Hospital of Brest, Brest, France.

6 University Clermont Auvergne, CROC and Teaching Hospital EA3847, Odontology Department, Clermont-Ferrand, France

7 Department of surgery, Faculty of medicine, University of Sherbrooke, Sherbrooke, Canada

8 Laboratory of psychology: Cognition, Behaviour, Communication (LP3C), EA1285, Rennes, France

9 Department of Psychology, University of Western Brittany (UBO), Brest, France.

10 ORPHY, Optimisation of Physiological Regulations, EA4324, Faculty of Medicine and Health Sciences, University of Western Brittany (UBO), Brest, France

11 Respiratory Functional Exploration Unit, University Hospital of Brest, Brest, France.

CB initiated the idea for the project.

CB and ALFB developed the study design.

MC, GL, BQ, AK, AW, SM, MAGM, FR, LM and AD provided advice for the study design.

GL and CB are responsible for supervision of project. CB will conduct the recruitment.

AK will conduct the training programme.

CB, ALFB and MC will conduct the outcomes assessments and will contribute to the analysis and interpretation of the data.

Both authors will contribute to the analyses and interpretation of the data.

ALFB, CB and MC wrote early drafts of the manuscript.

All authors approved the final version of this protocol.



1  
2 5b Name and contact information for the trial sponsor:  
3

4 Rémi BRAJEUL, directeur adjoint  
5 Délégation à la Recherche Clinique et à l'Innovation (DRCI)  
6 CHRU de Brest  
7 2 Avenue Foch  
8 29609 Brest Cedex  
9 France  
10

11  
12  
13 5c Role of study sponsor and funders :  
14

- 15 - Evaluation of serious adverse events
- 16 - Transmission of annual safety reports
- 17 - Quality assurance and monitoring activities
- 18 - Approval of any amendment of the protocol
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1 Background and 6a Fibromyalgia affects 1.4 to 2.2% of the general population concerning  
2 rationale 6a predominately women (more than 80% of subjects). This syndrome is  
3 characterised by extensive and diffuse pain, mainly muscular and  
4 articular, impairing the functional abilities of the subjects. The  
5 symptoms most frequently described by fibromyalgia patients are  
6 chronic fatigue, sleep disorders, cognitive disorders and emotional  
7 disturbances (3,4). This symptomatology leads to a serious  
8 deterioration in quality of life, sometimes with a physical disability  
9 leading to social isolation and difficulties in staying in employment  
10 (recurrent work stoppages).  
11 The diagnosis is based on the symptoms and their severity as  
12 described by the patients (5–8). Currently, there is no etiological  
13 treatment for fibromyalgia syndrome. The treatments are therefore  
14 only symptomatic.  
15  
16  
17  
18

### 19 **Physiopathology of fibromyalgia**

20 The mechanisms of dysfunctional pain, without any identifiable organic  
21 lesions, are mostly central (1) and related to dysfunction of the stress  
22 axis (autonomic nervous system and corticotropic axis) (9–11).  
23 At rest, fibromyalgia patients showed an increased sympathetic  
24 response and decreased parasympathetic tone (12,13). This  
25 neurovegetative dystonia is a marker of dysfunction of the stress axis  
26 (14).  
27 Malfunctions of the corticotropic axis in fibromyalgia have been  
28 described multiple times, also marking the dysfunction of the stress  
29 axis. But the form taken by this dysfunction differs according to the  
30 different studies (15–19). The variability of salivary cortisol in response  
31 to stress reflects that of plasma free cortisol. Salivary cortisol is  
32 therefore a method of choice in experimental stress studies (20).  
33 Whatever form they take, these dysfunctions compromise the body's  
34 adaptation to daily stressful stimuli.  
35  
36  
37  
38

39 Studies show that this deficit of the stress axis (neurovegetative  
40 dystonia and dysfunctional corticotropic axis) is concurrent with  
41 fibromyalgia (21) and associated with alteration of pain control (9–11).  
42 Pain control system and stress axis have close anatomical and  
43 functional links. Nociceptive, neurovegetative and corticotropic  
44 systems interact with the central nervous system. The central  
45 neuromediators implicated in the regulation of the stress axis are  
46 mostly common with those of the pain neuromodulation (endogenous  
47 opioids, norepinephrine, serotonin, etc.).  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Elite athlete's overtraining syndrome: model of stress axis dysfunction

An overtraining elite athlete may be considered as a model of dysfunction of the stress axis associated with neurovegetative dystonia. The physical and psychological effort of training is known to induce stress. High-level athletes could present an overtraining syndrome when adaptation limits of the stress axis are reached. This stress-induced phenomenon corresponds to an imbalance between training quantity and recovery. Overtrained athletes present a deconditioning syndrome close to fibromyalgia symptoms (chronic pain, sleep disorders, neurovegetative dystonia, etc.) (22–26).

### Physical activity and fibromyalgia

Most studies have shown that physical activity is more efficient compared to pharmacological treatments on fibromyalgia symptoms (27,28). Literature reviews and meta-analyses highly support the benefits of physical training in fibromyalgia patients (decreased pain and depression and improvement in overall health and physical abilities) (29)(30). Practice of aerobic exercise in fibromyalgia patients is strongly recommended by The American Pain Society (31), the Association of Medical Scientific Societies in Germany (32), the Canadian Rheumatology Association (5) and the European League Against Rheumatism (EULAR) (33). Physical exercise is the first-line treatment recommended in fibromyalgia. However there is still no consensus on the modalities of these types of training (frequency, duration, and intensity). Currently, the mechanisms underlying those specific training effects have to be defined.

The steady physical activity rebalancing autonomic system is associated with cardiovascular benefits. Fundamental endurance increases parasympathetic tone and decrease sympathetic response (34–37). Thus, strategies to rebalance the autonomic system are the most promising therapies for fibromyalgia (13,36,37).

In this study, we propose to validate a therapeutic alternative that aims to treat fibromyalgia by rebalancing the stress axis. This treatment consists of a specific supervised and individualised training program, over 2 years. This training protocol is individually adjusted in order to rebalance the neurovegetative system (parasympathetic and sympathetic). Central neuroplasticity induced by training should regulate endogenous pain control mechanisms.

Objectives 7 The *main objective* is to assess the effectiveness of a specific training program on endogenous pain controls in fibromyalgia patients. The *secondary objectives* are to rebalance the autonomic nervous system and the corticotropic axis, to improve life and sleep quality and to reintegrate patients into society and work.

1 Trial design 8 This randomised double-blinded trial will compare an "active" program  
2 to a "control" program in fibromyalgia patients.  
3  
4  
5  
6

7 **Methods: Participants, interventions, and outcomes**  
8

9 Study setting 9 Patients will be recruited at the pain center of the university hospital of  
10 Brest on the basis of general criteria. Patients should follow a re-  
11 exercise program for 24 months. The assessments will take place (i)  
12 before, (ii) between 6 to 9 months (depending the training level) and  
13 (iii) at the end of the training (24 months), in the neurological functional  
14 explorations department of the university hospital of Brest (France).  
15  
16  
17

18 Eligibility criteria 10 The inclusion criteria are: female subjects; aged of 18 to 65 years; with  
19 a diagnosis of fibromyalgia clearly established according to the criteria  
20 of the American College of Rheumatology (ACR) 2010; with a body  
21 mass index (BMI) between 18.5 and 29.9kg/m<sup>2</sup>; spontaneous pain  
22 intensity higher than 3/10 on a visual analog scale (VAS); pain  
23 experienced at least 3 days a week; pain caused by palpation equal to  
24 or higher than 4/10 on a VAS.  
25  
26

27 The non-inclusion criteria are: patients with a systemic disease  
28 (treated or not) generating pain of the musculoskeletal system;  
29 presenting pain other than fibromyalgia; presenting a contraindication  
30 to physical activity; having any active pathology; having modified in the  
31 last 2 months any pharmacological treatment; having a psychiatric  
32 diagnosis; taking drugs that affect cortisol secretion (decrease or  
33 increase); non-cooperating.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 Interventions 11a The training program is planned over two years (24 months) for both  
3 groups (active/control). A minimum of 4 to 6 weeks is needed to  
4 observe a decrease in symptoms (38). This two-year duration is the  
5 minimum average training time (depending on the individual progress  
6 of each patient), necessary to regain central neuroplasticity sufficient  
7 to put back into operation diffuse noxious inhibitory controls (DNIC)  
8 and neurovegetative system (39).  
9  
10 The frequency, intensity, and duration of these training sessions are  
11 based upon the results of a preliminary study. Pain was significantly  
12 reduced and symptoms, such as quality of life, sleep quality, anxiety,  
13 were also highly improved in subjects undergoing this specific training  
14 after 5 years (39). The American Pain Society recommends an  
15 intensity of 60 to 70% of the age-adjusted maximum heart rate  
16 (HRmax). At the early stage, the intensity and duration of the training  
17 sessions will be adapted to the physical condition of each subject. In  
18 order to promote adherence of our patients and to limit pain  
19 exacerbation, exercise intensity will start very low and then gradually  
20 increase to reach the neurovegetative goal (31)(40).  
21  
22  
23

#### **Active training group:**

*The first 6 to 9 months:* fundamental endurance training.

Subjects will perform 3 sessions per week of 45 minutes of fundamental endurance (moderate-intensity continuous training MICT: 60% HRmax), including 2 sessions supervised by a physiotherapist and 1 independent session.

*From 6-9 months (according to the rhythm, abilities, and limits) to 24 months:* Patients will begin the second stage of training: 3 sessions per week of 45 minutes each (moderate-intensity continuous training MICT (60% HRmax) and high-intensity interval training HIIT) with 1 supervised session and 2 independent sessions. When the patient reaches the initial HR goal, "fundamental endurance" will be associated with "interval training" at a high frequency intensity. HIIT will consist of 5 stages of 1 to 4 minutes at 85-90% HRmax (80-85%  $\dot{V}O_2$ max), interspersed by 1 to 4 minutes of active recovery at 60-75% HRmax (50-70%  $\dot{V}O_2$ max). Intensity will be assessed objectively using a heart rate monitor (FT2, Polar). □At baseline, Tanaka's age-based prediction equation ( $208-0.7 \times \text{age}$ ) will calculate HRmax. After 6-9 months of training, a maximal-effort graded exercise test will determine HRmax and  $\dot{V}O_2$ max for each patient.

#### **Control group:**

Patients will perform the same infra active training (low-intensity continuous training: LICT <50% HRmax) over two years. Supervision, monitoring, and frequency of sessions (3 x 45 minutes per week) in both groups will be equivalent.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant: If a patient cannot achieve the specific training requested after 9 months of study, the patient will not complete the second phase of training.
- 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence: Patients will be contacted to record progress, difficulties and if necessary, to encourage them to adhere to their program. These calls will improve the compliance and will limit patients lost to follow-up.  
Patients will perform a 6-minute walk test (6MWT) every 6 months (with physiotherapist).
- 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial: This specific protocol will be associated with psychotherapeutic approaches. In addition to the training program, multidisciplinary bio-psycho-social cares will be given in the pain center of the university hospital of Brest (France).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Outcomes 12 **Primary outcomes:** In order to assess endogenous pain mechanisms, such as diffuse noxious inhibitory controls (DNIC), temporal summation (TS) and perception of pain, we will use an experimental method developed by Tousignant-Laflamme and Marchand (2008). According to this well-characterised paradigm, we will induce in single session two tonic heat pain stimulations separated by a cold pressor test (1,47–49). The VAS improvements (stimulation test) obtained in the both groups will be compared.


**Secondary outcomes:**  
A simple verbal scale, a visual analog scale, and the Saint Antoine Pain Questionnaire (QDSA), will perform the **assessment of pain**. A **pain quantitative assessment** will be performed with a pressure algometer (pressure pain threshold: PPT).  
Questionnaires will assess **patient anxiodepressive state** (Hospital Anxiety Depression Scale), **the impact of fibromyalgia on daily life** (Fibromyalgia Impact Questionnaire), **sleep quality and quantity** (Pittsburgh Sleep Quality Index), **the level of physical activity and the sedentary lifestyle** (International Physical Activity Questionnaire), **the antecedents of perceived stress** (Perceived Stress Scale).  
**Blood Pressure** (BP) and **Heart Rate** (HR) will be recorded.  
**Corticotropic axis** will be assessed using measurement of salivary cortisol and salivary flow.

Quantitative assessment (salivary cortisol, blood pressure, PPT quantified by pain threshold pressure, questionnaires assessment) will be analysed by comparing the improvements obtained between both groups.

Participant  
timeline

13 The training program is planned over two years (24 months) for both groups (active/control). Subjects will perform 3 training sessions per week of 45 minutes.  
Patient will participate in 4 visits (1 inclusion visit and 3 assessment visits) during these two years.

Figure 1:  
Flow chart  
of  
DouFiSport





1	Sample size	14	Population size is based on an expected difference of 20 points
2			(stimulation test) (1) between the two groups, for a quantitative primary
3			endpoint (delta VAS) of standard deviation equal to 35, and a power
4			set at 80%. Therefore a minimum of 48 subjects per group is required
5			for assessment. In order to take into account loss to follow-up, the
6			sample of 110 subjects, 55 per group will be recruited.
7			
8			
9	Recruitment	15	Patients will be recruited at the pain centre of the university hospital of
10			Brest on the basis of general criteria.
11			

### Methods: Assignment of interventions (for controlled trials)

#### Allocation:

16	Sequence generation	16a	Patients will be randomised at the end of the first stimulation test
17			(second visit: V2), which is just before the initiation of the training. The
18			test is stratified by age and BMI. The cut off is set at 50 years for age
19			and 25kg/m <sup>2</sup> for BMI (two strata [18-25] and ]25-30 []).
20			
21			
22	Allocation concealment mechanism	16b	Electronic randomisation via Capture System
23			
24			
25			
26	Implementation	16c	The allocation sequence will generate by the Center of Clinical
27			Investigation (CIC) at the hospital university of Brest (France).
28			The principal investigator will enrol participants, and will assign
29			participants to interventions.
30			
31			
32	Blinding (masking)	17a	Who will be blinded after assignment to interventions:
33			Patients will be blinded (they will not be informed of their group
34			(active/control)).
35			The investigators, outcome assessors and data analysts will be
36			blinded.
37			
38		17b	If blinded, circumstances under which unblinding is permissible:
39			Due to the nature of the intervention (physical activity protocol), the
40			coaching staff will not be blinded.
41			
42			
43			

### Methods: Data collection, management, and analysis

1 Data collection 18a Measurements and questionnaires will be carried out (i) at baseline,  
2 methods (ii) between 6 to 9 months, and (iii) at the end of the 24 months of  
3 training.

#### 4 **Sociodemographic and clinical data**

5 At baseline, data on age, sex, marital status, education level, and  
6 occupation will be collected. Height and weight will be recorded.  
7 Medical background and pain characteristics will be noted. All current  
8 drug and non-drug therapies (including tried and stopped) will also be  
9 collected, as well as their effectiveness on pain.

#### 10 **Questionnaires and pain assessments**

- 11 • The **assessment of pain** will be performed by a simple verbal  
12 scale and using a visual analog scale (VAS). The Saint Antoine  
13 Pain Questionnaire (QDSA) will also assess pain. A **pain**  
14 **quantitative assessment** will be performed with a pressure  
15 algometer (pressure pain threshold: PPT).  
16 • The Hospital Anxiety Depression Scale (HADS) will assess the  
17 **patient anxiodepressive state** (41).  
18 • The Fibromyalgia Impact Questionnaire (FIQ) will assess **the**  
19 **impact of fibromyalgia on daily life** (42).  
20 • The Pittsburgh Sleep Quality Index (PSQI) will assess **sleep**  
21 **quality and quantity** (43,44).  
22 • The International Physical Activity Questionnaire (IPAQ) will  
23 record the **level of physical activity and the sedentary**  
24 **lifestyle**. The French long telephone questionnaire will be used  
25 (45).  
26 • The Perceived Stress Scale (PSS) will assess **the**  
27 **antecedents of perceived stress** (46).  
28  
29  
30  
31  
32  
33

#### 34 **Stimulation test**

35 In order to assess endogenous pain mechanisms, such as diffuse  
36 noxious inhibitory controls (DNIC), temporal summation (TS) and  
37 perception of pain, we will use an experimental method developed by  
38 Tousignant-Laflamme and Marchand (2008) (1,47–49).

39 - **Thermode test or temporal summation test (P1):** a tonic heat  
40 pain will be administered for 2 minutes on the patient's right arm, using  
41 a thermode (CE marking n°226). The starting temperature is 32°C  
42 (skin temperature under normal conditions in temperate room (20-  
43 22°C)) (50) and will quickly reach a fixed value. The experimental  
44 temperature will be individually determined to induce 50/100 on a VAS  
45 and will remain constant during the test period (2 minutes).

46 Throughout this entire period, the patient will evaluate their pain  
47 intensity using a Computerised Visual Analog Scale (CoVAS).

48 - **Cold pressor test (P2):** to elicit a prolonged pain sensation in  
49 order to trigger diffuse noxious inhibitory control (DNIC) (51), the  
50 patient's right arm will be immersed for 2 minutes in a cold water bath  
51 maintained at 12°C. The patient will continuously evaluate their pain  
52 intensity using a CoVAS.

53 Following this cold pressor test, the thermode test will be again  
54 performed (**P3**).

55 Pain difference between the two (P3/P1) tonic heat pain stimulations  
56 will measure DNIC activation and represents pain modulation.  
57  
58  
59  
60

**Measurement of salivary cortisol and salivary flow**

Corticotrophic axis will be assessed using measurement of salivary cortisol. Cortisol release is pulsatile (10 to 20 peaks per day) and follows a nycthemeral cycle. Maximum cortisol level is reached in the early morning. In the morning of each consultation (at baseline, in the middle and at the end of training), patients will collect salivary sample (i) for 2 minutes, when they wake up and (ii) for 2 minutes, 30 minutes later. The salivary cortisol level is measured in nmol/l. The flow rate is calculated in ml.min<sup>-1</sup>. Samples will be frozen at -20°C. As salivary cortisol is stable, samples can be stored for many weeks in the freezer (52). After completion of all assessment sessions, sample analysis will be completed. To avoid inter-laboratory variation, the same laboratory will assay the samples.

**Recording of Blood Pressure (BP) and Heart Rate (HR)**

After 10 minutes at rest, lying down, BP and HR will be recorded. Then, BP and HR will be measured when the patient stands up and once per minute during 4 minutes when the patient remains standing.

- 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols: To limit dropout, patients will be called to encourage them and to discuss any difficulties. In second stage of training and to limit a possible long-term monotonous effect, physical activity type could be diversified in both groups. The training session will be adapted in the active group (MICT will be associated with HIIT) to reduce sympathetic hyperactivity. In order to improve compliance and long-term achievement of training, the patient may choose the physical activity type performed without supervision. If a patient cannot achieve the specific training requested after 9 months of study, the patient will not complete the second phase of training. Nevertheless, she will carry out all assessment visits. The main analysis will be performed on an intent-to-treat basis.



Data  
management

19 **Case report forms (CRF):**

All data collected must be recorded in the CRF immediately after the procedure. Each missing data will have to be coded. The researcher will carry out a double data entry. In addition, Checks on the consistency of these data will be instantly carried out.

Data on individuals included in the study will be made anonymous. Only the first letter of the subject's name, and the first letter of her first name will be recorded, with a specific code number.

**Quality Assurance and Control:**

A researcher commissioned by the study sponsor will ensure proper achievement of the study and, of data collection, recording and, reporting.

**Storage:**

During the study period, documents will be stored in the neurological functional explorations department of the university hospital of Brest. At the end of the study period, all archived documents will be transferred to a centralized archiving site (Central Archives Service - Brest) and, will be placed under the sponsor responsibility for 15 years according to institutional practices.

Statistical  
methods

20a *Primary outcome analysis:* The VAS improvements (stimulation test) obtained in the both groups will be compared using the Student's test. If the required normality assumption is not sustainable, a nonparametric Wilcoxon test will be used. An alpha risk of 0.05 will be set as the limit of statistical significance. The main analysis will be performed on an intent-to-treat basis. A complementary analysis using a linear model with adjustment for age and BMI factors will be completed.

*The secondary outcomes* (quantitative: salivary cortisol, blood pressure, PPT quantified by pain threshold pressure, questionnaires assessment) will be analysed in a similar way by comparing the improvements obtained between both groups.

**Methods: Monitoring**

Data monitoring

21a Because of the nature of the study (excluding health product and, duration of the study), a monitoring committee independent from the sponsor will not be constituted.  
A researcher commissioned by the study sponsor will ensure proper achievement of the study, and of data collection, recording and reporting.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 21b The study may be stopped early for reasons of safety (in the event of unexpected serious adverse event occurrences), efficacy or futility. The sponsor reserves the right to stop the study at any time, if the desired sample size is not achieved.
- Harms 22 **The investigator** is responsible for recording and reporting all serious adverse events (EvIG) occurring during the entire study period. Regardless of the causal relationship between EvIG and the study, any EvIG will be described on the form dedicated to this matter («EvIG initial report» or «EvIG follow-up report») and will be notified to the sponsor within a time frame of 24 hours after the event occurs.
- All other adverse events (non-serious adverse events) will be reported on adverse event form of the CRF. The date of occurrence, description, intensity, duration, treatment, aetiology, accountability and the decisions taken will be specified.
- The sponsor** has to analyse EvIG (the causality of the EvIG and their expected or unexpected character). The sponsor have to report all unexpected EvIG to Eudravigilance (European pharmacovigilance database), the French Health Authorities (ANSM), the Committee for the Protection of Persons (CPP) and, to the investigators. Each year, the sponsor will draft a safety report that will include:
- the list of unexpected and expected EvIG,
  - a concise and critical analysis of the safety of patients included in the study.
- Each adverse events will be monitored until the it will be completely resolved even if after the study period.
- Auditing 23 A researcher commissioned by the sponsor will audit trial conduct. The investigator and his team undertake to make themselves available during regular Quality Control visits by this researcher. During these visits, informed consent, adherence to study protocol and, CRF data quality, will be reviewed. The investigator undertakes to accept quality control audits carried out by the sponsor, and by the competent authorities.
- Ethics and dissemination**
- Research ethics approval 24 The Committee for the Protection of Persons West VI approved this study on 02/12/2014.

1			
2	Protocol	25	Important protocol modifications by the investigator (eg, changes to
3	amendments		eligibility criteria, outcomes, analyses) have to be approved by the
4			sponsor. The sponsor must obtain a favourable opinion of the CPP
5			and an authorization of the «Agence nationale de sécurité du
6			médicament et des produits de santé» (ANSM) to enable the
7			application of these amendments. A new consent of the patient
8			participating will be collected if necessary.
9			
10	Consent or assent	26a	Patients will be informed of the objectives, constraints, risks and
11			benefits of the study. Patients will be informed of their rights to refuse
12			to participate or to withdraw from the study at any time. All information
13			will be on information and consent form given to the patient. To be
14			included, patients will sign informed written consent. The investigator
15			will collect free, informed, and written consent of the patient before
16			definitive inclusion in the study.
17			
18			
19		26b	Additional consent provisions for collection and use of participant data
20			and biological specimens in ancillary studies, if applicable: No
21			collection will be formed.
22			
23	Confidentiality	27	Data on individuals included in the study will be made anonymous.
24			Only the first letter of the subject's name, and the first letter of her first
25			name will be recorded, with a specific code number. The investigators
26			will take all necessary precautions to ensure the confidentiality of the
27			information in particular with regard to patient identity.
28			
29			
30	Declaration of	28	None declared.
31	interests		
32			
33	Access to data	29	In accordance with good clinical practice, the sponsor is responsible
34			for seeking the agreement of those involved in this research with a
35			view to ensure direct access to source data, source documents and
36			reports in all research place (particularly during quality control).
37			In accordance with the legislative provisions in force (articles L.1121-3
38			et R.5121-13 of the French Public Health Code), the investigators will
39			be making documents and necessary individual data available to
40			researcher charged with study control and monitoring.
41			
42			
43			
44	Ancillary and	30	Pursuant to the provisions of article L1121-10 of the French Public
45	post-trial care		Health Code, the sponsor (CHRU of Brest) undertakes to take out a
46			civil liability insurance contract.
47			
48	Dissemination	31a	The results of this study will be published in specialised scientific
49	policy		journals. These results will be presented to participants and the public
50			at a free public lecture organised by the health promotion department
51			of the city of Brest. These results will also be presented to healthcare
52			professionals and other relevant groups in pain and/or physical activity
53			congresses. In addition, a doctoral thesis will be carried out on this
54			project.
55			
56			
57			
58			
59			
60			

## Appendices

Informed consent materials	32	See attached documentation
Biological specimens	33	Not applicable.

---

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

## References

1. Tousignant-Laflamme Y, Pagé S, Goffaux P, Marchand S. An experimental model to measure excitatory and inhibitory pain mechanisms in humans. *Brain Res.* 16 sept 2008;1230:73•9.
2. Woda A, L'heveder G, Ouchchane L, Bodéré C. Effect of experimental stress in 2 different pain conditions affecting the facial muscles. *J Pain Off J Am Pain Soc.* mai 2013;14(5):455•66.
3. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. *Arthritis Rheum.* févr 1990;33(2):160•72.
4. Cánovas R, León I, Roldán MD, Astur R, Cimadevilla JM. Virtual reality tasks disclose spatial memory alterations in fibromyalgia. *Rheumatol Oxf Engl.* oct 2009;48(10):1273•8.
5. Fitzcharles M, Shir Y, Ablin JN, Buskila D, Amital H, Henningsen P, et al. Classification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines. *Evid-Based Complement Altern Med ECAM.* 2013;2013:528952.
6. Egloff N, von Känel R, Müller V, Egle UT, Kokinogenis G, Lederbogen S, et al. Implications of proposed fibromyalgia criteria across other functional pain syndromes. *Scand J Rheumatol.* 2015;44(5):416•24.
7. Moyano S, Kilstein JG, Alegre de Miguel C. New diagnostic criteria for fibromyalgia: Here to stay? *Reumatol Clin.* août 2015;11(4):210•4.
8. Wolfe F, Fitzcharles M-A, Goldenberg DL, Häuser W, Katz RL, Mease PJ, et al. Comparison of Physician-Based and Patient-Based Criteria for the Diagnosis of Fibromyalgia. *Arthritis Care Res.* mai 2016;68(5):652•9.
9. Bodéré C, Woda A. La douleur orofaciale idiopathique: une douleur fonctionnelle. *Douleur Analgésie.* 21 juin 2009;22(2):89•95.
10. Woda A, Dao T, Gremeau-Richard C. Steroid dysregulation and stomatodynia (burning mouth syndrome). *J Orofac Pain.* 2009;23(3):202•10.
11. Woda A, L'heveder G, Ouchchane L, Bodéré C. Effect of experimental stress in 2 different pain conditions affecting the facial muscles. *J Pain Off J Am Pain Soc.* mai 2013;14(5):455•66.



- 1 12. Cohen H, Neumann L, Shore M, Amir M, Cassuto Y, Buskila D. Autonomic  
2 dysfunction in patients with fibromyalgia: application of power spectral analysis of heart rate  
3 variability. *Semin Arthritis Rheum*. févr 2000;29(4):217•27.
- 4 13. da Cunha Ribeiro RP, Roschel H, Artioli GG, Dassouki T, Perandini LA, Calich AL, et  
5 al. Cardiac autonomic impairment and chronotropic incompetence in fibromyalgia. *Arthritis*  
6 *Res Ther*. 2011;13(6):R190.
- 7 14. Martinez-Lavin M. Fibromyalgia as a sympathetically maintained pain syndrome. *Curr*  
8 *Pain Headache Rep*. oct 2004;8(5):385•9.
- 9 15. Kadetoff D, Kosek E. Evidence of reduced sympatho-adrenal and hypothalamic-  
10 pituitary activity during static muscular work in patients with fibromyalgia. *J Rehabil Med*.  
11 sept 2010;42(8):765•72.
- 12 16. Tak LM, Cleare AJ, Ormel J, Manoharan A, Kok IC, Wessely S, et al. Meta-analysis  
13 and meta-regression of hypothalamic-pituitary-adrenal axis activity in functional somatic  
14 disorders. *Biol Psychol*. mai 2011;87(2):183•94.
- 15 17. Riva R, Mork PJ, Westgaard RH, Lundberg U. Comparison of the cortisol awakening  
16 response in women with shoulder and neck pain and women with fibromyalgia.  
17 *Psychoneuroendocrinology*. févr 2012;37(2):299•306.
- 18 18. Geiss A, Rohleder N, Anton F. Evidence for an association between an enhanced  
19 reactivity of interleukin-6 levels and reduced glucocorticoid sensitivity in patients with  
20 fibromyalgia. *Psychoneuroendocrinology*. mai 2012;37(5):671•84.
- 21 19. Bote ME, García JJ, Hinchado MD, Ortega E. Inflammatory/stress feedback  
22 dysregulation in women with fibromyalgia. *Neuroimmunomodulation*. 2012;19(6):343•51.
- 23 20. Hellhammer DH, Wüst S, Kudielka BM. Salivary cortisol as a biomarker in stress  
24 research. *Psychoneuroendocrinology*. févr 2009;34(2):163•71.
- 25 21. Clauw D, Ablin J. The relationship between « stress » and pain: lessons learned from  
26 fibromyalgia and related conditions. In: *Current topics in pain*. Castro-Lopes editor. XIIth  
27 World Congress on Pain. Seattle: IASP press; 2009. p. p.245-270.
- 28 22. McKenzie DC. Markers of excessive exercise. *Can J Appl Physiol Rev Can Physiol*  
29 *Appl*. févr 1999;24(1):66•73.
- 30 23. MacKinnon LT. Special feature for the Olympics: effects of exercise on the immune  
31 system: overtraining effects on immunity and performance in athletes. *Immunol Cell Biol*. oct  
32 2000;78(5):502•9.
- 33 24. Iellamo F, Pigozzi F, Parisi A, Di Salvo V, Vago T, Norbiato G, et al. The stress of  
34 competition dissociates neural and cortisol homeostasis in elite athletes. *J Sports Med Phys*  
35 *Fitness*. déc 2003;43(4):539•45.
- 36 25. Baumert M, Brechtel L, Lock J, Hermsdorf M, Wolff R, Baier V, et al. Heart rate  
37 variability, blood pressure variability, and baroreflex sensitivity in overtrained athletes. *Clin J*  
38 *Sport Med Off J Can Acad Sport Med*. sept 2006;16(5):412•7.
- 39 26. Kajaia T, Maskhulia L, Chelidze K, Akhalkatsi V, Kakhbrishvili Z. The effects of non-  
40 functional overreaching and overtraining on autonomic nervous system function in highly  
41 trained athletes. *Georgian Med News*. mars 2017;(264):97•103.
- 42 27. Fontenele JB, Felix FHC. Exercise for fibromyalgia: evidence for an integrated  
43 modulation of autonomic and nociception neural regulation. *Rheumatol Int*. déc  
44 2012;32(12):4075•6.
- 45 28. Rossy LA, Buckelew SP, Dorr N, Hagglund KJ, Thayer JF, McIntosh MJ, et al. A  
46 meta-analysis of fibromyalgia treatment interventions. *Ann Behav Med Publ Soc Behav Med*.  
47 1999;21(2):180•91.



- 1 29. Busch AJ, Webber SC, Brachaniec M, Bidonde J, Bello-Haas VD, Danyliw AD, et al.  
2 Exercise therapy for fibromyalgia. *Curr Pain Headache Rep.* oct 2011;15(5):358•67.
- 3 30. Woda A, L'heveder G, Ouchchane L, Bodéré C. Effect of experimental stress in 2  
4 different pain conditions affecting the facial muscles. *J Pain Off J Am Pain Soc.* mai  
5 2013;14(5):455•66.
- 6 31. Society AP, éditeur. *Guideline for the Management of Fibromyalgia Syndrome Pain  
7 in Adults and Children.* American Pain Society; 2005. 109 p.
- 8 32. Häuser W, Arnold B, Eich W, Felde E, Flügge C, Henningsen P, et al. Management  
9 of fibromyalgia syndrome – an interdisciplinary evidence-based guideline. *GMS Ger Med  
10 Sci.* 2008;6:Doc14.
- 11 33. Macfarlane GJ, Kronisch C, Atzeni F, Häuser W, Choy EH, Amris K, et al. EULAR  
12 recommendations for management of fibromyalgia. *Ann Rheum Dis.* déc 2017;76(12):e54.
- 13 34. Melanson EL, Freedson PS. The effect of endurance training on resting heart rate  
14 variability in sedentary adult males. *Eur J Appl Physiol.* sept 2001;85(5):442•9.
- 15 35. Reland S, Ville NS, Wong S, Gauvrit H, Kervio G, Carré F. Exercise heart rate  
16 variability of older women in relation to level of physical activity. *J Gerontol A Biol Sci Med  
17 Sci.* juill 2003;58(7):585•91.
- 18 36. de Abreu SB, Lenhard A, Mehanna A, de Souza HCD, Correa FM de A, Hasser EM,  
19 et al. Role of paraventricular nucleus in exercise training-induced autonomic modulation in  
20 conscious rats. *Auton Neurosci Basic Clin.* 15 juin 2009;148(1•2):28•35.
- 21 37. Martins-Pinge MC. Cardiovascular and autonomic modulation by the central nervous  
22 system after aerobic exercise training. *Braz J Med Biol Res Rev Bras Pesqui Médicas E  
23 Biológicas Soc Bras Biofísica Al.* sept 2011;44(9):848•54.
- 24 38. Häuser W, Klose P, Langhorst J, Moradi B, Steinbach M, Schiltenswolf M, et al.  
25 Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review  
26 and meta-analysis of randomised controlled trials. *Arthritis Res Ther.* 2010;12(3):R79.
- 27 39. Bodéré C, Bodéré YT, Quinio B, Woda A, Misery L. Specific training program for the  
28 treatment of fibromyalgia: a prospective controlled study. In: 14th world congress on pain -  
29 TF505. Milan, Italy: IASP; 2012.
- 30 40. Lannersten L, Kosek E. Dysfunction of endogenous pain inhibition during exercise  
31 with painful muscles in patients with shoulder myalgia and fibromyalgia. *Pain.* oct  
32 2010;151(1):77•86.
- 33 41. Krag NJ, Nørregaard J, Larsen JK, Danneskiold-Samsøe B. A blinded, controlled  
34 evaluation of anxiety and depressive symptoms in patients with fibromyalgia, as measured  
35 by standardized psychometric interview scales. *Acta Psychiatr Scand.* juin  
36 1994;89(6):370•5.
- 37 42. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire:  
38 development and validation. *J Rheumatol.* mai 1991;18(5):728•33.
- 39 43. Osorio CD, Gallinaro AL, Lorenzi-Filho G, Lage LV. Sleep quality in patients with  
40 fibromyalgia using the Pittsburgh Sleep Quality Index. *J Rheumatol.* sept  
41 2006;33(9):1863•5.
- 42 44. Omachi TA. Measures of sleep in rheumatologic diseases: Epworth Sleepiness Scale  
43 (ESS), Functional Outcome of Sleep Questionnaire (FOSQ), Insomnia Severity Index (ISI),  
44 and Pittsburgh Sleep Quality Index (PSQI). *Arthritis Care Res.* nov 2011;63 Suppl 11:S287-  
45 296.
- 46 45. Crinière L, Lhommet C, Caille A, Giraudeau B, Lecomte P, Couet C, et al.  
47 Reproducibility and validity of the French version of the long international physical activity  
48 questionnaire in patients with type 2 diabetes. *J Phys Act Health.* août 2011;8(6):858•65.
- 49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59

- 1 46. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *J Health*  
2 *Soc Behav.* déc 1983;24(4):385•96.
- 3 47. Marchand S, Arsenault P. Spatial summation for pain perception: interaction of  
4 inhibitory and excitatory mechanisms. *Pain.* févr 2002;95(3):201•6.
- 5 48. Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in fibromyalgia is  
6 related to a deficit of endogenous pain inhibition. *Pain.* mars 2005;114(1•2):295•302.
- 7 49. Granot M, Granovsky Y, Sprecher E, Nir R-R, Yarnitsky D. Contact heat-evoked  
8 temporal summation: tonic versus repetitive-phasic stimulation. *Pain.* juin  
9 2006;122(3):295•305.
- 10 50. Barrett KE, Barman SM, Boitano S, Brooks H. *Ganong's Review of Medical*  
11 *Physiology*, 24th Edition. 24 edition. New York: McGraw-Hill Education / Medical; 2012. 768  
12 p.
- 13 51. Potvin S, Paul-Savoie E, Morin M, Bourgault P, Marchand S. Temporal summation of  
14 pain is not amplified in a large proportion of fibromyalgia patients. *Pain Res Treat.*  
15 2012;2012:938595.
- 16 52. Kirschbaum C, Hellhammer DH. Salivary cortisol in psychoneuroendocrine research:  
17 recent developments and applications. *Psychoneuroendocrinology.* 1994;19(4):313•33.
- 18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description
<b>Administrative information</b>		
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry
	2b	All items from the World Health Organization Trial Registration Data Set
Protocol version	3	Date and version identifier
Funding	4	Sources and types of financial, material, and other support
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors
	5b	Name and contact information for the trial sponsor
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)
<b>Introduction</b>		
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention
	6b	Explanation for choice of comparators
Objectives	7	Specific objectives or hypotheses
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)

1  
2 **Methods: Participants, interventions, and outcomes**

3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size

45 **Methods: Assignment of interventions (for controlled trials)**

46 Allocation:

47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions
---------------------	-----	--

1			
2	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central
3	concealment		telephone; sequentially numbered, opaque, sealed envelopes),
4	mechanism		describing any steps to conceal the sequence until interventions are
5			assigned
6			
7	Implementation	16c	Who will generate the allocation sequence, who will enrol participants,
8			and who will assign participants to interventions
9			
10	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial
11	(masking)		participants, care providers, outcome assessors, data analysts), and
12			how
13			
14		17b	If blinded, circumstances under which unblinding is permissible, and
15			procedure for revealing a participant's allocated intervention during
16			the trial
17			

### 18 **Methods: Data collection, management, and analysis**

19			
20	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other
21	methods		trial data, including any related processes to promote data quality (eg,
22			duplicate measurements, training of assessors) and a description of
23			study instruments (eg, questionnaires, laboratory tests) along with
24			their reliability and validity, if known. Reference to where data
25			collection forms can be found, if not in the protocol
26			
27			
28		18b	Plans to promote participant retention and complete follow-up,
29			including list of any outcome data to be collected for participants who
30			discontinue or deviate from intervention protocols
31			
32	Data	19	Plans for data entry, coding, security, and storage, including any
33	management		related processes to promote data quality (eg, double data entry;
34			range checks for data values). Reference to where details of data
35			management procedures can be found, if not in the protocol
36			
37	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.
38	methods		Reference to where other details of the statistical analysis plan can be
39			found, if not in the protocol
40			
41			
42		20b	Methods for any additional analyses (eg, subgroup and adjusted
43			analyses)
44			
45		20c	Definition of analysis population relating to protocol non-adherence
46			(eg, as randomised analysis), and any statistical methods to handle
47			missing data (eg, multiple imputation)
48			

### 49 **Methods: Monitoring**

50			
51	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role
52			and reporting structure; statement of whether it is independent from
53			the sponsor and competing interests; and reference to where further
54			details about its charter can be found, if not in the protocol.
55			Alternatively, an explanation of why a DMC is not needed
56			
57			
58			
59			
60			

	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor

### **Ethics and dissemination**

Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions
	31b	Authorship eligibility guidelines and any intended use of professional writers
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code

## Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable

---

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

# BMJ Open

## Impact of a specific training program on the neuromodulation of pain in female fibromyalgia patients (DouFiSport): A 24-month, controlled, randomised, double-blind protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023742.R2
Article Type:	Protocol
Date Submitted by the Author:	14-Nov-2018
Complete List of Authors:	<p>Le Fur Bonnabesse, Anais; Universite de Bretagne Occidentale Faculte de Medecine et des Sciences de la Sante de Brest, LIEN, EA4685; Universite de Bretagne Occidentale UFR d'Odontologie</p> <p>Cabon, Mathilde; Universite de Bretagne Occidentale Faculte de Medecine et des Sciences de la Sante de Brest, LIEN, EA4685</p> <p>L'Heveder, Gildas; CHRU de Brest, Explorations fonctionnelles neurologiques</p> <p>Kermarrec, Aurélie ; CHRU de Brest, IFMK</p> <p>Quinio, Bertrand; CHRU de Brest, Centre d'évaluation et de traitement de la douleur</p> <p>Woda, Alain; Universite Clermont Auvergne Faculte de Chirurgie Dentaire, CROC EA3847</p> <p>Marchand, Serge; Universite de Sherbrooke Faculte de medecine et des sciences de la sante, Department of surgery</p> <p>Dubois, Amandine; Laboratoire de psychologie, Cognition, Behaviour, Communication (LP3C), EA1285; Universite de Bretagne Occidentale UFR Lettres et Sciences Humaines a Brest, Département de psychologie</p> <p>Giroux-Metges, Marie-Agnes; Universite de Bretagne Occidentale Faculte de Medecine et des Sciences de la Sante de Brest, ORPHY EA4324; CHRU de Brest, Explorations fonctionnelles respiratoires</p> <p>Rannou, Fabrice; Universite de Bretagne Occidentale Faculte de Medecine et des Sciences de la Sante de Brest, ORPHY EA4324; CHRU de Brest, Explorations fonctionnelles respiratoires</p> <p>Misery, Laurent; Universite de Bretagne Occidentale Faculte de Medecine et des Sciences de la Sante de Brest, LIEN EA4685</p> <p>Bodéré, Céline; Universite de Bretagne Occidentale Faculte de Medecine et des Sciences de la Sante de Brest, LIEN EA4685; CHRU de Brest, Centre d'évaluation et de traitement de la douleur</p>
<b>Primary Subject Heading</b>:	Sports and exercise medicine
Secondary Subject Heading:	Medical education and training, Rehabilitation medicine, Rheumatology, Pharmacology and therapeutics
Keywords:	PAIN MANAGEMENT, MEDICAL EDUCATION & TRAINING, REHABILITATION MEDICINE, FIBROMYALGIA



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Impact of a specific training program on the neuromodulation of pain in female fibromyalgia patients (DouFiSport): A 24-month, controlled, randomised, double-blind protocol

Anaïs Le Fur-Bonnabesse<sup>1,2,3</sup>, Mathilde Cabon<sup>1</sup>, Gildas L'Heveder<sup>4</sup>, Aurélie Kermarrec<sup>5</sup>, Bertrand Quinio<sup>3</sup>, Alain Woda<sup>6</sup>, Serge Marchand<sup>7</sup>, Amandine Dubois<sup>8,9,1</sup>, Marie-Agnès Giroux-Metges<sup>10,11</sup>, Fabrice Rannou<sup>10,11</sup>, Laurent Misery<sup>1</sup>, Céline Bodéré<sup>1,2,3</sup>.

1 LIEN, EA4685, Faculty of Medicine and Health Sciences, University of Western Brittany (UBO), Brest, France

2 Dental Faculty, University of Western Brittany (UBO), Brest, France

3 Pain Assessment and Treatment Centre, University Hospital of Brest, Brest, France

4 Neurological functional explorations, University Hospital of Brest, Brest, France.

5 Physiotherapy Training Institute, University Hospital of Brest, Brest, France.

6 University Clermont Auvergne, CROC and Teaching Hospital EA3847, Odontology Department, Clermont-Ferrand, France

7 Department of Surgery, Faculty of Medicine, University of Sherbrooke, Sherbrooke, Canada.

8 Laboratory of Psychology: Cognition, Behaviour, Communication (LP3C), EA1285, Rennes, France.

9 Department of Psychology, University of Western Brittany (UBO), Brest, France.

10 ORPHY, Optimisation of Physiological Regulations, EA4324, Faculty of Medicine and Health Sciences, University of Western Brittany (UBO), Brest, France.

11 Respiratory Functional Exploration Unit, University Hospital of Brest, Brest, France.

**Corresponding author: Anaïs Le Fur-Bonnabesse**

anais.lefurbonnabesse@univ-brest.fr

anais.bonnabesse@gmail.com

## **ABSTRACT**

### **INTRODUCTION**

The main symptom of fibromyalgia (FM) is diffuse pain. There is currently no etiological treatment for FM. However, all pain associations and best practice guidelines strongly advocate the practice of aerobic physical activity to improve the symptoms of FM subjects. The mechanisms of dysfunctional pain are mostly central and related to stress axis dysfunction (autonomic nervous system and corticotropic axis). Our main objective is to assess the efficacy of a specific training program on endogenous pain control mechanisms in female fibromyalgia patients. Further aims include rebalancing the autonomic neurovegetative system, improving quality of life and sleep quality, and reintegrating patients into society and work.

### **METHODS AND ANALYSIS**

110 female FM patients diagnosed on ACR 2010 criteria, aged 18–65 years and meeting inclusion conditions will be recruited and randomised into two groups (active and semi-active). The training program will consist of three 45-minute sessions per week of supervised, individualised physical activity over two years. Only the intensity of the exercises will differ between the two groups (moderate-intensity versus low-intensity).

All outcome measures will be conducted at baseline (T0), after 6–9 months of training (T6-9), and after 24 months of training (T24). The primary endpoint will be improvement of pain modulation (activation of diffuse noxious inhibitory control (DNIC)) evaluated by the stimulation test. The secondary endpoint will be relief of pain, anxiety, depression, stress, sleep disorders, pain impact on life quality, and improved heart rate, blood pressure and salivary cortisol.

### **ETHICS AND DISSEMINATION**

This study is approved by the Committee for the Protection of Persons West VI. The results will be published in specialised scientific journals and will be presented at scientific meetings on pain and/or physical activity. Trial registration: NCT02486965.

## **Strengths and limitations of this study**

- ▶ First randomised controlled double-blind trial to assess the effects of a long-term training program (24 months) on pain control in fibromyalgia.
- ▶ The protocol of the training program is designed to rebalance the neurovegetative system and thereby treat fibromyalgia.
- ▶ Physical activity intensity will be assessed objectively using a heart rate monitor.
- ▶ The dropout rate in patients may be high.
- ▶ Due to the nature of the intervention, the coaching staff cannot be blinded.

## INTRODUCTION

Fibromyalgia affects 1.4–2.2% of the general population, predominately women (more than 80% of subjects). This syndrome is characterised by extensive diffuse pain, mainly muscular and articular, impairing the functional abilities of the subjects. The symptoms most frequently described by fibromyalgia patients are chronic fatigue, sleep disorders, cognitive disorders and emotional disturbances (1,2). They lead to a severe deterioration in quality of life, sometimes with physical disability leading to social isolation and difficulties staying in employment (recurrent sick leave).

Diagnosis is based on the symptoms and their severity as described by the patients (3–6). There is currently no etiological treatment for fibromyalgia syndrome. Treatments are therefore only symptomatic.

### **Physiopathology of fibromyalgia**

The mechanisms of dysfunctional pain, with no identifiable organic lesions, are mostly central (7) and related to dysfunction of the stress axis (autonomic nervous system and corticotropic axis) (8,9).

At rest, fibromyalgia patients show an increased sympathetic response and decreased parasympathetic tone (10,11). This neurovegetative dystonia is a marker of dysfunction of the stress axis (12).

Malfuncions of the corticotropic axis in fibromyalgia have often been described, also marking the dysfunction of the stress axis. However, the form taken by this dysfunction differs according to the study (13–17). The variability of salivary cortisol in response to stress reflects that of plasma free cortisol. Salivary cortisol is therefore a method of choice in experimental stress studies (18). Whatever their form, these dysfunctions all compromise the body's adaptation to daily stressful stimuli.

Studies show that this deficit of the stress axis (neurovegetative dystonia and dysfunctional corticotropic axis) is concurrent with fibromyalgia (19) and associated with altered pain control (8,9). The pain control system and the stress

1  
2  
3 axis have close anatomical and functional links. Nociceptive, neurovegetative and  
4 corticotropic systems interact with the central nervous system. The central  
5 neuromediators involved in the regulation of the stress axis are mostly common  
6 with those of pain neuromodulation (endogenous opioids, norepinephrine,  
7 serotonin, etc.).  
8  
9  
10  
11  
12

### 13 14 **Elite athlete's overtraining syndrome: a model of stress axis** 15 **dysfunction**

16  
17 An overtraining elite athlete may be considered as a model of dysfunction of the  
18 stress axis associated with neurovegetative dystonia. The physical and  
19 psychological effort of training is known to induce stress. High-level athletes can  
20 present an overtraining syndrome when the adaptation limits of the stress axis  
21 are reached. This stress-induced phenomenon corresponds to an imbalance  
22 between training quantity and recovery. Overtrained athletes present a  
23 deconditioning syndrome close to fibromyalgia symptoms (chronic pain, sleep  
24 disorders, neurovegetative dystonia, intense fatigue, etc.) (20–24).  
25  
26  
27  
28  
29  
30  
31  
32  
33

### 34 **Physical activity and fibromyalgia**

35  
36 Most studies have shown that physical activity is more efficacious on  
37 fibromyalgia symptoms than pharmacological treatments (25,26). Literature  
38 reviews and meta-analyses strongly support the benefits of physical training in  
39 fibromyalgia patients (decreased pain and depression and improvement in  
40 overall health and physical abilities) (27). Practice of aerobic exercise in  
41 fibromyalgia patients is strongly recommended by The American Pain Society  
42 (28), the Association of Medical Scientific Societies in Germany (29), the  
43 Canadian Rheumatology Association (3) and the European League Against  
44 Rheumatism (EULAR) (30). Physical exercise is the first-line treatment  
45 recommended in fibromyalgia, but there is still no consensus on the modalities of  
46 such training (frequency, duration, and intensity). The mechanisms underlying  
47 these specific training effects remain to be determined.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Steady physical activity rebalancing the autonomic system is associated with  
4 cardiovascular benefits. Physical activity increases parasympathetic tone and  
5 decreases sympathetic response (31–34). Mechanisms and structures involved  
6 in the activation and regulation of the neurovegetative system may interact with  
7 the central nervous system. Central relationships between the neurovegetative  
8 system and the motor cortex, the limbic system, the hypothalamus, the pituitary  
9 gland and the basal ganglia result in the release of analgesic neurotransmitters  
10 such as noradrenalin, serotonin and endogenous opioids (35)(36). This release  
11 of neurotransmitters due to exercise leads to increased endogenous inhibition  
12 and so decreases diffuse pain in FM (35). Central nervous system plasticity  
13 induced by physical training can regulate both cardiovascular adaptations (34)  
14 and endogenous pain control mechanisms (37)(38). Thus strategies to rebalance  
15 the autonomic system are the most promising therapies for fibromyalgia  
16 (11,33,34).  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 In this study, we set out to validate a therapeutic alternative that aims to treat  
31 fibromyalgia by rebalancing the stress axis. This treatment consists of a specific,  
32 supervised, individualised training program lasting 2 years. This training  
33 protocol is individually adjusted to rebalance the neurovegetative system  
34 (parasympathetic and sympathetic). Central neuroplasticity induced by training  
35 should regulate endogenous pain control mechanisms. This specific protocol will  
36 be associated with psychotherapeutic approaches. In addition to the training  
37 program, multidisciplinary bio-psycho-social care will be given at the pain centre  
38 of the University Hospital of Brest (3).  
39  
40  
41  
42  
43  
44  
45  
46  
47

## 48 **Objectives**

49 Our *main objective* is to assess the efficacy of a specific training program on  
50 endogenous pain control in fibromyalgia patients. Our *secondary objectives* are to  
51 rebalance the autonomic nervous system and the corticotropic axis, improve life  
52 and sleep quality and reintegrate patients into society and work.  
53  
54  
55  
56  
57  
58  
59  
60

## *METHODS AND ANALYSIS*

### **Design and setting**

This randomised, double-blind trial will compare an "active" program to a "semi-active" program in fibromyalgia patients. Patients will be recruited at the pain centre of the University Hospital of Brest on the basis of general criteria. Patients are to follow a re-exercise program for 24 months. The assessments will take place (i) before, (ii) between 6 and 9 months (depending the training level) and (iii) at the end of training (24 months), in the neurological functional explorations department of the University Hospital of Brest (Fig.1).

### **Patient involvement**

The specific training program of this study was developed based on the results of a pilot study (39), data from literature and the experiences of fibromyalgia patients recorded at the pain centre of the University Hospital of Brest. These patients reported the benefits, constraints, difficulties, and effects of their training program on their symptoms. This information has allowed adjustments to be made to the specific training program. Patients are not involved in the recruitment and conduct of the study. At the last assessment visit, patients will be asked to assess the burden of the program. On request, a report outlining the study findings will be given to study participants.

### **Study population**

110 fibromyalgia patients will be included. The inclusion criteria are: female; aged 18–65 years; diagnosis of fibromyalgia clearly established according to the criteria of the American College of Rheumatology (ACR) 2010; body mass index (BMI) 18.5–29.9 kg/m<sup>2</sup>; spontaneous pain intensity higher than 3/10 on a visual analogue scale (VAS); pain experienced at least 3 days a week; pain caused by palpation greater than or equal to 4/10 on a VAS.

The non-inclusion criteria are: systemic disease (treated or not) generating pain of the musculoskeletal system; pain other than fibromyalgia; contraindication to physical activity; any active health disorder; change in the last 2 months in any



1  
2  
3 pharmacological treatment; psychiatric diagnosis; taking drugs that affect  
4 cortisol secretion (decrease or increase); non-cooperating.  
5  
6  
7

## 8 **Sample size**

9  
10 Population size is calculated on an expected difference of 20 points (stimulation  
11 test) (7) between the two groups, for a quantitative primary endpoint (delta  
12 VAS) of standard deviation equal to 35, and a power set at 80%. At least 48  
13 subjects per group are therefore required. To take into account loss to follow-up,  
14 a sample of 110 subjects, i.e. 55 per group, will be recruited.  
15  
16  
17  
18  
19  
20

## 21 **Randomisation**

22  
23 Patients will be randomised at the end of the first stimulation test, just before  
24 initiation of the training. Randomisation will be conducted by the Centre for  
25 Clinical Investigation (CIC) at the University Hospital of Brest (electronic  
26 randomisation via Capture System). The test will be stratified by age and BMI.  
27 The cut-off will be set at 50 years for age and 25 kg/m<sup>2</sup> for BMI (two strata [18-  
28 25] and ]25-30 []).  
29  
30  
31  
32  
33  
34

## 35 **Training program**

36  
37 The training program is planned over two years (24 months) for both groups  
38 (active/semi-active). A minimum of 4–6 weeks is needed to observe a decrease  
39 in symptoms (39). This two-year duration is the minimum average training time  
40 (depending on the individual progress of each patient) necessary to regain a  
41 central neuroplasticity sufficient to restore diffuse noxious inhibitory controls  
42 (DNIC) and the neurovegetative system (40).  
43  
44  
45  
46  
47

48 The frequency, intensity, and duration of these training sessions are based on  
49 both data from the literature (39,41) and the results of a preliminary study. Pain  
50 was significantly reduced and symptoms such as quality of life, sleep quality and  
51 anxiety, were also strongly improved in subjects who had undergone this specific  
52 training after 5 years (40).  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The American Pain Society recommends an intensity of 60–70% of the age-  
4 adjusted maximum heart rate (HRmax). At the early stage, the intensity and  
5 duration of the training sessions will be adapted to the physical condition of each  
6 subject. The intensity exercise will be 3 on the Borg CR10 scale (39). To promote  
7 adherence of our patients and to limit pain exacerbation, exercise intensity will  
8 start very low and then increase very gradually to reach the neurovegetative goal  
9 (28)(42).

10  
11  
12  
13  
14  
15 The ideal frequency is three training sessions per week each lasting 45 minutes  
16 (39,40).

### 17 18 19 20 21 **Active training group**

#### 22 *First 6–9 months*

23  
24 Subjects will perform three sessions per week of 45 minutes of moderate-  
25 intensity continuous training (MICT) (65–75% HRmax), including two sessions  
26 supervised by a physiotherapist specially trained and one independent session.

#### 27 28 29 *From 6–9 months (according to pace, abilities, and limits) to 24 months*

30  
31 Patients will begin the second stage of training: three sessions per week of at  
32 least 45 minutes each (MICT and high-intensity interval training (HIIT)) with one  
33 supervised session and two independent sessions. When the patient reaches the  
34 initial HR goal, continuous training will be associated with interval training. HIIT  
35 will consist of 5 stages of 1–4 minutes at 85–90% HRmax, interspersed by 1–4  
36 minutes of active recovery at 65–75% HRmax. Intensity will be assessed  
37 objectively using a heart rate monitor (FT2, Polar). At baseline, Tanaka's age-  
38 based prediction equation ( $208 - 0.7 \times \text{age}$ ) will calculate HRmax. After 6–9  
39 months of training, a maximal-effort graded exercise test will determine HRmax  
40 and  $\text{VO}_2\text{max}$  for each patient.

### 41 42 43 44 45 46 47 48 49 50 51 **Semi-active training group**

52  
53 Patients will perform the same infra-active training (low-intensity continuous  
54 training: LICT < 50% HRmax) for two years. Supervision, monitoring, and  
55 frequency of sessions ( $3 \times 45$  minutes per week) in both groups will be  
56 equivalent.

### **Training follow-up (for both groups)**

Patients will be contacted to record progress, difficulties and if necessary to encourage them to adhere to their program. These calls will improve compliance and limit patients lost to follow-up (43,44). Subjects will note the characteristics (frequency, duration, intensity, type of activity, and supervision) of each training session (both supervised and independent) in a specific training logbook. The physiotherapist will frequently ask patients about their independent training session to provide advice and motivate them. The follow-up at the pain centre will assess compliance with the training protocol.

Patients will perform a 6-minute walk test (6MWT) every 6 months (with a physiotherapist). If a patient cannot achieve the specific training requested after 9 months of study, then she will not complete the second phase of training, but will nevertheless attend all assessment visits. The main analysis will be performed on an intent-to-treat basis.

## **Clinical data, measurements and assessments**

### **Sociodemographic and clinical data**

At baseline, data on age, sex, marital status, education level, and occupation will be collected. Height and weight will be recorded. Medical background and pain characteristics will be noted. All current drug and non-drug therapies (including tried and stopped) will also be collected, together with their effectiveness on pain.

### **Questionnaires and pain assessments**

Measurements and questionnaires will be carried out (i) at baseline, (ii) between 6 and 9 months, and (iii) at the end of the 24 months of training.

- The **assessment of pain** will be performed by a simple verbal scale and using a visual analogue scale (VAS). The Saint Antoine Pain Questionnaire (QDSA) will also assess pain. A **pain quantitative assessment** will be performed with a pressure algometer (pressure pain threshold: PPT).

- 1  
2  
3 – The Hospital Anxiety Depression Scale (HADS) will assess the **patient's**  
4 **anxiodepressive state** (45).
- 5  
6 – The Fibromyalgia Impact Questionnaire (FIQ) will assess **the impact of**  
7 **fibromyalgia on daily life** (46).
- 8  
9 – The Pittsburgh Sleep Quality Index (PSQI) will assess **sleep quality and**  
10 **quantity** (47,48).
- 11  
12 – The International Physical Activity Questionnaire (IPAQ) will record the **level**  
13 **of physical activity and sedentary lifestyle**. The French long telephone  
14 questionnaire will be used (49).
- 15  
16 – The Perceived Stress Scale (PSS) will assess **the antecedents of perceived**  
17 **stress** (50).
- 18  
19  
20  
21  
22

### 23 24 **Stimulation test**

25  
26 To assess endogenous pain mechanisms, such as diffuse noxious inhibitory  
27 controls (DNIC), temporal summation (TS) and perception of pain, we will use an  
28 experimental method developed by Tousignant-Laflamme and Marchand (2008).  
29 According to this well-characterised paradigm, we will induce in single session  
30 two tonic heat pain stimulations separated by a cold pressor test (7,51–53).  
31  
32  
33  
34  
35

36  
37 **Thermode test or temporal summation test (P1):** a tonic heat pain will be  
38 administered for 2 minutes on the patient's right arm, using a thermode (CE  
39 marking No. 226). The starting temperature is 32°C (skin temperature under  
40 normal conditions in a temperate room (20–22°C)) (54) and will quickly reach a  
41 fixed value. The experimental temperature will be individually determined to  
42 induce 50/100 on a VAS and will remain constant during the test period  
43 (2 minutes). Throughout this period, the patient will evaluate her pain intensity  
44 using a Computerised Visual Analog Scale (CoVAS).  
45  
46  
47  
48  
49  
50

51  
52 **Cold pressor test (P2):** to elicit a prolonged pain sensation to trigger diffuse  
53 noxious inhibitory control (DNIC) (55), the patient's right arm will be immersed  
54 for 2 minutes in a cold water bath maintained at 12°C. The patient will  
55 continuously evaluate her pain intensity using a CoVAS.  
56  
57  
58

59 Following this cold pressor test, the thermode test will be performed again **(P3)**.  
60

1  
2  
3 Pain difference between the two (P3/P1) tonic heat pain stimulations will  
4 measure DNIC activation, and represents pain modulation.  
5  
6  
7

### 8 **Measurement of salivary cortisol and salivary flow**

9  
10 Corticotropic axis will be assessed using measurement of salivary cortisol.  
11 Cortisol release is pulsatile (10–20 peaks per day) and follows a nycthemeral  
12 cycle. Cortisol level peaks in the early morning. In the morning of each  
13 consultation (at baseline, in the middle and at the end of training), patients will  
14 collect a salivary sample (i) for 2 minutes, when they wake up and (ii) for 2  
15 minutes, 30 minutes later. The salivary cortisol level is measured in nmol/l. The  
16 flow rate is calculated in ml.min<sup>-1</sup>. Samples will be frozen at –20°C. As salivary  
17 cortisol is stable, samples can be stored for many weeks in a freezer (56). After  
18 completion of all assessment sessions, sample analysis will be completed. To  
19 avoid inter-laboratory variation, the same laboratory will assay the samples.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

### 30 **Recording of blood pressure and heart rate**

31 After 10 minutes at rest, lying down, blood pressure (BP) and heart rate (HR)  
32 will be recorded. BP and HR will then be measured when the patient stands up  
33 and once per minute for 4 minutes while standing.  
34  
35  
36  
37  
38

### 39 **Blinding strategy**

40 Patients will not be informed of their group (active/semi-active). The  
41 investigators will not know the patient's group. Due to the nature of the  
42 intervention (physical activity protocol), the coaching staff will not be blinded.  
43  
44  
45  
46  
47

### 48 **Statistical analysis**

49 *Primary endpoint analysis:* The VAS improvements (stimulation test) obtained in  
50 the two groups will be compared using Student's *t*-test. If the required normality  
51 assumption is not sustainable, a nonparametric Wilcoxon test will be used. An  
52 alpha risk of 0.05 will be set as the limit of statistical significance. The main  
53 analysis will be performed on an intent-to-treat basis. A complementary analysis  
54 using a linear model with adjustment for age and BMI factors will be completed.  
55  
56  
57  
58  
59  
60

1  
2  
3 *The secondary endpoints* (quantitative data: salivary cortisol, blood pressure, PPT  
4 quantified by pain threshold pressure, questionnaire assessment) will be  
5 analysed in a similar way by comparing the improvements obtained between the  
6 two groups.  
7  
8  
9

## 10 11 12 **Methodological limitations**

13  
14 The methodology of this protocol is consistent with the recommendations of the  
15 Standard Protocol Items for Randomised Trials (SPIRIT). However, because of  
16 the nature of the intervention, the coaching staff cannot be blinded. Patients and  
17 investigators will be blinded.  
18  
19

20  
21 Given the study duration (2 years), potential participant dropout and loss to  
22 follow-up may be high. These risks were taken into account in setting sample  
23 size. To limit dropout, patients will be called to encourage them and to discuss  
24 any difficulties. In the second stage of training and to limit any long-term  
25 monotony effect, physical activity type can be diversified in both groups. The  
26 training session will be adapted in the active group (MICT will be associated with  
27 HIIT) to reduce sympathetic hyperactivity. To improve compliance and long-term  
28 achievement of training, the patient may choose the physical activity type  
29 performed without supervision.  
30  
31  
32  
33  
34  
35  
36  
37  
38

## 39 ***ETHICS AND DISSEMINATION***

### 40 41 **Ethics approval and consent to participate**

42  
43 The Committee for the Protection of Persons West VI approved this study.  
44 Patients will be informed of the objectives, constraints, risks and benefits of the  
45 study. To be included, patients must sign informed written consent. Data will be  
46 collected anonymously. The investigators will take all necessary precautions to  
47 ensure the confidentiality of the information, in particular with regard to patient  
48 identity.  
49  
50  
51  
52  
53

### 54 55 **Dissemination plan**

1  
2  
3 The results of this study will be published in specialised scientific journals. These  
4 results will also be presented in scientific meetings on pain and/or physical  
5 activity. In addition, a doctoral thesis will be written on this project.  
6  
7  
8  
9

10 TRIAL REGISTRATION NUMBER: NCT02486965  
11  
12  
13

### 14 **Acknowledgements**

15 The authors thank Julie Lelièvre, Marie Le Bellego and Youenn-Thor Bodéré for  
16 designing and implementing this protocol. The authors thank Richard Ryan for  
17 English language editing.  
18  
19

### 20 **Contributors**

21 CB initiated the idea for the project. CB and ALFB developed the study design.  
22 MC, GL, BQ, AK, AW, SM, MAGM, FR, LM and AD provided advice for the study  
23 design. GL and CB were responsible for supervision of the project. CB will  
24 conduct the recruitment. AK will conduct the training programme. CB, ALFB and  
25 MC will conduct the outcomes assessments and will contribute to the analysis  
26 and interpretation of the data. Both authors will contribute to the analyses and  
27 interpretation of the data. ALFB, CB and MC wrote early drafts of the manuscript.  
28 All authors approved the final version of this protocol.  
29  
30  
31

### 32 **Funding Statement**

33 This work is supported by the French Ministry of Health (Programme Hospitalier  
34 de Recherche Clinique Interrégional 2014, project No. 2014-A00743-44) PHRCi  
35 13-100  
36  
37

### 38 **Competing Interests**

39 None declared  
40  
41

### 42 **Ethics approval**

43 Committee for the Protection of Persons West VI  
44

### 45 **Provenance and peer review**

46 Not commissioned; externally peer-reviewed  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## References

1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. *Arthritis Rheum.* févr 1990;33(2):160-72.
2. Cánovas R, León I, Roldán MD, Astur R, Cimadevilla JM. Virtual reality tasks disclose spatial memory alterations in fibromyalgia. *Rheumatol Oxf Engl.* oct 2009;48(10):1273-8.
3. Fitzcharles M, Shir Y, Ablin JN, Buskila D, Amital H, Henningsen P, et al. Classification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines. *Evid-Based Complement Altern Med ECAM.* 2013;2013:528952.
4. Egloff N, von Känel R, Müller V, Egle UT, Kokinogenis G, Lederbogen S, et al. Implications of proposed fibromyalgia criteria across other functional pain syndromes. *Scand J Rheumatol.* 2015;44(5):416-24.
5. Moyano S, Kilstein JG, Alegre de Miguel C. New diagnostic criteria for fibromyalgia: Here to stay? *Reumatol Clin.* août 2015;11(4):210-4.
6. Wolfe F, Fitzcharles M-A, Goldenberg DL, Häuser W, Katz RL, Mease PJ, et al. Comparison of Physician-Based and Patient-Based Criteria for the Diagnosis of Fibromyalgia. *Arthritis Care Res.* mai 2016;68(5):652-9.
7. Tousignant-Laflamme Y, Pagé S, Goffaux P, Marchand S. An experimental model to measure excitatory and inhibitory pain mechanisms in humans. *Brain Res.* 16 sept 2008;1230:73-9.
8. Woda A, Dao T, Gremeau-Richard C. Steroid dysregulation and stomatodynia (burning mouth syndrome). *J Orofac Pain.* 2009;23(3):202-10.
9. Woda A, L'heveder G, Ouchchane L, Bodéré C. Effect of experimental stress in 2 different pain conditions affecting the facial muscles. *J Pain Off J Am Pain Soc.* mai 2013;14(5):455-66.
10. Cohen H, Neumann L, Shore M, Amir M, Cassuto Y, Buskila D. Autonomic dysfunction in patients with fibromyalgia: application of power spectral analysis of heart rate variability. *Semin Arthritis Rheum.* févr 2000;29(4):217-27.
11. da Cunha Ribeiro RP, Roschel H, Artioli GG, Dassouki T, Perandini LA, Calich AL, et al. Cardiac autonomic impairment and chronotropic incompetence in fibromyalgia. *Arthritis Res Ther.* 2011;13(6):R190.
12. Martinez-Lavin M. Fibromyalgia as a sympathetically maintained pain syndrome. *Curr Pain Headache Rep.* oct 2004;8(5):385-9.
13. Kadetoff D, Kosek E. Evidence of reduced sympatho-adrenal and hypothalamic-pituitary activity during static muscular work in patients with fibromyalgia. *J Rehabil Med.* sept 2010;42(8):765-72.
14. Tak LM, Cleare AJ, Ormel J, Manoharan A, Kok IC, Wessely S, et al. Meta-analysis and meta-regression of hypothalamic-pituitary-adrenal axis activity in functional somatic disorders. *Biol Psychol.* mai 2011;87(2):183-94.



15. Riva R, Mork PJ, Westgaard RH, Lundberg U. Comparison of the cortisol awakening response in women with shoulder and neck pain and women with fibromyalgia. *Psychoneuroendocrinology*. févr 2012;37(2):299-306.
16. Geiss A, Rohleder N, Anton F. Evidence for an association between an enhanced reactivity of interleukin-6 levels and reduced glucocorticoid sensitivity in patients with fibromyalgia. *Psychoneuroendocrinology*. mai 2012;37(5):671-84.
17. Bote ME, García JJ, Hinchado MD, Ortega E. Inflammatory/stress feedback dysregulation in women with fibromyalgia. *Neuroimmunomodulation*. 2012;19(6):343-51.
18. Hellhammer DH, Wüst S, Kudielka BM. Salivary cortisol as a biomarker in stress research. *Psychoneuroendocrinology*. févr 2009;34(2):163-71.
19. Clauw D, Ablin J. The relationship between « stress » and pain: lessons learned from fibromyalgia and related conditions. In: *Current topics in pain*. Castro-Lopes editor. XIth World Congress on Pain. Seattle: IASP press; 2009. p. p.245-270.
20. McKenzie DC. Markers of excessive exercise. *Can J Appl Physiol Rev Can Physiol Appl*. févr 1999;24(1):66-73.
21. MacKinnon LT. Special feature for the Olympics: effects of exercise on the immune system: overtraining effects on immunity and performance in athletes. *Immunol Cell Biol*. oct 2000;78(5):502-9.
22. Iellamo F, Pigozzi F, Parisi A, Di Salvo V, Vago T, Norbiato G, et al. The stress of competition dissociates neural and cortisol homeostasis in elite athletes. *J Sports Med Phys Fitness*. déc 2003;43(4):539-45.
23. Baumert M, Brechtel L, Lock J, Hermsdorf M, Wolff R, Baier V, et al. Heart rate variability, blood pressure variability, and baroreflex sensitivity in overtrained athletes. *Clin J Sport Med Off J Can Acad Sport Med*. sept 2006;16(5):412-7.
24. Kajaia T, Maskhulia L, Chelidze K, Akhalkatsi V, Kakhbrishvili Z. The effects of non-functional overreaching and overtraining on autonomic nervous system function in highly trained athletes. *Georgian Med News*. mars 2017;(264):97-103.
25. Fontenele JB, Felix FHC. Exercise for fibromyalgia: evidence for an integrated modulation of autonomic and nociception neural regulation. *Rheumatol Int*. déc 2012;32(12):4075-6.
26. Rossy LA, Buckelew SP, Dorr N, Hagglund KJ, Thayer JF, McIntosh MJ, et al. A meta-analysis of fibromyalgia treatment interventions. *Ann Behav Med Publ Soc Behav Med*. 1999;21(2):180-91.
27. Busch AJ, Webber SC, Brachaniec M, Bidonde J, Bello-Haas VD, Danyliw AD, et al. Exercise therapy for fibromyalgia. *Curr Pain Headache Rep*. oct 2011;15(5):358-67.
28. Society AP, éditeur. *Guideline for the Management of Fibromyalgia Syndrome Pain in Adults and Children*. American Pain Society; 2005. 109 p.

- 1  
2  
3 29. Häuser W, Arnold B, Eich W, Felde E, Flügge C, Henningsen P, et al.  
4 Management of fibromyalgia syndrome – an interdisciplinary evidence-based  
5 guideline. *GMS Ger Med Sci* [Internet]. 9 déc 2008 [cité 7 févr 2018];6. Disponible  
6 sur: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2703259/>
- 7 30. Macfarlane GJ, Kronisch C, Atzeni F, Häuser W, Choy EH, Amris K, et al.  
8 EULAR recommendations for management of fibromyalgia. *Ann Rheum Dis*. déc  
9 2017;76(12):e54.
- 10 31. Melanson EL, Freedson PS. The effect of endurance training on resting  
11 heart rate variability in sedentary adult males. *Eur J Appl Physiol*. sept  
12 2001;85(5):442-9.
- 13 32. Reland S, Ville NS, Wong S, Gauvrit H, Kervio G, Carré F. Exercise heart  
14 rate variability of older women in relation to level of physical activity. *J Gerontol*  
15 *A Biol Sci Med Sci*. juill 2003;58(7):585-91.
- 16 33. de Abreu SB, Lenhard A, Mehanna A, de Souza HCD, Correa FM de A,  
17 Hasser EM, et al. Role of paraventricular nucleus in exercise training-induced  
18 autonomic modulation in conscious rats. *Auton Neurosci Basic Clin*. 15 juin  
19 2009;148(1-2):28-35.
- 20 34. Martins-Pinge MC. Cardiovascular and autonomic modulation by the  
21 central nervous system after aerobic exercise training. *Braz J Med Biol Res Rev*  
22 *Bras Pesqui Médicas E Biológicas Soc Bras Biofísica Al*. sept 2011;44(9):848-54.
- 23 35. Brito RG, Rasmussen LA, Sluka KA. Regular physical activity prevents  
24 development of chronic muscle pain through modulation of supraspinal opioid  
25 and serotonergic mechanisms. *Pain Rep*. sept 2017;2(5):e618.
- 26 36. Da Silva Santos R, Galdino G. Endogenous systems involved in exercise-  
27 induced analgesia. *J Physiol Pharmacol Off J Pol Physiol Soc*. févr  
28 2018;69(1):3-13.
- 29 37. Naugle KM, Naugle KE, Fillingim RB, Samuels B, Riley JL. Intensity  
30 thresholds for aerobic exercise-induced hypoalgesia. *Med Sci Sports Exerc*. avr  
31 2014;46(4):817-25.
- 32 38. Law LF, Sluka KA. How does physical activity modulate pain? *Pain*.  
33 2017;158(3):369-70.
- 34 39. Häuser W, Klose P, Langhorst J, Moradi B, Steinbach M, Schiltenswolf M, et  
35 al. Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a  
36 systematic review and meta-analysis of randomised controlled trials. *Arthritis*  
37 *Res Ther*. 2010;12(3):R79.
- 38 40. Bodéré C, Bodéré YT, Quinio B, Woda A, Misery L. Specific training  
39 program for the treatment of fibromyalgia: a prospective controlled study. In:  
40 14th world congress on pain - TF505. Milan, Italy: IASP; 2012.
- 41 41. Bidonde J, Busch AJ, Bath B, Milosavljevic S. Exercise for adults with  
42 fibromyalgia: an umbrella systematic review with synthesis of best evidence.  
43 *Curr Rheumatol Rev*. 2014;10(1):45-79.
- 44 42. Lannersten L, Kosek E. Dysfunction of endogenous pain inhibition during  
45 exercise with painful muscles in patients with shoulder myalgia and  
46 fibromyalgia. *Pain*. oct 2010;151(1):77-86.
- 47 43. Franke K-J, Domanski U, Schroeder M, Jansen V, Artmann F, Weber U, et al.

- 1  
2  
3 Telemonitoring of home exercise cycle training in patients with COPD. *Int J*  
4 *Chron Obstruct Pulmon Dis.* 2016;11:2821-9.  
5  
6 44. Yasmin F, Banu B, Zakir SM, Sauerborn R, Ali L, Souares A. Positive  
7 influence of short message service and voice call interventions on adherence and  
8 health outcomes in case of chronic disease care: a systematic review. *BMC Med*  
9 *Inform Decis Mak.* 22 avr 2016;16:46.  
10  
11 45. Krag NJ, Nørregaard J, Larsen JK, Danneskiold-Samsøe B. A blinded,  
12 controlled evaluation of anxiety and depressive symptoms in patients with  
13 fibromyalgia, as measured by standardized psychometric interview scales. *Acta*  
14 *Psychiatr Scand.* juin 1994;89(6):370-5.  
15  
16 46. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact  
17 questionnaire: development and validation. *J Rheumatol.* mai  
18 1991;18(5):728-33.  
19  
20 47. Osorio CD, Gallinaro AL, Lorenzi-Filho G, Lage LV. Sleep quality in patients  
21 with fibromyalgia using the Pittsburgh Sleep Quality Index. *J Rheumatol.* sept  
22 2006;33(9):1863-5.  
23  
24 48. Omachi TA. Measures of sleep in rheumatologic diseases: Epworth  
25 Sleepiness Scale (ESS), Functional Outcome of Sleep Questionnaire (FOSQ),  
26 Insomnia Severity Index (ISI), and Pittsburgh Sleep Quality Index (PSQI).  
27 *Arthritis Care Res.* nov 2011;63 Suppl 11:S287-296.  
28  
29 49. Crinière L, Lhommet C, Caille A, Giraudeau B, Lecomte P, Couet C, et al.  
30 Reproducibility and validity of the French version of the long international  
31 physical activity questionnaire in patients with type 2 diabetes. *J Phys Act Health.*  
32 août 2011;8(6):858-65.  
33  
34 50. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress.  
35 *J Health Soc Behav.* déc 1983;24(4):385-96.  
36  
37 51. Marchand S, Arsenault P. Spatial summation for pain perception:  
38 interaction of inhibitory and excitatory mechanisms. *Pain.* févr  
39 2002;95(3):201-6.  
40  
41 52. Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in  
42 fibromyalgia is related to a deficit of endogenous pain inhibition. *Pain.* mars  
43 2005;114(1-2):295-302.  
44  
45 53. Granot M, Granovsky Y, Sprecher E, Nir R-R, Yarnitsky D. Contact heat-  
46 evoked temporal summation: tonic versus repetitive-phasic stimulation. *Pain.*  
47 juin 2006;122(3):295-305.  
48  
49 54. Barrett KE, Barman SM, Boitano S, Brooks H. Ganong's Review of Medical  
50 Physiology, 24th Edition. 24 edition. New York: McGraw-Hill Education /  
51 Medical; 2012. 768 p.  
52  
53 55. Potvin S, Paul-Savoie E, Morin M, Bourgault P, Marchand S. Temporal  
54 summation of pain is not amplified in a large proportion of fibromyalgia patients.  
55 *Pain Res Treat.* 2012;2012:938595.  
56  
57 56. Kirschbaum C, Hellhammer DH. Salivary cortisol in  
58 psychoneuroendocrine research: recent developments and applications.  
59 *Psychoneuroendocrinology.* 1994;19(4):313-33.  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure legends**

Figure 1. Flow Chart of DouFiSport

For peer review only




Figure 1: Flow Chart of DouFiSPort

209x297mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description
<b>Administrative information</b>		
Title	1	Impact of a specific training program on the neuromodulation of pain in fibromyalgia women (DouFiSport): a 24-month, controlled, randomised, double-blinded protocol.
Trial registration	2a	NCT02486965
Protocol version	3	version number 5.0 of 21/06/2016
Funding	4	This work is supported by the French Ministry of Health (Programme Hospitalier de Recherche Clinique Interrégional 2014) PHRCi 13-100

Roles and responsibilities

5a Names, affiliations, and roles of protocol contributors:

Anaïs Le Fur-Bonnabesse<sup>1,2,3</sup>, investigator  
 Mathilde Cabon<sup>1</sup>, investigator  
 Gildas L'Heveder<sup>4</sup>, co-ordinating investigator  
 Aurélie Kermarrec<sup>5</sup>, coaching staff (physiotherapist)  
 Bertrand Quinio<sup>3</sup>, scientific associate  
 Alain Woda<sup>6</sup>, scientific associate  
 Serge Marchand<sup>7</sup>, scientific associate  
 Amandine Dubois<sup>8,9,1</sup>, investigator  
 Marie-Agnès Giroux-Metges<sup>10,11</sup>, scientific associate  
 Fabrice Rannou<sup>10,11</sup> scientific associate  
 Laurent Misery<sup>1</sup>, scientific associate  
 Céline Bodéré<sup>1,2,3</sup>, principal investigator, scientific responsible

1 Laboratory of Interactions Keratinocytes-Neurons, EA4685, Faculty of Medicine and Health Sciences, University of Western Brittany (UBO), Brest, France

2 Dental faculty, University of Western Brittany (UBO), Brest, France

3 Assessment and treatment center of pain, University Hospital of Brest, Brest, France

4 Neurological functional explorations, University Hospital of Brest, Brest, France.

5 Training institute of physiotherapy University Hospital of Brest, Brest, France.

6 University Clermont Auvergne, CROC and Teaching Hospital EA3847, Odontology Department, Clermont-Ferrand, France

7 Department of surgery, Faculty of medicine, University of Sherbrooke, Sherbrooke, Canada

8 Laboratory of psychology: Cognition, Behaviour, Communication (LP3C), EA1285, Rennes, France

9 Department of Psychology, University of Western Brittany (UBO), Brest, France.

10 ORPHY, Optimisation of Physiological Regulations, EA4324, Faculty of Medicine and Health Sciences, University of Western Brittany (UBO), Brest, France

11 Respiratory Functional Exploration Unit, University Hospital of Brest, Brest, France.

CB initiated the idea for the project.

CB and ALFB developed the study design.

MC, GL, BQ, AK, AW, SM, MAGM, FR, LM and AD provided advice for the study design.

GL and CB are responsible for supervision of project. CB will conduct the recruitment.

AK will conduct the training programme.

CB, ALFB and MC will conduct the outcomes assessments and will contribute to the analysis and interpretation of the data.

Both authors will contribute to the analyses and interpretation of the data.

ALFB, CB and MC wrote early drafts of the manuscript.

All authors approved the final version of this protocol.



1  
2 5b Name and contact information for the trial sponsor:  
3

4 Rémi BRAJEUL, directeur adjoint  
5 Délégation à la Recherche Clinique et à l'Innovation (DRCI)  
6 CHRU de Brest  
7 2 Avenue Foch  
8 29609 Brest Cedex  
9 France  
10

11  
12  
13 5c Role of study sponsor and funders :  
14

- 15 - Evaluation of serious adverse events
  - 16 - Transmission of annual safety reports
  - 17 - Quality assurance and monitoring activities
  - 18 - Approval of any amendment of the protocol
- 19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Background and 6a Fibromyalgia affects 1.4 to 2.2% of the general population concerning  
2 rationale 6a predominately women (more than 80% of subjects). This syndrome is  
3 characterised by extensive and diffuse pain, mainly muscular and  
4 articular, impairing the functional abilities of the subjects. The  
5 symptoms most frequently described by fibromyalgia patients are  
6 chronic fatigue, sleep disorders, cognitive disorders and emotional  
7 disturbances (3,4). This symptomatology leads to a serious  
8 deterioration in quality of life, sometimes with a physical disability  
9 leading to social isolation and difficulties in staying in employment  
10 (recurrent work stoppages).  
11 The diagnosis is based on the symptoms and their severity as  
12 described by the patients (5–8). Currently, there is no etiological  
13 treatment for fibromyalgia syndrome. The treatments are therefore  
14 only symptomatic.  
15  
16  
17  
18

### 19 **Physiopathology of fibromyalgia**

20 The mechanisms of dysfunctional pain, without any identifiable organic  
21 lesions, are mostly central (1) and related to dysfunction of the stress  
22 axis (autonomic nervous system and corticotropic axis) (9–11).  
23 At rest, fibromyalgia patients showed an increased sympathetic  
24 response and decreased parasympathetic tone (12,13). This  
25 neurovegetative dystonia is a marker of dysfunction of the stress axis  
26 (14).  
27 Malfunctions of the corticotropic axis in fibromyalgia have been  
28 described multiple times, also marking the dysfunction of the stress  
29 axis. But the form taken by this dysfunction differs according to the  
30 different studies (15–19). The variability of salivary cortisol in response  
31 to stress reflects that of plasma free cortisol. Salivary cortisol is  
32 therefore a method of choice in experimental stress studies (20).  
33 Whatever form they take, these dysfunctions compromise the body's  
34 adaptation to daily stressful stimuli.  
35  
36  
37  
38

39 Studies show that this deficit of the stress axis (neurovegetative  
40 dystonia and dysfunctional corticotropic axis) is concurrent with  
41 fibromyalgia (21) and associated with alteration of pain control (9–11).  
42 Pain control system and stress axis have close anatomical and  
43 functional links. Nociceptive, neurovegetative and corticotropic  
44 systems interact with the central nervous system. The central  
45 neuromediators implicated in the regulation of the stress axis are  
46 mostly common with those of the pain neuromodulation (endogenous  
47 opioids, norepinephrine, serotonin, etc.).  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Elite athlete's overtraining syndrome: model of stress axis dysfunction

An overtraining elite athlete may be considered as a model of dysfunction of the stress axis associated with neurovegetative dystonia. The physical and psychological effort of training is known to induce stress. High-level athletes could present an overtraining syndrome when adaptation limits of the stress axis are reached. This stress-induced phenomenon corresponds to an imbalance between training quantity and recovery. Overtrained athletes present a deconditioning syndrome close to fibromyalgia symptoms (chronic pain, sleep disorders, neurovegetative dystonia, etc.) (22–26).

### Physical activity and fibromyalgia

Most studies have shown that physical activity is more efficient compared to pharmacological treatments on fibromyalgia symptoms (27,28). Literature reviews and meta-analyses highly support the benefits of physical training in fibromyalgia patients (decreased pain and depression and improvement in overall health and physical abilities) (29)(30). Practice of aerobic exercise in fibromyalgia patients is strongly recommended by The American Pain Society (31), the Association of Medical Scientific Societies in Germany (32), the Canadian Rheumatology Association (5) and the European League Against Rheumatism (EULAR) (33). Physical exercise is the first-line treatment recommended in fibromyalgia. However there is still no consensus on the modalities of these types of training (frequency, duration, and intensity). Currently, the mechanisms underlying those specific training effects have to be defined.

The steady physical activity rebalancing autonomic system is associated with cardiovascular benefits. Fundamental endurance increases parasympathetic tone and decrease sympathetic response (34–37). Thus, strategies to rebalance the autonomic system are the most promising therapies for fibromyalgia (13,36,37).

In this study, we propose to validate a therapeutic alternative that aims to treat fibromyalgia by rebalancing the stress axis. This treatment consists of a specific supervised and individualised training program, over 2 years. This training protocol is individually adjusted in order to rebalance the neurovegetative system (parasympathetic and sympathetic). Central neuroplasticity induced by training should regulate endogenous pain control mechanisms.

Objectives 7 The *main objective* is to assess the effectiveness of a specific training program on endogenous pain controls in fibromyalgia patients. The *secondary objectives* are to rebalance the autonomic nervous system and the corticotropic axis, to improve life and sleep quality and to reintegrate patients into society and work.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Trial design	8	This randomised double-blinded trial will compare an "active" program to a "control" program in fibromyalgia patients.
--------------	---	--

### Methods: Participants, interventions, and outcomes

Study setting	9	Patients will be recruited at the pain center of the university hospital of Brest on the basis of general criteria. Patients should follow a re-exercise program for 24 months. The assessments will take place (i) before, (ii) between 6 to 9 months (depending the training level) and (iii) at the end of the training (24 months), in the neurological functional explorations department of the university hospital of Brest (France).
---------------	---	--

Eligibility criteria	10	The inclusion criteria are: female subjects; aged of 18 to 65 years; with a diagnosis of fibromyalgia clearly established according to the criteria of the American College of Rheumatology (ACR) 2010; with a body mass index (BMI) between 18.5 and 29.9kg/m <sup>2</sup> ; spontaneous pain intensity higher than 3/10 on a visual analog scale (VAS); pain experienced at least 3 days a week; pain caused by palpation equal to or higher than 4/10 on a VAS.
----------------------	----	--

The non-inclusion criteria are: patients with a systemic disease (treated or not) generating pain of the musculoskeletal system; presenting pain other than fibromyalgia; presenting a contraindication to physical activity; having any active pathology; having modified in the last 2 months any pharmacological treatment; having a psychiatric diagnosis; taking drugs that affect cortisol secretion (decrease or increase); non-cooperating.

1 Interventions 11a The training program is planned over two years (24 months) for both  
2 groups (active/control). A minimum of 4 to 6 weeks is needed to  
3 observe a decrease in symptoms (38). This two-year duration is the  
4 minimum average training time (depending on the individual progress  
5 of each patient), necessary to regain central neuroplasticity sufficient  
6 to put back into operation diffuse noxious inhibitory controls (DNIC)  
7 and neurovegetative system (39).  
8  
9 The frequency, intensity, and duration of these training sessions are  
10 based upon the results of a preliminary study. Pain was significantly  
11 reduced and symptoms, such as quality of life, sleep quality, anxiety,  
12 were also highly improved in subjects undergoing this specific training  
13 after 5 years (39). The American Pain Society recommends an  
14 intensity of 60 to 70% of the age-adjusted maximum heart rate  
15 (HRmax). At the early stage, the intensity and duration of the training  
16 sessions will be adapted to the physical condition of each subject. In  
17 order to promote adherence of our patients and to limit pain  
18 exacerbation, exercise intensity will start very low and then gradually  
19 increase to reach the neurovegetative goal (31)(40).  
20  
21  
22  
23

#### **Active training group:**

*The first 6 to 9 months:* fundamental endurance training.

Subjects will perform 3 sessions per week of 45 minutes of fundamental endurance (moderate-intensity continuous training MICT: 60% HRmax), including 2 sessions supervised by a physiotherapist and 1 independent session.

*From 6-9 months (according to the rhythm, abilities, and limits) to 24 months:* Patients will begin the second stage of training: 3 sessions per week of 45 minutes each (moderate-intensity continuous training MICT (60% HRmax) and high-intensity interval training HIIT) with 1 supervised session and 2 independent sessions. When the patient reaches the initial HR goal, "fundamental endurance" will be associated with "interval training" at a high frequency intensity. HIIT will consist of 5 stages of 1 to 4 minutes at 85-90% HRmax (80-85%  $\dot{V}O_2$ max), interspersed by 1 to 4 minutes of active recovery at 60-75% HRmax (50-70%  $\dot{V}O_2$ max). Intensity will be assessed objectively using a heart rate monitor (FT2, Polar). □At baseline, Tanaka's age-based prediction equation ( $208-0.7 \times \text{age}$ ) will calculate HRmax. After 6-9 months of training, a maximal-effort graded exercise test will determine HRmax and  $\dot{V}O_2$ max for each patient.

#### **Control group:**

Patients will perform the same infra active training (low-intensity continuous training: LICT <50% HRmax) over two years. Supervision, monitoring, and frequency of sessions (3 x 45 minutes per week) in both groups will be equivalent.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant: If a patient cannot achieve the specific training requested after 9 months of study, the patient will not complete the second phase of training.
- 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence: Patients will be contacted to record progress, difficulties and if necessary, to encourage them to adhere to their program. These calls will improve the compliance and will limit patients lost to follow-up.  
Patients will perform a 6-minute walk test (6MWT) every 6 months (with physiotherapist).
- 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial: This specific protocol will be associated with psychotherapeutic approaches. In addition to the training program, multidisciplinary bio-psycho-social cares will be given in the pain center of the university hospital of Brest (France).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Outcomes 12 **Primary outcomes:** In order to assess endogenous pain mechanisms, such as diffuse noxious inhibitory controls (DNIC), temporal summation (TS) and perception of pain, we will use an experimental method developed by Tousignant-Laflamme and Marchand (2008). According to this well-characterised paradigm, we will induce in single session two tonic heat pain stimulations separated by a cold pressor test (1,47–49). The VAS improvements (stimulation test) obtained in the both groups will be compared.


**Secondary outcomes:**  
A simple verbal scale, a visual analog scale, and the Saint Antoine Pain Questionnaire (QDSA), will perform the **assessment of pain**. A **pain quantitative assessment** will be performed with a pressure algometer (pressure pain threshold: PPT).  
Questionnaires will assess **patient anxiodepressive state** (Hospital Anxiety Depression Scale), **the impact of fibromyalgia on daily life** (Fibromyalgia Impact Questionnaire), **sleep quality and quantity** (Pittsburgh Sleep Quality Index), **the level of physical activity and the sedentary lifestyle** (International Physical Activity Questionnaire), **the antecedents of perceived stress** (Perceived Stress Scale).  
**Blood Pressure** (BP) and **Heart Rate** (HR) will be recorded.  
**Corticotropic axis** will be assessed using measurement of salivary cortisol and salivary flow.

Quantitative assessment (salivary cortisol, blood pressure, PPT quantified by pain threshold pressure, questionnaires assessment) will be analysed by comparing the improvements obtained between both groups.

Participant  
timeline

13 The training program is planned over two years (24 months) for both  
groups (active/control). Subjects will perform 3 training sessions per  
week of 45 minutes.  
Patient will participate in 4 visits (1 inclusion visit and 3 assessment  
visits) during these two years.

Figure 1:  
Flow chart  
of  
DouFiSport





1			
2	Sample size	14	Population size is based on an expected difference of 20 points
3			(stimulation test) (1) between the two groups, for a quantitative primary
4			endpoint (delta VAS) of standard deviation equal to 35, and a power
5			set at 80%. Therefore a minimum of 48 subjects per group is required
6			for assessment. In order to take into account loss to follow-up, the
7			sample of 110 subjects, 55 per group will be recruited.
8			
9	Recruitment	15	Patients will be recruited at the pain centre of the university hospital of
10			Brest on the basis of general criteria.
11			

### 12 **Methods: Assignment of interventions (for controlled trials)**

#### 13 Allocation:

14			
15			
16	Sequence	16a	Patients will be randomised at the end of the first stimulation test
17	generation		(second visit: V2), which is just before the initiation of the training. The
18			test is stratified by age and BMI. The cut off is set at 50 years for age
19			and 25kg/m <sup>2</sup> for BMI (two strata [18-25] and ]25-30 []).
20			
21			
22	Allocation	16b	Electronic randomisation via Capture System
23	concealment		
24	mechanism		
25			
26	Implementation	16c	The allocation sequence will generate by the Center of Clinical
27			Investigation (CIC) at the hospital university of Brest (France).
28			The principal investigator will enrol participants, and will assign
29			participants to interventions.
30			
31			
32	Blinding	17a	Who will be blinded after assignment to interventions:
33	(masking)		Patients will be blinded (they will not be informed of their group
34			(active/control)).
35			The investigators, outcome assessors and data analysts will be
36			blinded.
37			
38		17b	If blinded, circumstances under which unblinding is permissible:
39			Due to the nature of the intervention (physical activity protocol), the
40			coaching staff will not be blinded.
41			
42			
43			

### 44 **Methods: Data collection, management, and analysis**

1 Data collection methods 18a Measurements and questionnaires will be carried out (i) at baseline,  
2 (ii) between 6 to 9 months, and (iii) at the end of the 24 months of  
3 training.

#### 4 **Sociodemographic and clinical data**

5 At baseline, data on age, sex, marital status, education level, and  
6 occupation will be collected. Height and weight will be recorded.  
7 Medical background and pain characteristics will be noted. All current  
8 drug and non-drug therapies (including tried and stopped) will also be  
9 collected, as well as their effectiveness on pain.

#### 10 **Questionnaires and pain assessments**

- 11 • The **assessment of pain** will be performed by a simple verbal  
12 scale and using a visual analog scale (VAS). The Saint Antoine  
13 Pain Questionnaire (QDSA) will also assess pain. A **pain**  
14 **quantitative assessment** will be performed with a pressure  
15 algometer (pressure pain threshold: PPT).
- 16 • The Hospital Anxiety Depression Scale (HADS) will assess the  
17 **patient anxiodepressive state** (41).
- 18 • The Fibromyalgia Impact Questionnaire (FIQ) will assess **the**  
19 **impact of fibromyalgia on daily life** (42).
- 20 • The Pittsburgh Sleep Quality Index (PSQI) will assess **sleep**  
21 **quality and quantity** (43,44).
- 22 • The International Physical Activity Questionnaire (IPAQ) will  
23 record the **level of physical activity and the sedentary**  
24 **lifestyle**. The French long telephone questionnaire will be used  
25 (45).
- 26 • The Perceived Stress Scale (PSS) will assess **the**  
27 **antecedents of perceived stress** (46).

#### 28 **Stimulation test**

29 In order to assess endogenous pain mechanisms, such as diffuse  
30 noxious inhibitory controls (DNIC), temporal summation (TS) and  
31 perception of pain, we will use an experimental method developed by  
32 Tousignant-Laflamme and Marchand (2008) (1,47–49).

33 - **Thermode test or temporal summation test (P1):** a tonic heat  
34 pain will be administered for 2 minutes on the patient's right arm, using  
35 a thermode (CE marking n°226). The starting temperature is 32°C  
36 (skin temperature under normal conditions in temperate room (20-  
37 22°C)) (50) and will quickly reach a fixed value. The experimental  
38 temperature will be individually determined to induce 50/100 on a VAS  
39 and will remain constant during the test period (2 minutes).

40 Throughout this entire period, the patient will evaluate their pain  
41 intensity using a Computerised Visual Analog Scale (CoVAS).

42 - **Cold pressor test (P2):** to elicit a prolonged pain sensation in  
43 order to trigger diffuse noxious inhibitory control (DNIC) (51), the  
44 patient's right arm will be immersed for 2 minutes in a cold water bath  
45 maintained at 12°C. The patient will continuously evaluate their pain  
46 intensity using a CoVAS.

47 Following this cold pressor test, the thermode test will be again  
48 performed (**P3**).

49 Pain difference between the two (P3/P1) tonic heat pain stimulations  
50 will measure DNIC activation and represents pain modulation.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Measurement of salivary cortisol and salivary flow**

Corticotropic axis will be assessed using measurement of salivary cortisol. Cortisol release is pulsatile (10 to 20 peaks per day) and follows a nycthemeral cycle. Maximum cortisol level is reached in the early morning. In the morning of each consultation (at baseline, in the middle and at the end of training), patients will collect salivary sample (i) for 2 minutes, when they wake up and (ii) for 2 minutes, 30 minutes later. The salivary cortisol level is measured in nmol/l. The flow rate is calculated in ml.min<sup>-1</sup>. Samples will be frozen at -20°C. As salivary cortisol is stable, samples can be stored for many weeks in the freezer (52). After completion of all assessment sessions, sample analysis will be completed. To avoid inter-laboratory variation, the same laboratory will assay the samples.

**Recording of Blood Pressure (BP) and Heart Rate (HR)**

After 10 minutes at rest, lying down, BP and HR will be recorded. Then, BP and HR will be measured when the patient stands up and once per minute during 4 minutes when the patient remains standing.

- 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols: To limit dropout, patients will be called to encourage them and to discuss any difficulties. In second stage of training and to limit a possible long-term monotonous effect, physical activity type could be diversified in both groups. The training session will be adapted in the active group (MICT will be associated with HIIT) to reduce sympathetic hyperactivity. In order to improve compliance and long-term achievement of training, the patient may choose the physical activity type performed without supervision. If a patient cannot achieve the specific training requested after 9 months of study, the patient will not complete the second phase of training. Nevertheless, she will carry out all assessment visits. The main analysis will be performed on an intent-to-treat basis.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Data management 19 **Case report forms (CRF):**  
All data collected must be recorded in the CRF immediately after the procedure. Each missing data will have to be coded. The researcher will carry out a double data entry. In addition, Checks on the consistency of these data will be instantly carried out.

Data on individuals included in the study will be made anonymous. Only the first letter of the subject's name, and the first letter of her first name will be recorded, with a specific code number.

**Quality Assurance and Control:**  
A researcher commissioned by the study sponsor will ensure proper achievement of the study and, of data collection, recording and, reporting.

**Storage:**  
During the study period, documents will be stored in the neurological functional explorations department of the university hospital of Brest. At the end of the study period, all archived documents will be transferred to a centralized archiving site (Central Archives Service - Brest) and, will be placed under the sponsor responsibility for 15 years according to institutional practices.

29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

Statistical methods 20a *Primary outcome analysis:* The VAS improvements (stimulation test) obtained in the both groups will be compared using the Student's test. If the required normality assumption is not sustainable, a nonparametric Wilcoxon test will be used. An alpha risk of 0.05 will be set as the limit of statistical significance. The main analysis will be performed on an intent-to-treat basis. A complementary analysis using a linear model with adjustment for age and BMI factors will be completed.

*The secondary outcomes* (quantitative: salivary cortisol, blood pressure, PPT quantified by pain threshold pressure, questionnaires assessment) will be analysed in a similar way by comparing the improvements obtained between both groups.

#### Methods: Monitoring

48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Data monitoring 21a Because of the nature of the study (excluding health product and, duration of the study), a monitoring committee independent from the sponsor will not be constituted.

A researcher commissioned by the study sponsor will ensure proper achievement of the study, and of data collection, recording and reporting.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

21b The study may be stopped early for reasons of safety (in the event of unexpected serious adverse event occurrences), efficacy or futility. The sponsor reserves the right to stop the study at any time, if the desired sample size is not achieved.

## Harms

22 **The investigator** is responsible for recording and reporting all serious adverse events (EvIG) occurring during the entire study period. Regardless of the causal relationship between EvIG and the study, any EvIG will be described on the form dedicated to this matter («EvIG initial report» or «EvIG follow-up report») and will be notified to the sponsor within a time frame of 24 hours after the event occurs.

All other adverse events (non-serious adverse events) will be reported on adverse event form of the CRF. The date of occurrence, description, intensity, duration, treatment, aetiology, accountability and the decisions taken will be specified.

**The sponsor** has to analyse EvIG (the causality of the EvIG and their expected or unexpected character). The sponsor have to report all unexpected EvIG to Eudravigilance (European pharmacovigilance database), the French Health Authorities (ANSM), the Committee for the Protection of Persons (CPP) and, to the investigators. Each year, the sponsor will draft a safety report that will include:

- the list of unexpected and expected EvIG,
- a concise and critical analysis of the safety of patients included in the study.

Each adverse events will be monitored until the it will be completely resolved even if after the study period.

## Auditing

23 A researcher commissioned by the sponsor will audit trial conduct. The investigator and his team undertake to make themselves available during regular Quality Control visits by this researcher. During these visits, informed consent, adherence to study protocol and, CRF data quality, will be reviewed. The investigator undertakes to accept quality control audits carried out by the sponsor, and by the competent authorities.

## Ethics and dissemination

Research ethics approval 24 The Committee for the Protection of Persons West VI approved this study on 02/12/2014.

1			
2	Protocol	25	Important protocol modifications by the investigator (eg, changes to
3	amendments		eligibility criteria, outcomes, analyses) have to be approved by the
4			sponsor. The sponsor must obtain a favourable opinion of the CPP
5			and an authorization of the «Agence nationale de sécurité du
6			médicament et des produits de santé» (ANSM) to enable the
7			application of these amendments. A new consent of the patient
8			participating will be collected if necessary.
9			
10	Consent or assent	26a	Patients will be informed of the objectives, constraints, risks and
11			benefits of the study. Patients will be informed of their rights to refuse
12			to participate or to withdraw from the study at any time. All information
13			will be on information and consent form given to the patient. To be
14			included, patients will sign informed written consent. The investigator
15			will collect free, informed, and written consent of the patient before
16			definitive inclusion in the study.
17			
18			
19		26b	Additional consent provisions for collection and use of participant data
20			and biological specimens in ancillary studies, if applicable: No
21			collection will be formed.
22			
23	Confidentiality	27	Data on individuals included in the study will be made anonymous.
24			Only the first letter of the subject's name, and the first letter of her first
25			name will be recorded, with a specific code number. The investigators
26			will take all necessary precautions to ensure the confidentiality of the
27			information in particular with regard to patient identity.
28			
29			
30	Declaration of	28	None declared.
31	interests		
32			
33	Access to data	29	In accordance with good clinical practice, the sponsor is responsible
34			for seeking the agreement of those involved in this research with a
35			view to ensure direct access to source data, source documents and
36			reports in all research place (particularly during quality control).
37			In accordance with the legislative provisions in force (articles L.1121-3
38			et R.5121-13 of the French Public Health Code), the investigators will
39			be making documents and necessary individual data available to
40			researcher charged with study control and monitoring.
41			
42			
43			
44	Ancillary and	30	Pursuant to the provisions of article L1121-10 of the French Public
45	post-trial care		Health Code, the sponsor (CHRU of Brest) undertakes to take out a
46			civil liability insurance contract.
47			
48	Dissemination	31a	The results of this study will be published in specialised scientific
49	policy		journals. These results will be presented to participants and the public
50			at a free public lecture organised by the health promotion department
51			of the city of Brest. These results will also be presented to healthcare
52			professionals and other relevant groups in pain and/or physical activity
53			congresses. In addition, a doctoral thesis will be carried out on this
54			project.
55			
56			
57			
58			
59			
60			

## Appendices

Informed consent materials	32	See attached documentation
Biological specimens	33	Not applicable.

---

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

## References

1. Tousignant-Laflamme Y, Pagé S, Goffaux P, Marchand S. An experimental model to measure excitatory and inhibitory pain mechanisms in humans. *Brain Res.* 16 sept 2008;1230:73•9.
2. Woda A, L'heveder G, Ouchchane L, Bodéré C. Effect of experimental stress in 2 different pain conditions affecting the facial muscles. *J Pain Off J Am Pain Soc.* mai 2013;14(5):455•66.
3. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. *Arthritis Rheum.* févr 1990;33(2):160•72.
4. Cánovas R, León I, Roldán MD, Astur R, Cimadevilla JM. Virtual reality tasks disclose spatial memory alterations in fibromyalgia. *Rheumatol Oxf Engl.* oct 2009;48(10):1273•8.
5. Fitzcharles M, Shir Y, Ablin JN, Buskila D, Amital H, Henningsen P, et al. Classification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines. *Evid-Based Complement Altern Med ECAM.* 2013;2013:528952.
6. Egloff N, von Känel R, Müller V, Egle UT, Kokinogenis G, Lederbogen S, et al. Implications of proposed fibromyalgia criteria across other functional pain syndromes. *Scand J Rheumatol.* 2015;44(5):416•24.
7. Moyano S, Kilstein JG, Alegre de Miguel C. New diagnostic criteria for fibromyalgia: Here to stay? *Reumatol Clin.* août 2015;11(4):210•4.
8. Wolfe F, Fitzcharles M-A, Goldenberg DL, Häuser W, Katz RL, Mease PJ, et al. Comparison of Physician-Based and Patient-Based Criteria for the Diagnosis of Fibromyalgia. *Arthritis Care Res.* mai 2016;68(5):652•9.
9. Bodéré C, Woda A. La douleur orofaciale idiopathique: une douleur fonctionnelle. *Douleur Analgésie.* 21 juin 2009;22(2):89•95.
10. Woda A, Dao T, Gremeau-Richard C. Steroid dysregulation and stomatodynia (burning mouth syndrome). *J Orofac Pain.* 2009;23(3):202•10.
11. Woda A, L'heveder G, Ouchchane L, Bodéré C. Effect of experimental stress in 2 different pain conditions affecting the facial muscles. *J Pain Off J Am Pain Soc.* mai 2013;14(5):455•66.



- 1 12. Cohen H, Neumann L, Shore M, Amir M, Cassuto Y, Buskila D. Autonomic  
2 dysfunction in patients with fibromyalgia: application of power spectral analysis of heart rate  
3 variability. *Semin Arthritis Rheum.* févr 2000;29(4):217•27.
- 4 13. da Cunha Ribeiro RP, Roschel H, Artioli GG, Dassouki T, Perandini LA, Calich AL, et  
5 al. Cardiac autonomic impairment and chronotropic incompetence in fibromyalgia. *Arthritis*  
6 *Res Ther.* 2011;13(6):R190.
- 7 14. Martinez-Lavin M. Fibromyalgia as a sympathetically maintained pain syndrome. *Curr*  
8 *Pain Headache Rep.* oct 2004;8(5):385•9.
- 9 15. Kadetoff D, Kosek E. Evidence of reduced sympatho-adrenal and hypothalamic-  
10 pituitary activity during static muscular work in patients with fibromyalgia. *J Rehabil Med.*  
11 sept 2010;42(8):765•72.
- 12 16. Tak LM, Cleare AJ, Ormel J, Manoharan A, Kok IC, Wessely S, et al. Meta-analysis  
13 and meta-regression of hypothalamic-pituitary-adrenal axis activity in functional somatic  
14 disorders. *Biol Psychol.* mai 2011;87(2):183•94.
- 15 17. Riva R, Mork PJ, Westgaard RH, Lundberg U. Comparison of the cortisol awakening  
16 response in women with shoulder and neck pain and women with fibromyalgia.  
17 *Psychoneuroendocrinology.* févr 2012;37(2):299•306.
- 18 18. Geiss A, Rohleder N, Anton F. Evidence for an association between an enhanced  
19 reactivity of interleukin-6 levels and reduced glucocorticoid sensitivity in patients with  
20 fibromyalgia. *Psychoneuroendocrinology.* mai 2012;37(5):671•84.
- 21 19. Bote ME, García JJ, Hinchado MD, Ortega E. Inflammatory/stress feedback  
22 dysregulation in women with fibromyalgia. *Neuroimmunomodulation.* 2012;19(6):343•51.
- 23 20. Hellhammer DH, Wüst S, Kudielka BM. Salivary cortisol as a biomarker in stress  
24 research. *Psychoneuroendocrinology.* févr 2009;34(2):163•71.
- 25 21. Clauw D, Ablin J. The relationship between « stress » and pain: lessons learned from  
26 fibromyalgia and related conditions. In: *Current topics in pain.* Castro-Lopes editor. XIIth  
27 World Congress on Pain. Seattle: IASP press; 2009. p. p.245-270.
- 28 22. McKenzie DC. Markers of excessive exercise. *Can J Appl Physiol Rev Can Physiol*  
29 *Appl.* févr 1999;24(1):66•73.
- 30 23. MacKinnon LT. Special feature for the Olympics: effects of exercise on the immune  
31 system: overtraining effects on immunity and performance in athletes. *Immunol Cell Biol.* oct  
32 2000;78(5):502•9.
- 33 24. Iellamo F, Pigozzi F, Parisi A, Di Salvo V, Vago T, Norbiato G, et al. The stress of  
34 competition dissociates neural and cortisol homeostasis in elite athletes. *J Sports Med Phys*  
35 *Fitness.* déc 2003;43(4):539•45.
- 36 25. Baumert M, Brechtel L, Lock J, Hermsdorf M, Wolff R, Baier V, et al. Heart rate  
37 variability, blood pressure variability, and baroreflex sensitivity in overtrained athletes. *Clin J*  
38 *Sport Med Off J Can Acad Sport Med.* sept 2006;16(5):412•7.
- 39 26. Kajaia T, Maskhulia L, Chelidze K, Akhalkatsi V, Kakhbrishvili Z. The effects of non-  
40 functional overreaching and overtraining on autonomic nervous system function in highly  
41 trained athletes. *Georgian Med News.* mars 2017;(264):97•103.
- 42 27. Fontenele JB, Felix FHC. Exercise for fibromyalgia: evidence for an integrated  
43 modulation of autonomic and nociception neural regulation. *Rheumatol Int.* déc  
44 2012;32(12):4075•6.
- 45 28. Rossy LA, Buckelew SP, Dorr N, Hagglund KJ, Thayer JF, McIntosh MJ, et al. A  
46 meta-analysis of fibromyalgia treatment interventions. *Ann Behav Med Publ Soc Behav Med.*  
47 1999;21(2):180•91.



- 1 29. Busch AJ, Webber SC, Brachaniec M, Bidonde J, Bello-Haas VD, Danyliw AD, et al.  
2 Exercise therapy for fibromyalgia. *Curr Pain Headache Rep.* oct 2011;15(5):358•67.
- 3 30. Woda A, L'heveder G, Ouchchane L, Bodéré C. Effect of experimental stress in 2  
4 different pain conditions affecting the facial muscles. *J Pain Off J Am Pain Soc.* mai  
5 2013;14(5):455•66.
- 6 31. Society AP, éditeur. *Guideline for the Management of Fibromyalgia Syndrome Pain  
7 in Adults and Children.* American Pain Society; 2005. 109 p.
- 8 32. Häuser W, Arnold B, Eich W, Felde E, Flügge C, Henningsen P, et al. Management  
9 of fibromyalgia syndrome – an interdisciplinary evidence-based guideline. *GMS Ger Med  
10 Sci.* 2008;6:Doc14.
- 11 33. Macfarlane GJ, Kronisch C, Atzeni F, Häuser W, Choy EH, Amris K, et al. EULAR  
12 recommendations for management of fibromyalgia. *Ann Rheum Dis.* déc 2017;76(12):e54.
- 13 34. Melanson EL, Freedson PS. The effect of endurance training on resting heart rate  
14 variability in sedentary adult males. *Eur J Appl Physiol.* sept 2001;85(5):442•9.
- 15 35. Reland S, Ville NS, Wong S, Gauvrit H, Kervio G, Carré F. Exercise heart rate  
16 variability of older women in relation to level of physical activity. *J Gerontol A Biol Sci Med  
17 Sci.* juill 2003;58(7):585•91.
- 18 36. de Abreu SB, Lenhard A, Mehanna A, de Souza HCD, Correa FM de A, Hasser EM,  
19 et al. Role of paraventricular nucleus in exercise training-induced autonomic modulation in  
20 conscious rats. *Auton Neurosci Basic Clin.* 15 juin 2009;148(1•2):28•35.
- 21 37. Martins-Pinge MC. Cardiovascular and autonomic modulation by the central nervous  
22 system after aerobic exercise training. *Braz J Med Biol Res Rev Bras Pesqui Médicas E  
23 Biológicas Soc Bras Biofísica Al.* sept 2011;44(9):848•54.
- 24 38. Häuser W, Klose P, Langhorst J, Moradi B, Steinbach M, Schiltenswolf M, et al.  
25 Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review  
26 and meta-analysis of randomised controlled trials. *Arthritis Res Ther.* 2010;12(3):R79.
- 27 39. Bodéré C, Bodéré YT, Quinio B, Woda A, Misery L. Specific training program for the  
28 treatment of fibromyalgia: a prospective controlled study. In: 14th world congress on pain -  
29 TF505. Milan, Italy: IASP; 2012.
- 30 40. Lannersten L, Kosek E. Dysfunction of endogenous pain inhibition during exercise  
31 with painful muscles in patients with shoulder myalgia and fibromyalgia. *Pain.* oct  
32 2010;151(1):77•86.
- 33 41. Krag NJ, Nørregaard J, Larsen JK, Danneskiold-Samsøe B. A blinded, controlled  
34 evaluation of anxiety and depressive symptoms in patients with fibromyalgia, as measured  
35 by standardized psychometric interview scales. *Acta Psychiatr Scand.* juin  
36 1994;89(6):370•5.
- 37 42. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire:  
38 development and validation. *J Rheumatol.* mai 1991;18(5):728•33.
- 39 43. Osorio CD, Gallinaro AL, Lorenzi-Filho G, Lage LV. Sleep quality in patients with  
40 fibromyalgia using the Pittsburgh Sleep Quality Index. *J Rheumatol.* sept  
41 2006;33(9):1863•5.
- 42 44. Omachi TA. Measures of sleep in rheumatologic diseases: Epworth Sleepiness Scale  
43 (ESS), Functional Outcome of Sleep Questionnaire (FOSQ), Insomnia Severity Index (ISI),  
44 and Pittsburgh Sleep Quality Index (PSQI). *Arthritis Care Res.* nov 2011;63 Suppl 11:S287-  
45 296.
- 46 45. Crinière L, Lhommet C, Caille A, Giraudeau B, Lecomte P, Couet C, et al.  
47 Reproducibility and validity of the French version of the long international physical activity  
48 questionnaire in patients with type 2 diabetes. *J Phys Act Health.* août 2011;8(6):858•65.
- 49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59

- 1 46. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *J Health*  
2 *Soc Behav.* déc 1983;24(4):385•96.
- 3 47. Marchand S, Arsenault P. Spatial summation for pain perception: interaction of  
4 inhibitory and excitatory mechanisms. *Pain.* févr 2002;95(3):201•6.
- 5 48. Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in fibromyalgia is  
6 related to a deficit of endogenous pain inhibition. *Pain.* mars 2005;114(1•2):295•302.
- 7 49. Granot M, Granovsky Y, Sprecher E, Nir R-R, Yarnitsky D. Contact heat-evoked  
8 temporal summation: tonic versus repetitive-phasic stimulation. *Pain.* juin  
9 2006;122(3):295•305.
- 10 50. Barrett KE, Barman SM, Boitano S, Brooks H. *Ganong's Review of Medical*  
11 *Physiology*, 24th Edition. 24 edition. New York: McGraw-Hill Education / Medical; 2012. 768  
12 p.
- 13 51. Potvin S, Paul-Savoie E, Morin M, Bourgault P, Marchand S. Temporal summation of  
14 pain is not amplified in a large proportion of fibromyalgia patients. *Pain Res Treat.*  
15 2012;2012:938595.
- 16 52. Kirschbaum C, Hellhammer DH. Salivary cortisol in psychoneuroendocrine research:  
17 recent developments and applications. *Psychoneuroendocrinology.* 1994;19(4):313•33.
- 18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description
<b>Administrative information</b>		
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry
	2b	All items from the World Health Organization Trial Registration Data Set
Protocol version	3	Date and version identifier
Funding	4	Sources and types of financial, material, and other support
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors
	5b	Name and contact information for the trial sponsor
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)
<b>Introduction</b>		
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention
	6b	Explanation for choice of comparators
Objectives	7	Specific objectives or hypotheses
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)

## Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size

## Methods: Assignment of interventions (for controlled trials)

### Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions
---------------------	-----	--

1			
2	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central
3	concealment		telephone; sequentially numbered, opaque, sealed envelopes),
4	mechanism		describing any steps to conceal the sequence until interventions are
5			assigned
6			
7	Implementation	16c	Who will generate the allocation sequence, who will enrol participants,
8			and who will assign participants to interventions
9			
10	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial
11	(masking)		participants, care providers, outcome assessors, data analysts), and
12			how
13			
14		17b	If blinded, circumstances under which unblinding is permissible, and
15			procedure for revealing a participant's allocated intervention during
16			the trial
17			

### 18 **Methods: Data collection, management, and analysis**

19			
20	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other
21	methods		trial data, including any related processes to promote data quality (eg,
22			duplicate measurements, training of assessors) and a description of
23			study instruments (eg, questionnaires, laboratory tests) along with
24			their reliability and validity, if known. Reference to where data
25			collection forms can be found, if not in the protocol
26			
27			
28		18b	Plans to promote participant retention and complete follow-up,
29			including list of any outcome data to be collected for participants who
30			discontinue or deviate from intervention protocols
31			
32	Data	19	Plans for data entry, coding, security, and storage, including any
33	management		related processes to promote data quality (eg, double data entry;
34			range checks for data values). Reference to where details of data
35			management procedures can be found, if not in the protocol
36			
37	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.
38	methods		Reference to where other details of the statistical analysis plan can be
39			found, if not in the protocol
40			
41			
42		20b	Methods for any additional analyses (eg, subgroup and adjusted
43			analyses)
44			
45		20c	Definition of analysis population relating to protocol non-adherence
46			(eg, as randomised analysis), and any statistical methods to handle
47			missing data (eg, multiple imputation)
48			

### 49 **Methods: Monitoring**

50			
51	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role
52			and reporting structure; statement of whether it is independent from
53			the sponsor and competing interests; and reference to where further
54			details about its charter can be found, if not in the protocol.
55			Alternatively, an explanation of why a DMC is not needed
56			
57			
58			
59			
60			

1		21b	Description of any interim analyses and stopping guidelines, including
2			who will have access to these interim results and make the final
3			decision to terminate the trial
4			
5	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and
6			spontaneously reported adverse events and other unintended effects
7			of trial interventions or trial conduct
8			
9			
10	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and
11			whether the process will be independent from investigators and the
12			sponsor
13			

### **Ethics and dissemination**

14			
15			
16	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board
17			(REC/IRB) approval
18			
19	Protocol amendments	25	Plans for communicating important protocol modifications (eg,
20			changes to eligibility criteria, outcomes, analyses) to relevant parties
21			(eg, investigators, REC/IRBs, trial participants, trial registries, journals,
22			regulators)
23			
24	Consent or assent	26a	Who will obtain informed consent or assent from potential trial
25			participants or authorised surrogates, and how (see Item 32)
26			
27		26b	Additional consent provisions for collection and use of participant data
28			and biological specimens in ancillary studies, if applicable
29			
30	Confidentiality	27	How personal information about potential and enrolled participants will
31			be collected, shared, and maintained in order to protect confidentiality
32			before, during, and after the trial
33			
34			
35	Declaration of interests	28	Financial and other competing interests for principal investigators for
36			the overall trial and each study site
37			
38	Access to data	29	Statement of who will have access to the final trial dataset, and
39			disclosure of contractual agreements that limit such access for
40			investigators
41			
42	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for
43			compensation to those who suffer harm from trial participation
44			
45	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to
46			participants, healthcare professionals, the public, and other relevant
47			groups (eg, via publication, reporting in results databases, or other
48			data sharing arrangements), including any publication restrictions
49			
50		31b	Authorship eligibility guidelines and any intended use of professional
51			writers
52			
53		31c	Plans, if any, for granting public access to the full protocol, participant-
54			level dataset, and statistical code
55			
56			
57			
58			
59			
60			

**Appendices**

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable

---

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.